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ABSTRACT
Sepsis is a condition that arises from the host’s own exaggerated response to an infection,
directed towards pathogens, but causing multiple organ failure. Sepsis is one of the most
common causes of death, and a considerable absorber of healthcare resources. This
frequently fatal condition, despite progress in technology and improving knowledge of
pathophysiology, is still poorly understood, carries high mortality and morbidity rates,
and survivors are often left with permanent disabilities and poor health outcomes.
Initial presentation of sepsis is often nonspecific, making diagnosis difficult, and
causing lifesaving treatment delays. Sepsis guidelines are derived from emerging
evidence-based research. While there is a general consensus that the optimal approach to
sepsis management is early recognition and rapid intervention, evidence supporting
treatment guidelines is evolving and inconsistent. A mandatory quality improvement
measure to implement Sepsis Early Management Bundle (SEP-1) went into effect on
October 1, 2015, in the settings utilized for this project. An evidence-based project was
conducted to evaluate the interventions and the effectiveness of the sepsis protocol on
patients’ health outcomes and assess whether implementation of the protocol reflected in
reduced hospital length of stay, decreased mortality, morbidity, antibiotics utilization and
rehospitalizations in a community hospital in the coastal region of South Carolina. A 19month data collection, retrospective review, and data analysis included 158 participants
in two groups, pre-and post-implementation of the protocol.
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Results showed that mortality and hospital stay were considerably reduced after
the protocols were implemented; however, readmission rates increased, and morbidity
increased. Implementing the mandated protocol actually did not uniformly influence the
efficiency of interventions. Results of this study can be used to validate the need for
improvement and recommend innovative approaches to therapeutic and diagnostic
methods that could facilitate earlier and more targeted interventions.
Future studies are needed to identify approaches that can help sepsis survivors to
regain independence, return to prior living arrangements, and avoid rehospitalization.
Measures of sepsis guideline effectiveness should focus on not only immediate results
and mortality rates, but also return to function and long-term effects affecting survivors.
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CHAPTER I
INTRODUCTION
Sepsis, also known as blood poisoning, is a common, debilitating, and potentially
deadly medical condition. The word sepsis is derived from the ancient Greek word for
rotten flesh, decay, and putrefaction (Marik, 2014). Although clinical criteria that define
sepsis remain controversial, the term refers to the systemic inflammatory response
following microbial infection with the presence of some degree of organ dysfunction
(Vincent, Opal, Marshall, & Tracey, 2013).
Background and Significance
Defined as a whole body inflammatory response to an infection (Bone, 1992), it is
a serious widespread systemic overreaction. Sepsis is more common than heart attack,
and claims more lives than any cancer (World Sepsis Day, 2015). It can rapidly progress
to a substantial acute organ dysfunction known as severe sepsis, and by triggering a
cascade of mechanisms can lead to septic shock, multi-organ failure, and death. Septic
shock is associated with overwhelming infection, usually by gram-negative bacteria,
although it may be produced by other bacteria, viruses, fungi, and protozoa. It is thought
to result from the action of endotoxins or other products of the infectious agent on the
vascular system causing large volumes of blood to be sequestered in the capillaries and
veins; activation of the complement and kinin systems and the release of histamine,
cytokines, prostaglandins, and other mediators may be involved (Farlex Partner Medical
1

Dictionary, 2012). Clinical characteristics of sepsis include initial chills and fever, warm
flushed skin, increased cardiac output and hypotension, and specific inflammatory
parameters; if therapy is ineffective, it may progress to the clinical picture associated with
septic shock (Farlex Partner Medical Dictionary, 2012).
This condition carries a high mortality rate and a positive outcome depends on
early recognition, timely diagnosis, and prompt implementation of aggressive treatments.
However, in its early stages sepsis often presents itself in a nonspecific manner making it
difficult to recognize and diagnose. Typical clinical characteristics of sepsis are not
always obvious, sepsis is often underrecognized and its mortality remains high (Silva,
Andriolo, Atallah, & Salomão, 2013).
Sepsis is predominantly detrimental among vulnerable and susceptible populaces
such as the immunocompromised, young children, and older adults. Older age is an
independent predictor of sepsis mortality (Martin, Mannino, & Moss, 2006). Persons
older than 65 years of age with multiple comorbidities are at a higher risk for
complications from infections than the general population. Presentation of early sepsis is
particularly ambiguous in this age group; therefore, a lower threshold and a higher index
of suspicion are required to identify sepsis in older patients (Nasa, Juneja, & Singh,
2012).
Similarly, recognizing sepsis can be delayed in patients with an impaired immune
system such as those with diabetes, HIV/AIDS, hepatic failure, alcohol dependence, or
who had organ transplants. Other high-risk populations are those patients with altered
physiology such as pregnant or postpartum women. Neonates and young infants are at
particularly high risk because they have immature immune systems.
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While sepsis affects people of all ages, races, and genders, it is especially
damaging and more frequently fatal among underprivileged and disadvantaged
populations (Martinet al., 2006). Variations in age, gender, and medical comorbidities
including diabetes and renal failure create additional complexity that influences the
outcomes in septic patients (Iskander, Osuchowski, Stearns-Kurosawa, Kurosawa,
Stepien, Valentine, & Remick, 2013).
Currently, there is no specific single pharmacological intervention or therapeutic
measure for sepsis, with the exception of antibiotics; therefore, the care of septic patients
remains mainly supportive, and even with optimal currently available therapy, septic
patients still experience unacceptably high morbidity and mortality (Iskander, et al.,
2013). Saving lives depends not just on treatments specific to a particular infection, but
rather a focus on early recognition and awareness of sepsis, rapid antimicrobial therapy
and resuscitation, and vital organ support (World Sepsis Day, 2015).
Scope of the Problem
Sepsis is a medical emergency where each hour matters. Chances of survival can
be greatly improved by rapidly recognizing the condition and responding with
appropriate approaches such as appropriate antimicrobial therapy (AAT) and prompt
resuscitation. For many years, the inflammatory dynamics of sepsis have been
incompletely understood. Over two decades ago, sepsis was first recognized as an
inflammatory response to infection, and our understanding of the mechanism of the septic
process and pathophysiology has evolved over time. Years of research and multiple
clinical trials have been conducted; however, optimal treatments and best practice
strategies are still controversial today, partially because the pathophysiology of sepsis is
3

still not entirely understood. Despite best available treatment, sepsis continues to be a
major cause of morbidity and death (Iskander, et al., 2013).
Although implementation of early, rapid, aggressive treatment has improved
mortality, those who survive sepsis frequently suffer from severe long-term consequences
of later onset morbidity, permanent disability, and premature death. Septic patients often
develop recurrent infections, nutritional deficiency, and sustainable organ injury before
leaving the hospital in a debilitated functional state and often are rehospitalized with
returning infection (Iskander, et al., 2013). Many are left with sustainable physical and
mental impairments; some are on permanent hemodialysis or have amputated limbs.
While some studies have shown a positive effect of early aggressive treatment, others
have found no benefit compared with usual care. Optimal sepsis management strategies
still need to be determined, and more research is needed to address the best practice. Our
understanding of the mechanisms and complexity of sepsis pathophysiology presents
substantial challenges to finding innovative treatments. Despite extensive research,
currently available therapies do not provide a cure. A more individualized approach to
developing improved therapeutic response is needed (Iskander, et al., 2013).
It is expected that the incidence of sepsis will continue to grow in a milieu of
antimicrobial resistance, aging populations, wider use of immunosuppressive therapies,
and more accessible medical technology and interventions. Despite an overall decline in
the proportional mortality from sepsis, the total number of patients dying from sepsis is
greater than in the past; moreover, sepsis survivors have increased long-term mortality,
and are often left with considerable functional deficits and decreased the quality of life
(Martin, Mannino, Eaton, & Moss, 2003).
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Mortality
Sepsis is a serious global healthcare problem. More common than heart attack
and claiming more lives than any cancer, sepsis remain major global health problems
with an estimated number of deaths between 15-19 million per year worldwide (Tiru, et
al., 2015). Although sepsis accounted for approximately 2% of all hospitalizations in
2008 in the United States, it was responsible for 17% of hospital deaths, and patients
hospitalized with sepsis were sicker, and stayed longer (Hall, Williams, & DeFrances,
2014). Sepsis is currently the 10th leading cause of death in the United States and the 10th
leading cause of death in South Carolina (Centers for Disease Control and Prevention,
2014).
In developed countries, sepsis is a leading cause of mortality. In the United States
alone, there are 750,000 cases and 200,000 deaths from severe sepsis annually (Wang et
al., 2010). Each year in the United States, sepsis results in 570,000 emergency
department visits, and has a 20% to 50% mortality rate (Perelman School of Medicine at
the University of Pennsylvania, 2013). In 2011, nearly 40% of sepsis cases resulted in
death within 28 days (Stearns-Kurosawa, Osuchowski, Valentine, Kurosawa, & Remick,
2011). In 2014, the overall mortality rate increased to above 50%, with even higher
mortality rates in patients with ischemic bowel, central nervous system (CNS) infection,
disseminated infection, and other intra-abdominal infection. Somewhat lower mortality
rates occur in those with obstructive uropathy-associated urinary tract infection,
enterocolitis/diverticulitis, pyelonephritis, cholecystitis/cholangitis, and intravascular
catheter infection (Leligdowicz et al., 2014).
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Figure I.1. Sepsis Hotspots in the U.S.
Credit: Penn Medicine (Perelman School of Medicine at the University of Pennsylvania, 2013)

Regional Distribution
The regional distribution of sepsis provides important insights. Researchers have
created the first United States map that pinpoints hotspots for infection and severe sepsis
related-deaths (Figure I.1). Areas with the highest sepsis mortality form contiguous
clusters in the Southeastern and mid-Atlantic regions. Researchers have sought to
determine the geographic distribution of sepsis to determine which areas of the country
require vital public health resources and identified “hotspots” with notable clusters
located in the Midwest, mid-Atlantic, and the South (Perelman School of Medicine at the
University of Pennsylvania, 2013).
6

Sepsis in South Carolina. South Carolina has one of the highest sepsis attributed
death rates, ranking 37th in the nation, carrying an inpatient hospitalization mortality rate
of 14%. The annual sepsis incidence rate is 74.4 per 100,000 residents, as compared to
Minnesota’s 41.0 per 100,000 inhabitants (Wang, Devereaux, Yealy, Safford, & Howard,
2010). In South Carolina, sepsis is one of five top all-payer admission drivers; for
Medicare beneficiaries, it is the number one driver of 30-day readmissions (21.3%).
Higher rates of sepsis have been reported among South Carolina’s minorities,
underprivileged, and the elderly. According to United States Census Bureau (2014), 5%
of the Beaufort County population that is 65 years and older lives below poverty level.
Per DHEC’s publicly available data on Hospital Compare website for Beaufort County,
hospitals show the same or lower than the state average rate of the diagnosis of sepsis
(DHEC 2015).
Risk factors
Risk factors for sepsis and death from septic shock include chronic debilitating
conditions such as diabetes, treatment with immunosuppressant drugs, use of invasive
procedures and devices, the presence of lines, catheters, intravascular or prosthetic
devices, and genetic factors (Dellinger et al., 2013). Factors associated with increased
risk of developing sepsis also include complicated obstetric delivery, certain surgeries,
and trauma to the gastrointestinal tract, such as perforation of the small intestine,
infections such as urinary tract infection, pneumonia, cellulitis, meningitis, and many
others (Dellinger, et al., 2013). Additional risk factors for progression to septic shock
include prolonged time between onset of manifestations and initiation of treatment for
sepsis, misdiagnosis of infection, and use of ineffective antibiotics. Extended
7

hospitalization is associated with additional health complications, nosocomial infections,
and increased costs. Elderly patients are more prone to prolonged length of hospital stay
(LOS).
Survivors of sepsis are at increased risk of recurrent infections during the year
following their septic episode. They are 2.83 times more likely to develop a subsequent
infection, 3.78 times more likely to require rehospitalization for infection, and 3.61 times
more likely to die after hospital discharge (Wang et al., 2014). Sepsis has been
associated with the development of at least one new physical limitation for survivors and
a 3-fold risk of developing moderate to severe cognitive impairment (Iwashyna, Ely,
Smith, & Langa, 2010). Sepsis survivors report deterioration in the quality of life related
to poor physical function and overall declined health (Turi & Ah, 2013).
Epidemiology
Incidence. Sepsis can be acquired both in the community and in healthcare
facilities. CDC’s National Center for Health Statistics (NCHS, 2011) estimated
hospitalization with sepsis increased from 621,000 in the year 2000 to 1,141,000 in 2008.
Every minute one patient presents to emergency rooms with severe sepsis (Palleschi,
Sirianni, O’Connor, Dunn & Hasenau, 2014). It is projected that by the year 2020 an
additional 1,000,000 sepsis cases per year will occur in the United States due to the aging
population, the longevity of persons with chronic diseases, the spread of antibioticresistant organisms, an increase in invasive procedures, and increased use of
immunosuppressive and chemotherapeutic agents (Palleschi, Sirianni, O’Connor, Dunn
& Hasenau, 2014). Although epidemiologic data from 2004 to 2009 demonstrated a
decrease in in-hospital mortality from 35% to 26%, severe sepsis is the third most
8

common cause of death in the United States, after heart disease and malignant neoplasms
(Marik, 2014). Moreover, the incidence of sepsis increases an average of 13% every year
(Tiru et al., 2015). As a comparison to the rest of the world, this trend is also seen in
Australia, New Zealand, and in Europe. Population-based studies in the developed world
showed considerably increasing the burden on healthcare systems as populations in these
countries aged (Tiru et al., 2015).
Severe sepsis occurs disproportionally in hospitalized patients, 0.2:1,000 in
children and 26.2:1,000 in adults who are older than 85 years of age (Schub & Schub,
2015). The incidence of severe sepsis and septic shock is growing in the United States
due to the growing number of older adults, as well as high-risk patients in the general
population such as those immunocompromised with diabetes, on chemotherapy, or with
organ transplants. Moreover, increased sepsis occurrence is associated with greater use
of invasive procedures in healthcare settings, the use of broad-spectrum empiric
antimicrobials, and inappropriate prescribing of antibiotic, which promotes breeding of
resistant organisms.
Pathogenesis
The pathogenetic mechanisms associated with sepsis are remarkably complex. In
humans, pathogens are normally eradicated by immune and physiologic responses
restricted to a local infection site and the system returns to homeostasis. Normally the
immune system reacts to a source of infection by localized inflammation, where blood
vessels swell to allow more blood to flow, and become leaky so that the infectionfighting cells and clotting factors can get out of the blood vessels and into the tissues
where they’re needed (World Sepsis Day, 2015).
9

Sepsis is characterized by inappropriate regulation of these normal reactions and
rapid acceleration of the pathologic processes. The normal immune reaction goes to
overdrive affecting all of the body organs and tissues, leading to widespread
inflammation, poor perfusion, organ failure and septic shock (World Sepsis Day, 2015).
A number of biological mechanisms are activated leading to a cascade of events
on molecular and cellular levels, such as upregulation of lymphocyte costimulatory
molecules and rapid lymphocyte apoptosis, delayed apoptosis of neutrophils, enhanced
necrosis of cells and tissues, consequently dysfunctional coagulation mechanisms,
namely inappropriate intravascular fibrin deposition and disseminated intravascular
coagulation (DIC) (Stearns-Kurosawa, Osuchowski, Valentine, Kurosawa, & Remick,
2011). The paradox of DIC in the late stage of sepsis is that the patients are undergoing
nearly unrestricted clotting and, as a result, are at high risk for bleeding because platelets
and coagulation factors are consumed faster than they can be replaced, resulting in
prolonged clotting times. In septic shock organ damage may occur because small clots
form faster than they can be broken down, and they lodge in the microvascular beds of
organs, causing ischemia (Stearns-Kurosawa et al., 2011).
Pathophysiology. Sepsis is a potentially fatal host response to infection that
occurs in association with systemic inflammatory response syndrome (SIRS). SIRS is a
severe inflammatory reaction that is diagnosed when two or more specific criteria are
present, such as high or low temperature, increased heart rate, and respiratory rate,
decreased oxygenation, leukocytosis or leukopenia, and the presence of immature
neutrophils in the bloodstream (Table II.1) (Schub & Schub, 2015). SIRS can occur with
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or without an infection, but sepsis can only be diagnosed when SIRS occurs in a person
with a suspected or confirmed infection (Schub & Schub, 2015).
The sepsis response is a characteristic cascade of mechanisms leading to massive
vasodilation and results in a drop in blood pressure, which in turn inhibits adequate tissue
perfusion that can be associated with a multiple-organ failure. Severe sepsis is
characterized by multiple-organ dysfunction that results in septic shock, which is a severe
sepsis with persistent hypotension despite adequate fluid resuscitation, consequently
leading to death (Schub & Schub, 2015). The pathophysiological basis of sepsis has been
subject to constant change over the last decades. In today's understanding, sepsis is
primarily pathology of the immune system, triggered by an underlying infection but
perpetuated by the host's response itself (Uhle, Lichtenstern, Brenner, & Weigand, 2015).
Sepsis Etiology
The mechanisms of sepsis are not fully understood, making treatment difficult.
Infection is the most common cause of sepsis; however, in many sepsis patients, the
etiology is not clearly identified. Bacteria are by far the most common culprits, but most
types of microbes can cause sepsis, including bacteria, fungi, viruses and parasites such
as those causing malaria (World Sepsis Day, 2015). The bloodstream, skin, respiratory,
gastrointestinal, and genitourinary tracts are common sites of infection associated with
sepsis. Most infections are bacterial in origin but can also be fungal, viral, rickettsial, or
parasitic (Schub & Schub, 2015). The most common pathogens that cause sepsis are
associated with a high risk of hospital mortality are gram-positive bacteria including
staphylococci, enterococci, and streptococci, and from gram-negative spectrum including
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Escherichia coli, Pseudomonas, Klebsiella, Proteus, and Pseudomonas. A list of
common pathogens is shown in Appendix C Table C.1.
Presentation
Sepsis occurs as a result of infections such as pneumonia, urinary tract infections,
skin and wound infections, or from invasive medical procedures. Sepsis presentation
might include fever or hypothermia, hyperventilation, tachycardia, shaking chills, warm
skin, skin rashes, lethargy, confusion, coma, hyperglycemia, muscle weakness, bleeding
diathesis, increased cardiac output, and signs and symptoms that reflect the primary site
of infection (e.g., diarrhea, abdominal pain, and abdominal distention in cases of
gastrointestinal infection; severe headache, neck stiffness, and cervical/submandibular
lymphadenopathy in cases of head and neck infection). Severe sepsis and septic shock
are demonstrated by single or multiple organ failures such as a liver dysfunction (e.g.,
jaundice), cool skin, pancreatitis, renal failure, decreased cardiac output, acute respiratory
distress syndrome, multiple organ dysfunction syndrome, encephalopathy, neuropathy,
and DIC (Kalil, 2015).
Sepsis and Health Disparities
Biology, Geography, Climate, Environment
The type of organism causing severe sepsis is an important determinant of
outcome. Gram-positive organisms as a cause of sepsis have increased in frequency over
time and are now almost as common as gram-negative infections, likely due to greater
use of invasive procedures and the increasing proportion of hospital-acquired infections.
More frequent use of broad-spectrum antibiotics in increasingly sick patients hospitalized
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for longer periods of time resulted in an increased bacterial resistance to antibiotics
(Mayr, Yende & Angus, 2014).
Severe sepsis is more common in colder months. The fatality rate for sepsis is
also higher in winter, despite similar severity of illness. Sepsis related to respiratory
infections has the highest incidence in colder months, whereas genitourinary infections
are more frequent in summer. This seasonal variation relates to climate and is reflected
by the regional differences within the US: incidence variation is highest in the Northeast
and lowest in the South (Mayr et al., 2014).
Disparities among gender, race, age and socioeconomic status. Low
socioeconomic status, older age, male gender, African American race, and increased
burden of chronic health conditions are important risk factors for severe sepsis.
Psychosocial stressors, such as coping styles, housing and neighborhood quality,
consumption potential (e.g. the financial means to buy healthy food, warm clothing, etc.),
and the physical work environment shape health outcomes (WHO, 2010).
Epidemiological studies consistently report a higher incidence of severe sepsis
among Black compared to White patients. The underlying mechanisms of racial
disparities in infection and severe sepsis are poorly understood. A higher prevalence of
chronic kidney disease and diabetes, higher infection rates, overall lower socioeconomic
status and education levels among Black patients may partly explain higher sepsis rates
(Mayr, Yende & Angus, 2014).
Women appear to be at lower risk of developing sepsis than men. Men and
alcoholics are particularly prone to developing pneumonia while genitourinary infections
are more common among women (Mayr, Yende & Angus, 2014). Other determinants
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that shape health outcomes are behavioral factors such as nutrition, physical activity, and
tobacco and alcohol consumption. Mayr et al., (2014) reported an inverse relationship
between socioeconomic status and the risk of blood stream infection. A combination of
race, age, comorbidities and social and environmental factors all contribute to severe
sepsis-related hospitalization rates and poor outcomes. Other risk factors include
residence in long-term care facilities and institutions, malnutrition, immunocompromised
state and utilization of prosthetic devices (Mayr et al., 2014).
Disparities in sepsis incidence and mortality rates are higher for those
underprivileged who live in medically underserved areas (DHHS, 2014). Racial
disparities are associated with residence in medically and economically underserved
areas, median income, percent below the poverty level and educational attainment.
African Americans in South Carolina have a higher overall incidence rate of
hospitalization for sepsis than Caucasians (6.09 vs. 4.74 per 1,000; p<0.0001) (Rice,
Nadig, Simpson, Ford, & Goodwin, 2014). Large disparities exist in the incidence of
sepsis in African Americans, males, and in older adults in South Carolina (Esper, Moss,
Lewis, Nisbet, Mannino, & Martin, 2006).
The risk of dying from severe sepsis is considerably higher in elderly people, with
age as an independent risk factor for mortality (Nasa et al., 2012). Additional risk factors
for the elderly population include the presence of multiple comorbidities, inadequate
financial and healthcare resources, poor nutritional status, and lack of social support.
Infections in older adults often have ominous signs and are underrecognized in this highrisk population (Umberger, Callen, & Brown, 2015). Clinical presentation is often
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atypical, posing challenges in regards to sepsis recognition and leading to a delayed
diagnosis (Girard, Opal, & Ely, 2005).
Sepsis in the elderly population. Sepsis in the elderly population is a common
problem associated with considerable mortality and major consumption of healthcare
resources, and its incidence increases with age. Sepsis carries an unfavorable prognosis
for all age groups, but the elderly are among the most vulnerable and particularly
predisposed to sepsis (Martin et al., 2006). This is attributable to many risk factors such
as the age itself, multiple comorbidities, and the fact that older patients tend to be treated
less aggressively (Destarac & Ely, 2001). Clinicians must be keenly aware of
nonspecific expression of sepsis in this patient population, which include delirium,
weakness, anorexia, malaise, urinary incontinence, or falls (Girard, Opal, & Ely, 2005).
Fever may be blunted or absent, tachycardia and hypoxemia incidences can be lower
among patients with sepsis who were >75 years of age, and compared with younger
patients, tachypnea and altered mental status were more common among older patients
(Girard et al., 2005). Many elderly patients respond well to the evidence-based
diagnostic and management strategies if initiated in a timely manner. Delayed
recognition can lead to treatment failures (Girard et al., 2005).
An estimated 60-65% of all patients who develop sepsis in the United States are
65 years of age or older (Girard et al., 2005). The population of those aged 65 and older
in the United States increased 13.2% from 1990 to 2000 and continues to grow. In 2050,
the number of adults aged 65 and older is projected to double from 2012 and reach 83.7
million (AHR, 2014).
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The aging of the population in developed countries is believed to be largely
responsible for the increased incidence of sepsis (Martin et al., 2006). Those aged 65 and
over tend to be hospitalized for sepsis longer than the average length of stay (LOS), and
had an average LOS that was 43% higher than that of other patients. In those aged 65
and over, 20% of sepsis hospitalizations ended in death compared with 3% for other
reasons for hospitalizations in general (Hall, Williams, & DeFrances, 2014).
Financial Implications
Sepsis is the costliest diagnostic condition. Sepsis ranks number one for all-payer
hospital discharges, exceeding one million discharges a year and representing 5.2% of all
healthcare costs, and consuming 6.9% of Medicare payments annually. Sepsis
contributes to $20.3 billion in aggregate hospital costs to the annual economic burden of
the national healthcare system (Torio & Andrews, 2013). A major factor driving these
expenditures is that the average length of hospitalization for sepsis patients is 75 percent
longer than stays for other conditions (Hall, Williams, & DeFrances, 2014). However,
long-term consequences of sepsis draw attention to the true magnitude of this problem.
The total cost of sepsis treatment and care in the United States has been estimated at $400
billion annually (Lopez-Bushnell, Demaray, & Jaco, 2014). The cost of treating a patient
in the ICU with severe sepsis is 6 times greater than the cost of treating a patient in the
ICU who does not have sepsis (Ahrens & Tuggle, 2004).
As the impact of survivorship increases, the cost to society extends well beyond
lives lost (Tiru et al., 2015). Increased dependence and rehospitalizations of sepsis
survivors increase healthcare consumption and, along with increased mortality, all
contribute to the humanistic burden of severe sepsis (Tiru et al., 2015). While
16

socioeconomic positions shape specific determinants of health status, sepsis accounts for
disproportionate resource utilization and substantial mortality.
Description of the Clinical Problem
Sepsis is a major public health problem. Early identification and treatment save
lives and resources. It is a life-threatening condition that can rapidly progress to severe
sepsis, septic shock, multi-organ failure, and death. It is a serious, costly, often lethal
condition, and a common problem for most hospitals. Despite advances in technology
and some improvement in survival rate over last decade, sepsis continues to have high
mortality and poor outcomes.
Like the rest of the nation, a community-based, 100-bed hospital located in
coastal South Carolina has been experiencing a high incidence and mortality of sepsis
and struggling with poor patient outcomes. This hospital is a part of a large healthcare
organization that is composed of hospitals across the United States. This facility has
implemented the Surviving Sepsis Campaign (SSC) clinical guidelines as new protocols
for sepsis care in efforts to improve outcomes. Prior to the launching of the Sepsis
Bundle program the hospital was using previously established standards of care based on
evidence-based practice, however, these were applied inconsistently per individual
provider discretion. As of October 1, 2015, this hospital has implemented a set of new
protocols for sepsis management, as proposed by SSC guidelines, including the updated
3- and 6-hour management bundles. It included all the newest components of SSC
guidelines and preparation for implementation included staff education. An update to
existing Electronic Medical Record software was also implemented to recognize and
stratify patients with sepsis. The new update allowed the introduction of a new
17

computer-assisted sepsis alert to improve early recognition. The EMR now includes
clinical decision support system that helps to detect patients at risk of sepsis based on
entered values. The system alert is triggered by pre-programmed specific to sepsis vital
signs and laboratory values, and once activated, generates tasks for clinical staff. The
alert is delivered as a pop-up notification to the patients’ designated nurse, who then
electronically contacts a provider. The provider also receives an alert and is obligated to
document that action was taken (Amland, Lyons, Greene, & Haley, 2015). A sepsis
screening assessment task was also integrated into admission order sets in order to
improve the process of determining sepsis risk and facilitate recognition early in the
admission process.
Patient demographic characteristics in this hospital are diverse, but many are
elderly, over the age of 65, and many visiting the area. This demographic profile
accurately reflects population distribution in the county (Table I.1) (United States Census
Bureau, 2014).
Table I.1. South Carolina and Beaufort County Population >65 Demographic

Population, 2014 estimate
Persons 65 years and over, % 2013
(United States Census Bureau 2014).

Selected County

SC State

count
175,852
%
23.3

count
4,832,482
%
15.2

Project Background
Given the specific population characteristic for this hospital, with an average age
of patients with sepsis being 74 years, the original intent of this project was to
retrospectively evaluate elderly patients who were admitted to the hospital with sepsis or
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who developed sepsis while hospitalized. Diagnosing sepsis in this population is more
difficult because elderly patients may have an atypical response and a subtle, ambiguous
presentation of sepsis, such as altered mental status or falls. Therefore, lifesaving
treatments and therapeutic interventions for this population may often be delayed
(Destarac & Ely, 2001). Altered mental status in elderly patients may sometimes be the
sole symptom of sepsis on initial presentation; as a result, there is a high possibility that a
number of these patients are underdiagnosed. Given the atypical presentation of sepsis in
elderly patients, potential underdiagnosis likely contributed to negative outcomes in my
practice setting.
The initial purpose of this project was to illustrate an innovative approach to
initial sepsis screening in the emergency room and inpatient care that could facilitate
earlier recognition of sepsis among the elderly, and potentially improve sepsis survival in
this patient population. This would have been accomplished by adding a short cognitive
assessment to evaluate for acute mental status change, and including it as one of the SIRS
manifestations and a diagnostic criterion for severe sepsis.
While the core clinical staff and leaders were initially supportive, and the majority
of staff agreed that it would be a good step towards improving sepsis recognition among
the elderly, the idea met solid resistance for any attempt for implementation. Upon
further assessment, it became clear that the nursing and clinical staff in both the
emergency department and on units already felt overwhelmed with the number of
assessments required of them, and the notion of one more, even a brief one, was not
welcomed. Additionally, integration of a new assessment into the existing module in the
electronic medical record software could possibly be a difficult and costly process.

19

Given this development, the project was re-routed to focus on current sepsis guidelines
effectiveness and evaluation of their impact on patients’ health outcomes after the
protocol implementation. I am a member of an interdisciplinary team dedicated to
improving sepsis outcomes in this setting, and we are considering potential improvements
in diagnostic technology that would allow earlier identification of pathogens and targeted
treatment.
Evaluation of the success of changes that have already been implemented will
provide valuable data to guide the direction of future practice innovation. For
innovations that require organizational financial outlays, it is necessary to demonstrate
the need for such an investment as well as the potential benefit relative to cost.
Therefore, the first step is to assess the impact of recently implemented protocols.
Purpose of the Project
The purpose of this project was to evaluate the utilization and effectiveness of
current sepsis protocols in a community hospital in coastal South Carolina on health
outcomes. Specifically, to assess whether the protocol affected hospital length of stay,
mortality, morbidity, readmissions, appropriateness of antibiotics utilization, and
influenced the timing of initiating of interventions. Facilitators and barriers were
identified and examined. Findings are to be integrated with collaborative sepsis team
efforts, and the best practice recommendations will be presented to the hospital
administration. The ultimate goal of the project was to facilitate innovative approaches to
diagnostic methods and inpatient care that could improve sepsis treatment approach and
outcomes.
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PICO Question
The PICO question was formulated using the format developed by Melnyk and
Fineout-Overholt (2011) to identify the specific target population, the intervention of
interest, comparison of intervention, outcomes and the time frame.


[P] Population- Population of Selected Subjects



[I] Intervention- Experimental Intervention



[C] Comparison - Comparison of Intervention



[O] Outcomes- Results and Outcomes of Interventions



[T] Time -Time Frame

(Melnyk &. Fineout-Overholt, 2011, para. 4).
The PICO question used to guide this project was: In adult patients presenting with sepsis
before and after October 1, 2015, does implementation of a new sepsis protocol reflect in
improved outcomes such as reduced hospital LOS, decreased mortality, morbidity,
readmissions, and appropriate antibiotics utilization, and does it result in initiating early
treatments as compared to previous approaches?
The focus of the question was to evaluate the effectiveness of early interventions,
further identify the components of the current sepsis “bundles” protocol that are most
effective in the treatment and the most accurate in early recognition of sepsis, and explore
the degree to which the components favor clinical staff compliance and contribute to
improved patient outcomes.
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Definitions
Appropriate Antibiotic Therapy (AAT) in patients with severe sepsis and septic shock
means prompt achievement of antimicrobial’s therapeutic concentration in blood, tissue
penetration, and maintenance of optimal exposure at the infection site with broadspectrum antibiotics administered in a timely manner – as per the guideline protocol (Pea,
& Viale, 2009).
Bacteremia: Invasion of the bloodstream by bacteria (Gale Encyclopedia of Medicine,
2008).
Blood cultures: Incubation of a sample of blood in a suitable culture medium so as to
encourage reproduction of bacteria, which are possible causes of disease, for purposes of
identification (Collins Dictionary of Medicine, 2004).
Bundle: A group of interventions related to a disease process that, when executed
together, result in better outcomes than when implemented individually (Dellinger
&Vincent, 2005, p. 635).
Coagulation: Clotting; the process of changing from a liquid to a solid, said especially of
blood (that is, blood coagulation). In vertebrates, blood coagulation is a result of cascade
regulation from fibrin (Farlex Partner Medical Dictionary, 2012).
Comorbidity: Coexisting medical conditions or disease processes that are additional to an
initial diagnosis (Mosby's Medical Dictionary, 2009).
Crystalloid: A hydration solution that contains only electrolytes; a substance in a solution
that can diffuse through a semipermeable membrane (Mosby's Medical Dictionary,
2009).
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Extravascular: Outside the blood vessels or lymphatics or of any special blood vessel
(Farlex Partner Medical Dictionary 2012).
Fibrin: An insoluble protein that is essential for clotting of blood, formed from fibrinogen
by the action of thrombin (Dorland's Medical Dictionary, 2007).
Hyperventilation: Unusually or abnormally deep or rapid breathing; hyperventilation is
defined as breathing in excess of the metabolic needs of the body, eliminating more
carbon dioxide than is produced, and, consequently, resulting in respiratory alkalosis and
an elevated blood pH. The traditional definition of hyperventilation syndrome describes
"a syndrome, characterized by a variety of somatic symptoms induced by physiologically
inappropriate hyperventilation and usually reproduced by voluntary hyperventilation"
(Folgering, 1999, p. 365).
Hypoperfusion: A condition of acute peripheral circulatory failure due to derangement of
circulatory control or loss of circulating fluid. It is marked by hypotension and coldness
of the skin, and often by tachycardia and anxiety (Miller-Keane Encyclopedia, 2003):
Hypotension: Diminished tension; lowered blood pressure, systolic pressure less than 100
millimeters of mercury (mmHg) (Miller-Keane Encyclopedia, 2003).
ICU: Intensive Care Unit.
Immunocompromised: Also immunosuppressed, having impaired immune system, prone
to infection and more severe infection course.
Initial sepsis presentation: “Time zero” or sepsis onset, or onset of manifestations.
While pinpointing exactly the time of sepsis onset is difficult, if not impossible, it is the
time of reference that specific symptoms characteristic to sepsis were observed and
documented, also a marker for quality measures.
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In vitro: Within a glass; observable in a test tube; in an artificial environment (MillerKeane Encyclopedia, 2003).
Lactic acid: A compound formed in the body in anaerobic metabolism of carbohydrate
and also produced by bacterial action (Dorland's Medical Dictionary, 2007).
Length of Stay (LOS): It is the length of an inpatient episode of care, the number of days
patient stays in a hospital, calculated from the day of admission to day of discharge, and
based on the number of midnights spent in the hospital. Patients admitted and discharged
on the same day have a length of stay of less than one day (McGraw-Hill Concise
Dictionary of Modern Medicine, 2002)
Leukocytosis: An increase in the number of white cells in the blood, especially during an
infection. The presence of more than 11,000 white cells in a cubic millimeter of blood is
considered high.
Morbidity: A diseased condition or state.
Morbidity rate: The number of cases of a particular disease occurring in a single year per
a specified population unit, as x cases per 1000. It also may be calculated on the basis of
age groups, sex, occupation, or another population unit (Mosby's Medical Dictionary,
2009).
Mortality: The death rate, which reflects the number of deaths per unit of population in
any specific region, age group, disease, or other classification, usually expressed as
deaths per 1000, 10,000, or 100,000 (Mosby's Medical Dictionary, 2009).
Multi-drug resistance: The resistance of bacteria, especially against more than two of the
antibiotics that were once effective (Mosby's Medical Dictionary, 2009).

24

Oliguria: Scant urine production, diminished capacity to form and pass urine, less than
500 mL in 24 hours.
Organ hypoperfusion: It may be demonstrated by an increase in serum lactate level,
oliguria, an acute alteration in mentation, or altered circulation to the peripheral
extremities. Organ dysfunction is often evidenced by arterial hypoxemia, acute
respiratory distress syndrome (ARDS), acute renal failure, thrombocytopenia, and/or
disseminated intravascular coagulation (DIC).
Pathogen: Any disease-producing agent or microorganism (Miller-Keane Encyclopedia,
2003):
Pathophysiology: The study of structural and functional changes in tissue and organs that
lead to disease, also derangement of function seen in disease; alteration in function as
distinguished from structural defects (Farlex Partner Medical Dictionary, 2012).
Perfusion: The act of pouring through or over; especially the passage of a fluid through
the vessels of a specific organ (Miller-Keane Encyclopedia, 2003).
Permeability: A condition of the capillary wall structure that allows blood elements and
waste products to pass through the capillary wall to tissue spaces (Mosby's Medical
Dictionary, 2009).
Polymerase chain reaction (PCR): A rapid technique for in vitro amplification of specific
DNA or RNA sequences, allowing small quantities of short sequences to be analyzed
without cloning (Miller-Keane Encyclopedia, 2003).
Readmission or rehospitalization: Defined as an admission to a hospital within 30 days of
a discharge (CMS, 2014). The return of a patient to inpatient hospital care shortly after
discharge (typically within 30 days of discharge) (Farlex Medical Dictionary, 2009).
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Sepsis: Referred to as bloodstream infection or blood poisoning, infections are the cause
of sepsis and can originate anywhere from within the body. It is the presence of various
pathogenic organisms, or their toxins, in the blood or tissues (Farlex Partner Medical
Dictionary, 2012). Some of the more common sites include liver or gallbladder, kidneys,
lungs, bowel, and skin (Medline Plus, 2006).
Severe Sepsis: It is the presence of defined sepsis in addition to organ damage,
hypoperfusion, organ dysfunction, or hypotension. A condition defined clinically as
'Sepsis associated with organ dysfunction, hypotension, or hypoperfusion abnormalities
such as lactic acidosis, oliguria, or an acute alteration in mental status; it is part of a
continuum of a biologic inflammatory response to infection that evolves toward septic
shock (McGraw-Hill Concise Dictionary of Modern Medicine, 2002).
Septic shock: A possible consequence of bacteremia; bacterial toxins, and the immune
system response to them, cause a dramatic drop in blood pressure, preventing the delivery
of blood to the organs, despite resuscitative attempts. Septic shock can lead to multipleorgan failure including respiratory failure, and may cause rapid death (Gale Encyclopedia
of Medicine, 2008).
Tachycardia: An abnormally rapid heart rate, especially one above 100 beats per minute
in an adult (American Heritage Dictionary, 2011).
Vasodilation: Widening of the lumen of blood vessels (Farlex Partner Medical Dictionary
2012).
Vasopressor: A drug producing vasoconstriction and a rise in systemic arterial blood
pressure (Farlex Partner Medical Dictionary, 2012).
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Supporting Framework
Model for improvement
A model for improvement was utilized as the framework and guide for this
quality improvement project. The model is based on W. Edwards Deming’s Plan-DoStudy-Act (PDSA), which has been widely used in healthcare improvement programs
(Langley et al., 2009). PDSA cycles provide a structure for iterative testing of changes to
improve the quality of systems. This method tests a change before its implementation by
planning it, trying it, observing the results and acting on what is learned with the overall
objective of improving the process or outcome (Van Tiel et al., 2006). The PDSA cycle
presents a pragmatic scientific method for testing changes in complex systems (Moen &
Norman, 2006) and in a small scale. These pragmatic principles of PDSA cycles endorse
measurements over time to assess the impact of interventions, promote prediction of the
outcome, and allow the use of small-scale, iterative approaches to test interventions,
which enables rapid assessment and provides flexibility to adapt the change (Taylor et al.,
2014).
The four stages - plan, do, study, and act - mirror the scientific experimental
method of formulating a hypothesis, collecting data to test this hypothesis, analyzing and
interpreting the results and making inferences to iterate the hypothesis (Speroff &
O'Connor, 2004). There are two similar approaches to process improvement: a Plan-DoStudy-Act (PDSA) (Langley et al., 2009) and Plan-Do-Check-Act (PDCA) (Bushell,
1992). The PDSA cycle was originally developed by Walter A. Shewhart as the PDCA
cycle. W. Edwards Deming modified Shewhart's cycle to PDSA, replacing "Check" with
"Study." The terms PDSA and PDCA are often used interchangeably in reference to the
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method (Taylor et al., 2014). For the purpose of this project, both PDSA and PDCA are
considered but I refer to the methodologies generally as ‘PDSA’ cycles unless otherwise
stated. Both methods are broadly accepted in healthcare process improvement activities
(Taylor et al., 2014).
The process’ cycles provide a structure for repetitive testing of changes to
improve the quality of systems, and require that plans be tested on a small scale before
implementing them system-wide. The method also builds continuous improvement into
planning through data collection on the effectiveness of the new process or change
(Bushell, 1992). The PDSA method to improve quality in healthcare is a change model
that aims to generate advance in processes and outcomes.
The PDSA model includes two components, which comprise three improvement
questions, and the PDSA cycle (Langley et al., 2009). Figure I.2 provides a visual
representation of the model for improvement. The objectives of the improvement
questions are to establish groundwork to guide improvement efforts, subsequently to set
measurable goals, quantify measures to demonstrate improvement, and choose variables
(Institute for Healthcare Improvement, 2014). The three improvement questions are:
1. What are we trying to accomplish?
a. Set aims: identify sepsis protocols’ features (individually selected
components) that made a difference in the specific population.
b. Summarize outcomes and compare findings for both preimplementation and post-implementation groups.
c. By using data, substantiate the need for improvement and recommend
practice change.
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d. Establish and corroborate support system for this evidence-based
project.
2. How will we know that a change is an improvement?
a. Based on scientific literature establish benchmarks for review, collect
data and measure outcomes. Changes should reflect in the measures.
3. What changes can we make that will result in improvement?
a. Form a dedicated team, stakeholders buy-in and involve people in the
decision-making process (Langley et al., 2009).
The second part of the model in the PDSA cycle, also called the Deming Cycle, is
a four-step approach to solving problems, described as the trial-and-learn process
allowing identification of the most effective solution before implementation. The method
follows a prescribed four-stage cyclic learning approach to adapt changes aimed at
improvement. In the ‘plan’ stage a change aimed at improvement is identified, the ‘do’
stage sees this change tested, the ‘study’ stage examines the success of the change and the
‘act’ stage identifies adaptations and next steps to inform a new cycle (Taylor et al., 2014,
para. 7).
Step one: Plan
The process starts by identifying the problems (i.e., delayed recognition and
treatment of sepsis) and pinpointing the root cause(s), and this was accomplished by
asking a cascade of why questions.
1. Define objectives and identify problems such as delayed recognition and
treatment of sepsis leading to high mortality and morbidity, and long waiting
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time for culture results, consequently inappropriate antibiotic utilization that
promotes breeding of MDR organisms.
2. Ask the PICO question and plan to answer the question.
3. Plan data collection to answer the question.
4. Recognize barriers, enabling factors, and potentially modifiable factors for
sepsis management in hospitalized adults, while attempting to pinpoint the
root cause.
5. Develop a pragmatic strategy to overcome barriers. Determine which issues
are most significant and modifiable, which can be influenced by interventions,
and which factors to manipulate in order to create changes.
Step two: Do
Potential solutions were assessed and the most practical solution determined.
Many options must be taken into consideration such as stakeholders buy-in and the
budget. In my practice setting, new sepsis protocols have been implemented, while
additional solutions are under consideration.
1. Start to conduct study protocol by collecting baseline data and illustrating
demographic characteristics.
2. Collect data for follow-up measures and data analysis.
3. Analyze data.
Step three: Study, or Check
In this phase data were analyzed, outcomes evaluated and results summarized,
and any problems in the implementation of the designed intervention were identified
1. Examine and interpret results.
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2. Compare patients’ outcomes before and after sepsis guidelines
implementation, and evaluate the impact of practice change on outcomes.
3. Evaluate compliance with each element of the new sepsis guidelines to
compare the post-intervention group to prior performance to achieve a clearer
picture of Sepsis Bundles impact on health outcomes.
4. Based on obtained results evaluate the need for practice change.
Step four: Act
This stage is to determine the overall success or failure of the intervention and to
identify potential modifications to improve the intervention strategy. If necessary, new
changes are implemented, and the cycle repeats again starting at the first step. This step
is implemented in the practice setting following completion of the project.
1. Prepare and plan for the next PDSA cycle.
It is important to remember that this plan is circular. The benefits of PDSA are that it
provides standardized methods to achieving continuous improvement. If used correctly it
is time efficient, prevents implementing ineffective solutions and promotes teamwork.
This project reflects the evaluation of outcomes following the implementation of initial
practice changes, and the review of evidence may result in recommendations for further
action. (See Appendix D, Figures D.1 and D.2 for PDCA cycle template and PDSA
worksheet).
The cycle can be refined and repeated for Continual Process Improvement (CPI).
Process evaluation is used to monitor and document program implementation and can aid
in understanding the relationship between specific program elements and program
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outcomes. The evaluation model is based on CDC’s Framework for Program Evaluation
Steps: (German et al., 2001).
1. Engage stakeholders.
2. Describe the program.
3. Focus the evaluation design.
4. Gather credible evidence.
5. Justify conclusions.
6. Ensure use and share lessons learned.
Plan-Do-Study-Act Worksheet can be used as a tool for documenting the test of change.
See Appendix D, Figure D.1 and D.2 for PDSA worksheets and a template.

Figure I.2.2Model for Improvement
(Institute for Healthcare Improvement, 2014). (Langley et al., 2009, p. 24)
Used with permission; source: The Improvement Guide: A Practical Approach to Enhancing
Organizational Performance, 2nd Edition, Gerald Langley, Ronald Moen, Kevin Nolan, Thomas
Nolan, Clifford Norman, Lloyd Provost. Jossey-Bass Pub., San Francisco, 2009.
See Appendix L, Figures L.1 and L.2 for permission to use images.
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Summary
Despite advancing technology, availability of broad-spectrum antibiotics,
improved ability to manage infections, and modern intensive care, sepsis is still
associated with a substantial morbidity and mortality. Severe sepsis and septic shock
represent challenging problems for the healthcare system. While aggressive supportive
care with intravenous fluids and prompt antibiotics administration are critical, early
recognition is paramount. Precise isolating and identification of causative pathogens will
result in earlier de-escalation from broad-spectrum antimicrobials to targeted treatment
with the most appropriate antibiotics. Consequently, this can result in lowering the
chances of breeding multi-drug resistant organisms, reducing readmission rates, and lead
to improved outcomes and reduced costs. Collaborative work of interprofessional teams
and appropriate use of resources in approaches to sepsis treatment will positively affect
healthcare outcomes (Vazquez-Grande & Kumar, 2015). The following chapter contains
a review of the recent literature on the sepsis guidelines effects on patients’ outcomes.
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CHAPTER II
LITERATURE REVIEW
This chapter describes the results of a search for evidence for best practices to
promote early identification and management of sepsis in the clinical setting. It outlines
the search process and analysis of the evidence that was used to guide the project and
subsequent recommendations.
Search Process
A comprehensive literature review was conducted in search of evidence to
support recommendations for the practice innovation proposed in this paper. The process
of literature review and analysis of evidence utilized the Cumulative Index of Nursing
and Allied Health Literature (CINAHL), and CINAHL Plus, Cochrane Library, PubMed,
OvidSP, EbscoHost, Agency for Healthcare Research and Quality (AHRQ), National
Guideline Clearinghouse databases, Google Scholar, and other evidence-based resources.
Keywords and phrases used in the search for literature were: sepsis, severe sepsis, septic
shock, septicemia, sepsis guidelines, inpatient sepsis, sepsis bundle, bundle treatment,
SSC, and EGDT. Initial literature searches returned 27,773 articles; however, many of
those were either not supportive or not pertinent to the PICO question. Therefore, limits
and modifiers were applied to the search process in order to narrow results to studies that
were specific to the population of interest, measured patient outcomes in contrast to
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interventions, and relevant to this project. Filters included human subjects, adults,
articles published in the last ten, then last five years, clinical trials, randomized controlled
trials, controlled clinical trials, meta-analysis, systematic review, and peer-reviewed
journal articles.
A CINAHL database search was conducted and it was limited to full-text journal
articles published within last 10 years, between the year 2006 and 2016 which produced
2932 text results. Abstracts were reviewed, and in order to narrow the search and capture
the most recent publications, the search was further constricted to include a new time
frame from the year 2010 to 2016, with the same keywords and phrases used. Inclusion
criteria were hospitalized adults who were diagnosed with sepsis. After duplicates were
removed, a total of 66 potentially relevant publications were identified, of which 46 were
excluded, and 26 articles that could potentially contribute to answering the PICO
question were saved for further appraisal as supporting evidence. Cochrane Library
database search limited to trials published within last five years included the same search
terms: sepsis outcomes, treatment, guidelines, hospitalization, returned 28 full-text
results. Three of those results of high scientific power were relevant to the clinical
problem for this project. OvidSP database search returned 53 text results (search terms
used: malnutrition and elderly and hospital), and four were found to be relevant to the
clinical question. Lastly, further reapplication of the review inclusion criteria was
performed and search narrowed to full-text articles, and a final list of a total of 32
potentially relevant publications meeting criteria were selected.
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Review of the Literature
Overview of the Evidence
The following PICO question guided this extensive literature review and this
project: In adult patients presenting with sepsis before and after October 1, 2015, does
implementation of a new sepsis protocol reflect in improved outcomes such as reduced
hospital LOS, decreased mortality, morbidity, readmissions, and appropriate antibiotics
utilization, and does it result in initiating early treatments as compared to previous
approaches?
Several studies provided evidence-based practice strategies that focused on sepsis
management. Subsequently, by utilizing the criteria for evaluating studies (Melnyk &
Fineout-Overholt, 2011), 21 publications that offered supporting evidence and were
relevant to this project were selected. Articles were organized by type of study, and
quality rating. An evidence table was developed, highlighting threats to validity and
reliability, findings, and conclusions for each of the 21 articles selected (Appendix A,
Table A.1). Consequently, upon completion of the selection process, articles were
systematized accordingly to the level of evidence rating using the Evidence Level and
Quality Guide by Johns Hopkins Nursing Evidence-Based Practice: Model and
Guidelines (Dearrholt, 2012) (Appendix B, Table B.1).
The quality rating system provided an evaluation guide methodology where
studies were assigned a numerical and alphabetical value based on their level of evidence.
Level I was applicable for experimental studies, randomized controlled trial (RCT), and
systematic review of RCTs with or without meta-analysis. Level II was appropriate for
quasi-experimental studies, a systematic review of a combination of RCTs and quasi36

experimental, or quasi-experimental studies only, with or without meta-analysis. Level
III applied to non-experimental study, a systematic review of a combination of RCTs,
quasi-experimental and non-experimental studies, or non-experimental studies only, with
or without meta-analysis, qualitative study or systematic review. Level IV applied for the
opinion of respected authorities and/or nationally recognized expert committees or
consensus panels based on scientific evidence. Level V was assigned to studies based on
experiential and non-research evidence. Articles were also rated using quality guides and
assigned a letter A for high quality, B for good quality, C for low quality or presence of
major flaws.
Analysis of Evidence
Historical development of sepsis definition and guidelines
In 1991, a North American consensus conference introduced the idea that sepsis is
the host's inflammatory response to infection, and SIRS was defined by four variables:
temperature, heart rate, respiratory rate, and white blood cell count (Bone et al., 1992).
In 2001, a second consensus conference revisited the SIRS definition, expanded the list
of potential clinical criteria, but inadvertently made it less specific (Vincent et al., 2013).
As of October 1, 2015, the Center for Medicare and Medicaid Services (CMS) has
issued new benchmarks for the care of severe sepsis and septic shock (Figure II. 1) that
all hospitals in the U.S. must meet (Baciak, 2015). Current guidelines utilize several
different definitions for sepsis, including sepsis, severe sepsis, and septic shock along
with complicated strategies for systemic inflammatory response syndrome (SIRS) criteria
(Table II.1 and Figure II.2). Both SIRS and severe sepsis definitions raise controversies
among clinicians (Baciak, 2015). The severe sepsis definition was derived from SSC
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guidelines published in 2012 and based on 2003 International Sepsis Definition
Conference (Dellinger et al., 2013). SIRS and organ dysfunction definitions may be
inconsistent in some cases. For example, based on the current definitions virtually all
end-stage kidney or liver disease patients experiencing mild viral upper respiratory
infection producing fever or leukocytosis would meet the criteria of severe sepsis and
may consequently be overtreated (Baciak, 2015).

Figure II.1.3Sepsis Treatment Benchmarks
(Baciak, 2015, p. 1)
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Table II.1.2Criteria for SIRS
Criterion

Value

Temperature

>38°C or <36°C

Heart rate

>90 beats per minute

Respiratory rate

>20 or PaCO2<32 mm Hg

White blood cell count

>12 K or <4 K mm−3, or >10% bands

For a diagnosis of SIRS to be made, two of the four criteria need to be present (Schub & Schub,
2015).

Figure II.2.4Severe Sepsis, Organ Dysfunction, and Septic Shock Definitions

(Baciak, 2015, p. 1)
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Systemic Inflammatory Response Syndrome
The Systemic Inflammatory Response Syndrome (SIRS) concept creates many
controversies by being very nonspecific but very sensitive at the same time, meaning that
a great majority of patients admitted to an ICU every day meet the SIRS criteria (Table
II.1). SIRS can be caused by many non-infectious clinical processes or sterile
inflammation such as severe trauma, burns, pancreatitis, and ischemic events. If SIRS is
defined in the presence of infection, almost every acutely ill patient would meet the SIRS
criteria; therefore, all septic patients have a known or unknown source of infection, but
not all infected patients are septic (Vincent et al., 2013). Further, almost all infections,
minor of major, are associated with fever - a natural body response to the presence of the
pathogens. Fever is usually associated with tachycardia, leukocytosis, and even
hyperventilation; nevertheless, the absence of this response may occur in the presence of
microbial colonization or host’s immunocompromised status, two very different clinical
scenarios, not necessarily meaning sepsis (Vincent et al., 2013). Moreover, several such
stressors might be present simultaneously in any patient, making sepsis difficult to
diagnose. Since symptoms of sepsis can be vague especially in its early stage, all the
more difficult, if not impossible, is zeroing in on the time of initial sepsis onset, such an
important point of reference in current treatment guidelines and a marker for quality
measures. The more accurate is a different definition of sepsis, where sepsis is not
simply the host response to an infection or inflammation, but it is the “host's deleterious,
non-resolving inflammatory response to infection that leads to organ dysfunction”
(Vincent et al., 2013, para. 7).
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Guidelines development
In 1991, sepsis was first recognized as a systemic inflammatory reaction to
infection. In the following decade, a spotlight was shone on sepsis treatment and a new
approach was introduced to emergency departments (ED). In 2001, a landmark article by
Rivers et al. titled “Early Goal Directed Therapy (EGDT) in the Treatment of Severe
Sepsis and Septic Shock” (2001) documented a noteworthy short-term and long-term
mortality benefit when EGDT was implemented at the earliest stages of severe sepsis and
septic shock. The concept of EGDT was treating septic patients early while still in the
ED. (Rivers et al., 2001). Rivers et al. (2001) showed that utilizing EGDT resulted in
marked improvement in mortality compared to standard care.
The EGDT was the first structured approach that guided the first six hours of
resuscitation with more IV fluids, ionotropic support, blood transfusions; it involved
insertion of central line and central venous pressure (CVP), central venous oxygen
saturation (ScVO2) and mean arterial pressure (MAP) measures (Yealy et al, 2015).
Interventions were delivered according to specific hemodynamics, including CVP
endpoint 8-12 mmHg, MAP ≥ 65 and ScVO2 > 70% (Rivers et al., 2001). The single
center randomized trial enrolled relatively a small sample of 130 treatment and 133
control patients. The study demonstrated in-hospital mortality was 30.5% in the group
assigned to EGDT, compared to 46.5% in the standard therapy group in short-term
treatment (p=0.009). Mortality was 33.3% in EGDT group (p=0.01) compared to and
49.2% in the control group in 28-day mortality rate, and 44.4% EGDT group (p=0.03) to
56.9% standard therapy groups in 60-day long-term mortality outcomes (Rivers et al.,
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2001). Given those findings, central catheter driven approach became a mainstream
treatment for sepsis at that time.
In 2002, a collaborative effort among the Society of Critical Care Medicine, the
European Society of Intensive Care Medicine, and the International Sepsis Forum
resulted in the formation of the Surviving Sepsis Campaign (SSC) (Society of Critical
Care Medicine, 2014). SSC is a global initiative formed to reduce sepsis-related
mortality and improve short and long-term outcomes. For the past decade, SSC has been
in the frontline leading the efforts to improve sepsis outcomes worldwide. Based on
literature and expert opinion, SSC developed, and published, clinical practice
recommendations for management of severe sepsis and septic shock, which are focused
on increasing provider awareness and promoting early intervention (Haddad, Slesinger,
Wie, & LoVecchio, 2015). The SSC endorsed EGDT and proposed this approach as a
key strategy to decrease mortality among patients with severe sepsis or septic shock.
Since 2002, the Surviving Sepsis Campaign (SSC) has been promoting best
practice guidelines that optimize oxygen delivery and tissue perfusion, thus increase
patients’ chances of survival. EGDT involving a six-hour resuscitation protocol became
at that time the best practice strategy with objectives to maintain adequate organ
perfusion, control infection, limit barotrauma due to mechanical ventilation, and control
hyperglycemia (Haddad et al., 2015).
In 2010, another study demonstrated the superiority of lactic acid measurement
that involved simple peripheral venous blood draw over invasive CVP and ScvO2
measurements which required central line insertions (Jones, Shapiro, Trzeciak, Arnold,
Claremont, Kline, & Emergency Medicine Shock Research Network Investigators, 2010).
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Jones et al. (2010) evaluated lactate clearance efficacy versus central venous oxygen
saturation measurement. The results of this randomized controlled trial indicated that
measurement of lactate clearance; a quicker and more non-invasive measurement can be
an equally effective alternative to ScvO2 monitoring in goal-directed resuscitation. In
light of this evidence, the guidelines were revised and incorporated 3- and 6-hour
management bundles. The updated 2012 recommendations guidelines included these 3and 6- hour management bundles. They mandated measurement of lactate level,
obtaining blood cultures prior to administration of antibiotics, administering broadspectrum antibiotics, and infusing crystalloid fluids at a rate of 30 mL/kg for hypotension
or lactate > 4mmol/L (36 mg/dL) to maintain adequate MAP within three hours from
onset of sepsis. If hypotension does not respond to initial fluid resuscitation, the
guideline recommended administering within six hours vasopressors (for refractory
hypotension) to maintain MAP ≥ 65. In the event of persistent arterial hypotension
despite volume resuscitation, or if initial lactate was > 4 mmol/L (36 mg/dL), it is
recommended to monitor CVP and ScvO2 and re-measure lactate if initial lactate was
elevated. Targets for quantitative resuscitation included in the guidelines are CVP of > 8
mm Hg, ScvO2 of > 70%, and normalization of lactate (Haddad et al., 2015).
Dellinger, Levy, and Townsend (2010) showed an association between
compliance with the SSC Sepsis Bundles and decrease in sepsis mortality. In 2012, the
first national practice guidelines were endorsed by National Quality Forum (NQF) for the
management of severe sepsis and septic shock (Dellinger, 2015). These NQF 2012
guidelines named Sepsis 0500 included the seven components to be completed within
three- and six-hour period.

43

Under those guidelines, septic patients were undergoing invasive procedures such
as central venous catheters (CVC) insertion that unnecessarily delayed lifesaving
treatments. In 2014, the guidelines were revised in view of more new evidence based on
multicenter randomized trials the ProCESS and the ARISE studies. Both trials
demonstrated the lack of necessity for using invasive CVC insertion procedure for
monitoring CVP and ScvO2 as resuscitation measures. Given these results, NQF
guidelines were revised taking into account the above findings (SSC, 2014).
The paramount underpinning of these protocols has been an aggressive and early
treatment. SSC partnered with Institute for Healthcare Improvement (IHI) to incorporate
the concept of sets of sepsis management strategies into the diagnosis and treatment of
sepsis (SSC, 2014). The new guidelines included the same recommendation for
maximum allowed time frames for drawing blood cultures and lactic acid levels,
administering empiric antibiotics and providing IV fluids to patients with suspected
sepsis, but did not mandate CVP and ScvO2 measurements if other conditions are met.
For instance, patients presenting to ED with symptoms suspicious for sepsis, should have
blood drawn for serum lactate level and blood cultures, prior to administration of
antibiotics and broad spectrum IV antibiotics administered within three hours of triage
(time zero). However, delaying antibiotic administration in order to obtain blood cultures
was not recommended. If lactate level is 4mmol/L or higher or patients are hypotensive,
IV fluids are infused at a rate of 30 mL/kg. Subsequently, if patients do not respond to
initial fluid resuscitation, vasopressors are administered to maintain MAP at or above
65mmHg. If no adequate response is achieved, fluid volume is re-assessed by a focused
exam and two additional specific measures, which may include measurement of CVP and
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ScvO2, bedside cardiovascular ultrasound or dynamic assessment of fluid responsiveness
with passive leg raise or fluid challenge (Table II.2 and Table II.3) (SSC, 2014).
The guidelines were recognized and incorporated as new protocols for standards
of care, and have been serving as benchmarks for quality measurements (Haddad et al.,
2015). Since October 1, 2015, Center for Medicare and Medicaid Services (CMS)
mandated measurement of sepsis outcomes (SEP-1). This performance measure named
Early Management Bundle; Severe Sepsis/Septic Shock has been endorsed by NQF.
Consistent with Surviving Sepsis Campaign guidelines, it assesses measurements of
lactate, obtaining blood cultures, administering broad spectrum antibiotics, fluid
resuscitation, vasopressor administration, reassessment of volume status and tissue
perfusion, and repeat lactate measurement within three and six hours of presentation
(Joint Commission, 2014).
Current Practice
The SSC has been the leader in putting forth sepsis management guidelines and
best practice recommendations based on recent literature and expert opinion for decades.
In October 2012 NQF endorsed the management bundles and came forth the first national
sepsis guidelines in the United States (NQF 0500) that also currently serve as a
benchmark for healthcare quality measures for healthcare providers and federal
government (D’Amore et al., 2015). In light of new evidence published in the ProCESS
and the ARISE trials; the NQF Patient Safety Standing Committee reviewed the 0500
measure in April 2014, and removed mandatory CVP and ScvO2 monitoring (SSC,
2014). The protocol continues to be considered the appropriate approach to sepsis at this
time and the components are used as a quality measure matrix (Table II.2 and Table II.3).
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Table II.2.3SSC 3- and 6- hour Bundles
.
To be completed within 3 hours of
To be completed within 6 hours of time of
time of presentation*:
presentation
1. Measure lactate level
5. Apply vasopressors (for hypotension that does
not respond to initial fluid resuscitation) to maintain
a mean arterial pressure (map) ≥65mmhg
2. Obtain blood cultures prior to
administration of antibiotics

6. In the event of persistent hypotension after initial
fluid administration (map < 65 mm hg) or if initial
lactate was ≥4 mmol/l, re-assess volume status and
tissue perfusion and document findings according to
Table II.3.

3. Administer broad-spectrum
7. Re-measure lactate if initial lactate elevated.
antibiotics
4. Administer 30ml/kg
crystalloid for hypotension or
lactate ≥4mmol/L
* “Time of presentation” is defined as the time of triage in the emergency department or, if
presenting from another care venue, from the earliest chart annotation consistent with all elements
of severe sepsis or septic shock ascertained through chart review (SSC, 2014, para. 3).

Table II.3.4Sepsis Reassessment.
Document reassessment of volume status and tissue perfusion with the following:
Either
Or two of the following:
 Repeat focused exam (after initial
 Measure CVP
fluid resuscitation) by licensed
independent practitioner including
 Vital signs
 Measure ScvO2
 Cardiopulmonary, capillary refill
 Bedside cardiovascular ultrasound
 Pulse
 Dynamic assessment of fluid
responsiveness with passive leg raise
or fluid challenge
 And skin findings
(SSC, 2014, para. 4)

Updated definition of sepsis.
The terms of sepsis, severe sepsis, and septic shock have been used sometimes
interchangeably or inappropriately, and the actual definition of sepsis has not been
revised in over a decade. Meaningful progress has been made in medicine and
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technology since 2001. The sepsis definition was recently updated for the first time in 15
years by an international task force that included 19 experts in sepsis pathology,
epidemiology, and clinical trials. Definitions and clinical criteria were generated through
meetings, Delphi processes, analysis of electronic health record databases, and voting,
followed by circulation to international professional societies, requesting peer review and
endorsement. In 2016, the Society of Critical Care Medicine and the European Society of
Intensive Care Medicine released the Third International Consensus Definitions for
Sepsis and Septic Shock (Sepsis-3) re-defining sepsis (Singer et al., 2016). New criteria
were added for septic shock, and the standards for rapid sepsis shock recognition were
simplified. The concept of SIRS with its low specificity and high sensitivity lead to
misinterpretations and discrepancies in reported incidence and observed mortality,
therefore, it was eliminated (Singer et al., 2016).
According to Singer et al. (2016), too much emphasis has been placed on
inflammation, which is misleading, giving the impression that the sepsis process moves
in a sequence from sepsis through severe sepsis to septic shock. Singer et al. (2016)
defined sepsis as a “life-threatening organ dysfunction caused by a deregulated host
response to infection” (para. 4). The new definition offers better consistency for
epidemiologic studies and clinical trials. It allows for more reliable uniform data
collection methods for incidence and mortality reporting, and would facilitate earlier
recognition of sepsis, thus better timely management of this serious condition (Singer et
al., 2016).
Instead of diagnostic criteria known as SIRS, the new definition relies on known
or suspected infection with a change in Sequential Organ Failure Assessment (SOFA)
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score ≥ 2, or a modified quick SOFA. However, adoption of the new approach in many
hospitals will likely be hindered by CMS that still uses the SIRS-plus suspected infection
approach for description of sepsis as a benchmark for quality measures, for determining
payment and compliance with performance metrics such as the SEP-1 measure.
Shortly after the publication of the new sepsis definition, Simpson (2016)
expressed concern that the new definition may de-emphasize interventions at earlier
stages of sepsis when the syndrome is actually at its most treatable phase. Moreover,
over-simplifying the definition of sepsis, especially in light of still not precisely
understood pathophysiological features that define sepsis may inadvertently cause more
confusion (Simpson, 2016).
While the key is to simplify, not to further complicate, initial patient assessments
in order to expedite appropriate treatment initiation, ultimately all patients with sepsis
must receive optimal aggressive treatment. Regardless of definition, it is critical to
continue to strive to recognize sepsis early and initiate aggressive treatments for all forms
of sepsis.
Controversies of Sepsis Guidelines
Early Goal Directed Therapy: EGDT
In 2001, Rivers et al. published a single-center, randomized trial of protocolized
resuscitation for patients presenting to the emergency department (ED) with a septic
shock. The protocol included specific, 6-hour resuscitation algorithm, namely the EGDT.
Prior to the introduction of EGDT, goal-directed therapy (GDT) was utilized for severe
sepsis and septic shock in ICUs. Rivers et al. (2001) utilized a small sample of 236
patients, and the trial presents external validity threat due to single-center study, raising
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concerns for generalizability of the results. EGDT targeted primarily arterial and central
venous pressure and a ScvO2. SSC guidelines have endorsed EGDT since 2004, and a
number of following non-randomized, predominantly before–after studies subsequently
reported the benefit of EGDT on outcomes (Angus et al., 2015). However, based on new
evidence, the overall effectiveness of EGDT is uncertain. Recent studies have shown
conflicting results, including questionable benefits of some components of EGDT on
survival rate and length of hospital stay (LOS) (Zhang, Zhu, Han, & Fu, 2015).
Recently, the efficiency of EGDT has been called into question. Three
multicenter prospective randomized trials investigated the efficiency of EGDT: ProCESS
(Protocolized Care for Early Septic Shock), ARISE (Australasian Resuscitation in Sepsis
Evaluation) and ProMISe. (Delaney et al., 2013; Mouncey et al., 2015; Yealy et al.,
2014). Results of these three multicenter prospective randomized trials demonstrated no
significant decrease in sepsis morbidity or mortality when patients were treated with a
strict protocol-based resuscitation strategy over usual care at the discretion of the treating
physician.
The ProCESS trial evaluated whether all aspects of the original EGDT protocol
(Rivers, 2001) were necessary. Thirty-one academic EDs across the United States
participated in this study. A total of 1,341 patients meeting criteria for severe sepsis and
septic shock were included in data analysis; 439 patients received EGDT according to the
original protocol, 456 control patients received standard care, and 446 patients received
protocol-based standard therapy. Despite more aggressive therapy in the protocol-based
groups, there was no significant difference in 60- and 90-day mortality between the
treatment groups. There were no significant differences in the incidence and duration of
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cardiovascular or respiratory failure, LOS, in sepsis morbidity or mortality when patients
were treated with a strict protocol-based resuscitation strategy over usual care at the
discretion of the treating provider. This study outlined a protocol for administration of
fluid and vasoactive agents to reach goals for systolic blood pressure, shock index, and
fluid status, without mandating invasive venous access, aggressive blood transfusion, and
inotropic support. A combination of EGDT and protocol based therapy offers no survival
benefits as compared to not-protocol-based usual care. Generalization across various
healthcare settings and outside of the United States is uncertain, and more evidence is
needed (Yealy et al., 2014).
The ARISE multicenter prospective, randomized trial was designed to test the
EGDT hypothesis as compared to usual care (Delaney et al., 2013). This trial was
conducted from 2008-2014 at 51 tertiary care and non-tertiary care metropolitan and rural
hospitals across Australia and New Zealand, with 796 patients receiving care based on
the original EGDT resuscitation algorithm, and 804 control patients receiving usual care
at the discretion of the treating physician. The study results demonstrated that patients in
the EGDT group were more likely to receive vasopressor infusion, red-cell transfusion,
and dobutamine infusion. However, despite an increased rate of aggressive therapy, there
was no significant difference in 28- and 90- day mortality, hospital mortality, organ
support and LOS between the two treatment groups. Adherence to the EGDT algorithm
offered no survival advantage over usual care for patients presenting to the emergency
department with early septic shock (Delaney et al., 2013). This trial could not be blinded,
but the risk of bias was minimized through central randomization. In this study, EGDT
did not reduce all-cause mortality at 90 days in critically ill patients presenting to the
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emergency department with early septic shock. Therefore, the value of incorporating
EGDT into international guidelines as a standard of care is questionable (Peake et al.,
2014).
The ProMISe trial, a multicenter, pragmatic, open, parallel group randomized
controlled trial with integrated economic evaluation was conducted in 56 hospitals in
England from 2011- 2014 (Mouncey et al., 2015). The study included 1260 patients, 630
in the EGDT group and 630 receiving usual care. Interventions could not be blinded, but
the risk of bias was minimized through central randomization. There were no significant
differences between the EGDT and usual care groups in mortality (29.5% and 29.2%
respectively) or other outcomes including serious adverse events and health-related
quality of life. Moreover, on average, EGDT was associated with increased costs.
Adherence to a strict EGDT strict protocol and the addition of SCVO2 monitoring did not
lead to improvement in outcomes. Since the death rate was lower than anticipated in this
study, the outcomes may not apply to settings with higher mortality rates. Of note,
decreasing mortality is a trend in recent years, and many aspects of sepsis care have
evolved since the Rivers et al. (2001) study 15 years ago (Mouncey et al., 2015). This
trial of early goal-directed resuscitation for septic shock raised concern for the
effectiveness of this treatment; specifically, in patients with septic shock who were
identified early and received intravenous antibiotics and adequate fluid resuscitation
(Mouncey et al., 2015). These patients received strict EGDT protocol management and
despite that, improve outcomes were not demonstrated (Mouncey et al., 2015). The
aforesaid studies did not demonstrate the superiority of required use of a CVC to monitor
CVP and ScvO2 in all patients with septic shock who have received timely antibiotics
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and fluid resuscitation, compared with controls or in all patients with lactate >4 mmol/L
(Mouncey et al., 2015).
SSC guidelines promote EGDT as means for reduction of mortality; however,
conflicting results can be found in several recently published meta-analyses regarding
benefits of EGDT in patients with severe sepsis and septic shock. A recent meta-analysis
by Chelkeba, Ahmadi, Abdollahi, Najafi, & Mojtahedzadeh (2015) comprising RCTs
performed in different geographical regions of the world and including aforementioned
trials, showed that while EGDT does not significantly impact outcomes, it reduces
mortality especially in low to middle-income countries (Chelkeba et al., 2015). However,
the study also showed that EGDT paradoxically increases the hospital length of stay
(LOS) (Chelkeba et al., 2015).
Angus et al. (2015) conducted a meta-analysis of RCTs published from January
2000 to January 2015 (N=4735 patients) to determine whether EGDT compared with
usual care reduces mortality for ED patients with septic shock. The study showed that
EGDT is not superior to usual care for ED patients with septic shock, as it has no effect
on primary (EGDT: 23.2% versus control: 22.4%), or 90-day mortality rates, but
increases ICU resources utilization (Angus et al., 2015).
Zhang, Zhu, Han, and Fu, (2015) conducted a systematic review and metaanalysis of 10 RCTs on EGDT from 2001 to 2014 involving 4,157 patients and found no
significant difference in mortality between the EGDT and the control group. In this study
EGDT was found to be associated with a higher mortality rate in comparison with the
early lactate clearance group (RR 1.52, 95% CI: 1.06 to 2.18, P = 0.02). In the first six
hours, compared with usual care, patients in EGDT received more inotropic agents

52

(P = 0.04), fluid administration (P = 0.05), and red cell transfusion (P < 0.01). There
were no significant differences in length of ICU stay (P = 0.73) or in-hospital stay
(P = 0.57), ventilation rate (P = 0.53), and vasopressor support (P = 0.63). Zhang et al.
(2015) point out that contrary to most recent meta-analyses, earlier studies showed that
EGDT was associated with a survival benefit; however, previous studies were either
retrospective or before-after studies, or meta-analyses with imperfect methodologies or
designs. For example, one meta-analysis included 13 RCTs, but only 7 studies were in
the EGDT subgroup; also, some included protocols that differed from the one
recommended by the SSC guidelines, included non-sepsis patients, or did not include the
latest ARISE study (Zhang et al., 2015).
Gu, Wang, Bakker, Tang, and Liu, (2014) included 13 trials involving 2,525 adult
patients in their meta-analysis. The results suggested that EGDT significantly reduces
overall mortality in patients with sepsis, especially when initiated early (P = 0.01);
however, strong and definitive recommendations could not be made given the variable
quality of the studies. Another meta-analysis of RCTs by Yu, Chi, Wang, & Liu (2016)
the included five studies (N = 4,303) that utilized the EGDT protocol recommended by
SSC Guidelines. Overall, there were slight decreases in mortality within 28 days, 60
days and 90 days in the random-effect model in patients with severe sepsis or septic
shock receiving EGDT resuscitation; however, none of the differences reached statistical
significance (Yu et al., 2016). The authors pointed out that the included trials were not
sufficiently homogeneous and suggested that potential confounding factors in the
negative trials (ProCESS, ARISE, and ProMISe) might bias the results and diminish the
treatment effect of EGDT. Therefore, further well-designed studies should attempt to
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eliminate or reduce potential sources of bias to determine if EGDT has a mortality benefit
(Yu et al., 2016). Similar results and conclusions were reported in another recent metaanalysis (Xu, Yang, & Qiu, 2016) that included nine studies involving 5,202 patients with
severe sepsis and septic shock.
A multivariable model was used to assess outcome differences between the serial
lactate and no serial lactate cohorts to assess clinical outcomes. Lack of serial lactate
monitoring was independently associated with mortality. Serial lactate monitoring is
associated with an increase in crystalloid administration, resuscitation interventions, and
improved clinical outcomes in ED patients with severe sepsis and septic shock (Dettmer,
Holthaus, & Fuller, 2015).
EGDT has been endorsed in the guidelines of the SSC as a key strategy to
decrease mortality among patients with septic shock. However, Peake et al., (2014)
suggest that the value of incorporating EGDT into sepsis guidelines as a standard of care
is questionable.
IV Fluids. As of today, aggressive fluid resuscitation is a hallmark of sepsis
treatment and the standard of care in the management of patients with severe sepsis and
septic shock (Waechter et al., 2014). Bundled with timely antimicrobial treatment,
lactate measurement and blood cultures, the SSC recommends aggressive IV fluid
resuscitation; specifically, intensive fluid resuscitation to achieve a CVP greater than 8
mm Hg. Waetchter et al. (2014) retrospectively analyzed data from 24 ICUs in three
countries to determine how hospital mortality was influenced by combined use of fluids
and vasoactive agents. Results showed that these two treatments had strong, interacting
associations with mortality, and suggested that the focus during the first hour of
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resuscitation for septic shock should be aggressive fluid administration, only thereafter
starting vasoactive agents, while continuing aggressive fluid administration. These
recommendations are based on expert opinion without adequate experimental or
controlled human evidence (Hilton & Bellomo, 2012). Conversely, recent clinical trials
have demonstrated that this approach does not improve outcomes for patients with sepsis
(Marik & Bellomo, 2015).
Patients are often intravenously infused very large amounts of fluids (5-10 L)
early in the process of sepsis treatment (Marik, 2014). Hilton & Bellomo (2012)
observed that there is no evidence of research on humans that fluid resuscitation with
such massive amounts of fluids (recommended at least 30 mL/kg: Grade 1C) can reliably
improve blood pressure or end-organ perfusion. More recent publications suggest that
this particular measure may instead be harmful, causing iatrogenic injury, that the “less is
more” paradigm is perhaps more applicable in many sepsis cases, and recommend
limiting IV fluids to 20-30 mL/kg in small 500mL boluses (Marik, 2014, p. 1409). While
the multicenter clinical trials described previously, as well as subsequent meta-analyses
of EGDT, demonstrated a lack of improvement in outcomes using aggressive fluid
resuscitation, this approach is mandated by current SSC guidelines.
Marik and Bellomo (2015) argued that sepsis is primarily not a volume-depleted
state; rather, sepsis is associated with arterio- and venodilation together with
microcirculatory and myocardial dysfunction. Recent evidence demonstrates that most
patients are poorly responsive to fluids, based on the pathophysiology of sepsis, with the
loss of arterial tone, venodilation, reduced compliance, and reduced preload
responsiveness (Marik & Bellomo, 2015). Almost all of the administered fluid is
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sequestered in the tissues, resulting in severe edema and increasing the risk of organ
dysfunction. Therefore, a physiologic, hemodynamically guided conservative approach
to fluid therapy, coupled with assessment of fluid responsiveness in patients with sepsis,
is likely to reduce morbidity and improve outcomes (Marik & Bellomo, 2015). Initiation
of a vasopressor agent (norepinephrine) in patients who remain hypotensive (MAP <65
mm Hg) after receiving an initial bolus 20 to 30 mL/kg of crystalloid solution may be
more appropriate. Furthermore, using additional boluses as needed and utilizing the
passive leg-raising maneuver combined with minimally invasive cardiac output
monitoring to assess volume responsiveness represents a proper, collective approach
(Marik, 2014).
Antibiotics. Early studies on sepsis care suggested that with the implementation of a
structured resuscitation focusing largely on IV fluid resuscitation, timely broad-spectrum
antibiotics and vasopressor therapy improved outcomes (Rivers et al., 2001). In 2006,
following a retrospective medical records review of 2,154 adult patients with septic
shock, Kumar et al. (2006) demonstrated that an effective antimicrobial administration
within the first hour of documented hypotension was associated with increased survival.
The relationship between hospital survival and duration of time between onset of
recurrent or persistent hypotension and effective antimicrobial administration held
whether the infection was:


Clinically suspected or documented,



Culture positive or negative,



Bacteremic or nonbacteremic,



Community-acquired or nosocomial,
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Gram-positive, gram-negative, or fungal, or



Involving the respiratory, urinary, gastrointestinal/peritoneal and skin or soft
tissue sites
(Kumar et al., 2006).
The effect also held for additional subgroups including those with neutropenia.

Initiation of effective antimicrobial therapy within the first hour following the onset of
septic shock-related hypotension was associated with 79% survival to hospital discharge
(Kumar et al., 2006). For every additional hour of delay to effective antimicrobial
initiation in the first six hours after hypotension onset, survival dropped an average of
7.6% (Kumar et al., 2006). With effective antimicrobial initiation between the first and
second hour after hypotension onset, survival had already jumped to 70.5%. With the
appropriate antimicrobial therapy delay to 5–6 hours after hypotension onset, the survival
rate was just 42.0%, and by 9–12 hours, it was 25.4% (Kumar et al., 2006). Presented
data strongly support current international guidelines and suggest that empirical, broadspectrum antimicrobial administration should be considered an intrinsic component of
initial resuscitation of septic shock.
Ferrer et al (2014) and Gaieski et al. (2010) have suggested the dominance of
well-timed antibiotics administration for improved mortality in severe sepsis and septic
shock; specifically, that delay in first antibiotic administration was associated with
increased in-hospital mortality. These authors implied that timely administration of
appropriate antimicrobials is the primary determinant of mortality in patients with severe
sepsis and septic shock treated with early goal-directed therapy.
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Subsequent studies have failed to demonstrate such substantial results (Puskarich
et al. 2011; Sterling, Miller, Pryor, Puskarich, & Jones, 2015). Authors documented the
association between timing of initial antibiotic treatment and mortality of patients
undergoing sepsis protocol in emergency departments and found no association between
time from triage to initial antibiotic administration and hospital mortality.
Other studies have not demonstrated any increase in mortality with a delay of
antibiotic administration based on triage time. Contrary to Kumar et al. (2006), Sterling
et al. (2015) found no significant mortality benefit of administering antibiotics within
three hours of emergency department triage or within one hour of shock recognition in
severe sepsis and septic shock.
Despite many limitations, SSC guideline specific recommendations are to
administer IV antibiotics within the first hour of recognition of septic shock (grade 1B)
and severe sepsis without septic shock (grade 1C), and to initiate a “Sepsis Bundle”. The
bundle, in addition to other requirements also entails administration of broad-spectrum
antibiotics within three hours from ED triage (Dellinger et al., 2013). Whether the
antibiotics were administered within specified time frame is now one of the benchmarks
for the quality of care measure by Medicare. Interestingly, sepsis symptoms are often
quite subtle, especially in the early stage, and in many cases, it is impossible to denote the
exact time of initial sepsis onset. This may lead to inappropriate prescribing of
antibiotics in order to comply with the measure.
Mostly based on limited evidence and one aforementioned retrospective study by
Kumar et al. (2006), the SSC international consensus guidelines recommends
administering broad-spectrum antibiotics within the first hour of recognizing severe
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sepsis and septic shock (Dellinger et al., 2008, Levy et al., 2008). However, Kumar’s
inclusion of all ICU patients diagnosed with septic shock may have contributed to the
mortality rate (56%) reported in this study, which is inconsistent with the overall
mortality rate of 19% found in studies that included only ED cohort patients receiving
early aggressive resuscitation (Puskarich et al, 2011).
Appropriate antibiotic therapy in patients with severe sepsis and septic shock
should mean prompt achievement of antimicrobial’s therapeutic concentration in blood,
tissue penetration and maintenance of optimal exposure at the infection site with broadspectrum antibiotics administered in a timely manner – as per the guideline protocol.
Once the causative pathogens have been identified and tested for in vitro susceptibility,
subsequent de-escalation of antimicrobial therapy should be applied whenever feasible
(Pea, & Viale, 2009). The goal of appropriate antibiotic therapy must be pursued
decisively and with continuity, in view of the ongoing problem of antibiotic-resistant
infections and of the continued decrease in new antibiotics emerging (Pea, & Viale,
2009).
Despite an emphasis on the appropriateness of antibiotic administration,
measuring effects of antibiotics’ appropriateness and effectiveness against pathogens is
only possible with known culture and sensitivity data, not usually available for 24 to 96
hours; therefore, performing this measurement in the ED is nearly impossible (Puskarich
et al., 2011). Consequently, Puskarich et al. (2011) argued that it is inappropriate to
require this SSC standard when determining the effect of antibiotic timing on the
outcome.
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Sterling et al. (2015) reported no significant mortality benefit of administering
antibiotics within three hours of emergency department triage or within 1 hour of shock
recognition in severe sepsis and septic shock. These results suggest that currently
recommended timing metrics as measures of quality of care are not supported by the
available evidence (Sterling et al., 2015).

Current SSC SEP recommendations include a list of potent broad-spectrum
antibiotics that are approved for monotherapy for sepsis. According to the measure
specifications, if within three hours of presentation a broad-spectrum antibiotic approved
for monotherapy is not administered to a patient with severe sepsis, then a medical
practitioner must consult the “Combination Antibiotic Therapy Table” to administer
another approved antibiotic drug combination to satisfactorily meet the required measure
(Calderwood, Coopersmith, & Gerardi, 2015). This does not promote best practice and
has raised serious concerns among medical communities due to the potential unintended
consequences that may result (Calderwood et al., 2015)
While many septic patients require broad-spectrum antibiotics, in some cases a
more narrow-spectrum antibiotics that deliver a targeted therapy could be more
appropriate if the pathogen is highly suspected or known. However, the current measures
do not allow for administration of antibiotics that are not on the list, and there is a risk
that medical practitioners will be inappropriately prescribing antibiotics in order to avoid
payment penalties and comply with the Medicare sepsis measure (SEP-1).
Inappropriate antibiotic prescribing behaviors have led to the marked increase of
antibiotic resistant bacteria and have negatively impacted LOS and patient mortality with
conditions such as Clostridium difficile (C. diff) infection (Calderwood et al., 2015).
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CMS considered these concerns and showed some flexibility in attempting to incorporate
utilization of narrower spectrum agents for documented known sources of infection, such
as C. diff colitis and type II necrotizing fasciitis.
Antibiotic Stewardship
The choice of antibiotics is determined by many factors, such as the suspected or
known source of infection, the patient’s immunologic status, whether the infection is
nosocomial or community acquired, and knowledge of the local microbiology and
sensitivity patterns (Marik, 2014). Most of the time causative organisms are not known
at the time of presentation, and a broad-spectrum, empirical therapy is most appropriate,
and has been shown to reduce mortality when compared with the inappropriate therapy
(Marik, 2014). Once a pathogen is isolated, antibiotics should be de-escalated to more
narrow-spectrum acting agents. There are instances that continuation of dual
antimicrobial therapy is recommended, such as enterococcal infections, severe
intraabdominal infections, severe pneumonia, pneumococcal bacteremia, neutropenia,
and others. Empiric broad-spectrum antimicrobial treatment is aimed at achieving an
optimal therapeutic response, thus reducing mortality; however, this can expose patients
to overuse of antimicrobials and promote sprouting of multi-drug resistant pathogens.
Unfortunately, severe sepsis and septic shock are increasingly more and more
frequently caused by antibiotic-resistant pathogens, including Gram-negative nonfermenters, Methicillin Resistant Staphylococcus (MRSA), Vancomycin Resistant
Enterococcus (VRE), and Candida species (Zhang, Micek & Kollef, 2015). This
development calls for the use of progressively more powerful empiric, broad-spectrum
antibiotics, which might further promote resistance, breed “superbugs” or multi-drug
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resistant organisms, and cause severe complications such as C-difficile colitis. Aside
from causing delays in the delivery of appropriate antibiotic therapy (AAT), this problem
may eventually pose the risk of running into unavailability of appropriate, sufficiently
powerful antimicrobials (Zhang, Micek & Kollef, 2015).
The rising threat of antimicrobial resistance calls for rapid interventions with
appropriate antimicrobial choices in sepsis treatment. Therefore, robust antimicrobial
stewardship programs in hospitals and healthcare facilities are beneficial in attempts to
combat antibiotic resistance, reinfections, and superinfections. Clinicians in
collaboration with pharmacists and infection control departments should implement local
strategies aimed at timely delivery of appropriate antibiotic therapy to improve outcomes
and reduce the length of stay (Zhang Micek & Kollef, 2015). The hospital antibiotic
stewardship program is a multidisciplinary approach and a key component to preventing
increasing antimicrobial resistance (Fishman, 2006). De-escalation has been proposed as
a strategy to replace empirical broad-spectrum antimicrobial treatment by using a
narrower antimicrobial therapy; however, more research is needed to establish direct
evidence regarding safety and efficacy of early de-escalation of antimicrobial agents for
adults with sepsis, severe sepsis or septic shock (Silva, Andriolo, Atallah, & Salomão,
2013).
Timely application of AAT while avoiding the unnecessary use of antibiotics,
especially broad-spectrum agents when not warranted is necessary in the treatment of
infections; however, in order to successfully de-escalate antibiotics to narrower spectrum,
a proper identification of causative organisms and their specific sensitivity is paramount.
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Lack of ability to identify microbes is an important barrier to the effective treatment of
infections. Advances in new antibiotic development along with progressing technology
and evolving new rapid diagnostic techniques such as molecular diagnostics offer hope
for better outcomes. The transition from traditional, culture-based diagnosing methods to
molecular diagnostics will yield faster results and consequently better patients’ outcomes.
The advantage to such transition likely outweighs any risks; nevertheless, implementing
such change has been meeting much resistance (Mancini et al., 2010).
On September 18, 2014, the White House directed the federal government to step
up the fight against antibiotic-resistant bacteria. A science advisory was released, calling
for reducing antibiotics overuse to preserve the efficacy of existing antimicrobials, to
develop improved methods for conducting antibiotic stewardship programs in healthcare
settings and to develop and promote the use of new, rapid diagnostic technologies such as
molecular diagnostics and point-of-care diagnostics (Office of Press Secretary, 2014).
By the end of the calendar year 2016, the Department of Health and Human Services will
propose new regulations that require hospitals and other inpatient healthcare delivery
facilities to implement robust antibiotic stewardship programs that adhere to best
practices (Office of Press Secretary, 2014).
Molecular Diagnostics Technology
Human blood is naturally sterile. Current standard blood culture procedures
consist of inoculating blood cultures bottles and monitoring for the growth of
microorganisms, and any growth is assumed pathologic unless contaminated. Cultures
are then Gram stained, plated to appropriate media, and allowed to grow for 24 to 72
hours or longer, with subsequent subcultures and susceptibility to antibiotics testing
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results (Dekmezian, Beal, Damashek, Benavides, & Dhiman, 2015). This process creates
a considerable delay in initiating AAT from the initial collection of blood sample from
the patient to delivery of the most appropriate antimicrobial treatment. Newer
technologies such as molecular diagnostics offer rapid identification thus more efficient
infection treatment. Tests such as nucleic acid amplification tests, fluorescence in situ
hybridization (FISH), and matrix-assisted laser desorption ionization time-of-flight mass
spectrometry (MALDI-TOF MS) provide rapid identification of pathogens and
codetection of key resistance markers directly from positive blood cultures (Dekmezian
et al., 2015). For example, the Verigene Gram-Positive and Gram-Negative blood culture
assays are approved by the Food and Drug Administration to detect common grampositive and gram-negative organisms, as well as associated resistance markers within
three hours from positive blood cultures (Dekmezian et al., 2015).
Molecular technologies have significantly shortened the time to antimicrobial
isolate identification compared with conventional methods. Sango et al. (2013) evaluated
the impact of Enterococcus identification and resistance detection using Verigene Blood
Culture Gram-Positive. The intervention by an infectious disease and/or critical care
pharmacist on 74 patients with enterococcal bacteremia led to a significant decrease in
the meantime to appropriate antimicrobial therapy in the post-intervention group (23.4 h;
P = 0.005) compared with the pre-intervention group (Sango et al., 2013).
Bauer et al., (2010) in a single center study, evaluated clinical and economic
outcomes of rapid diagnostic polymerase chain reaction (PCR) methods on 156 patients
for methicillin-resistant S. aureus/S. aureus bacteremia and demonstrated that the mean
time to deescalate from empiric to narrow spectrum antibiotics in patients with
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methicillin-susceptible S. aureus bacteremia was 1.7 days shorter (P = 0.002), the mean
length of stay was 6.2 days shorter (P = 0.07), and the mean hospital costs were $21,387
less (P = 0.02) after PCR. Therefore, PCR allows rapid differentiation of S. aureus
bacteremia, enabling timely, effective therapy and is associated with decreased length of
stay and healthcare costs (Bauer et al., 2010).
A prospective randomized controlled trial evaluated outcomes associated with
rapid multiplex PCR (rmPCR) detection of bacteria, fungi, and resistance genes directly
from positive blood culture bottles, and demonstrated that the time from blood culture
Gram stain to microorganism identification was shorter in the intervention group (1.3
hours) vs control (22.3 hours) (P < .001) (Banerjee et al., 2015). Compared to the control
group, both intervention groups had decreased broad-spectrum antibiotic (control 56
hours, rmPCR 44 hours, rmPCR/AS 45 hours; P = .01) and increased narrow-spectrum
antibiotic (control 42 hours, rmPCR 71 hours, rmPCR/AS 85 hours; P = .04) use, and less
treatment of contaminants (control 25%, rmPCR 11%, rmPCR/AS 8%; P = .015)
(Banerjee et al., 2015). Time from Gram stain to appropriate antimicrobial de-escalation
or escalation was shortest in the rmPCR/AS group (de-escalation: rmPCR/AS 21 hours,
control 34 hours, rmPCR 38 hours, P < .001; escalation: rmPCR/AS 5 hours, control 24
hours, rmPCR 6 hours, P = .04). Groups did not differ in mortality, LOS, or cost
(Banerjee et al., 2015). Banerjee et al., (2015) reported decreased use of broad-spectrum
antimicrobials with the implementation of PCR diagnostic method, and the addition of
antimicrobial stewardship program enhanced antimicrobial de-escalation. Molecular
diagnostics allow rapid differentiation of bacteria, enabling timely, effective therapy;
moreover, it is associated with decreased length of stay and healthcare costs.
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Discussion of Best Practice to Address Problems
Sepsis is a rapidly growing public health problem for Americans. There has been
little change in long-term morbidity, despite changes in practice and technology.
Clinicians should anticipate more frequent sequelae of severe sepsis in their patient
populations, especially among elderly patients and in light of increasing antimicrobial
resistance. Although overall decreasing mortality has been a trend over the past decades
as many of aspects of sepsis management has changed since Rivers et al. (2001), high
incidence and difficult diagnostics of sepsis remains a major problem. The management
of patients with sepsis focuses on the early administration of antibiotics, IV fluids, and
vasoactive agents, followed by source control; unfortunately, there is no high-quality
evidence demonstrating that any of these interventions impact outcomes, especially when
the interventions are bundled together (Marik, 2014). However, it is likely that timely
administration of appropriate antibiotics is the single most important factor in reducing
both morbidity and mortality from sepsis (Marik, 2014).
Antibiotic Resistance
Since the invention of penicillin, we had access to many reliable antibiotics, and
as resistance has developed to particular drugs, new and more potent antimicrobials were
almost immediately manufactured. Today, however, for some bacterial strains, the
antibiotic market has shrunk, and in many cases of drug-resistant infections, the choices
of antimicrobial agents are limited. There are instances of highly resistant strains that
currently available antibiotics are not effective at all. Fewer antibiotics are available to
treat complicated infections, and the reason for this problem is multifaceted.
Inappropriate prescribing and erroneous taking of antibiotics both encourage the breeding
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of resistant organisms. Pharmaceutical companies are reluctant to make new antibiotics
for economical reasons. Medications are very expensive to develop and to undergo
clinical trials. Those that are prescribed for life, for example antihypertensive drugs,
antihyperglycemics, or antilipids can be profitable for the companies who develop them;
however, antibiotics are typically used for a short period of time and once used,
resistance already starts to develop. Pharmaceutical companies must be encouraged to
return to the manufacturing of antibiotics to help to combat this global problem, thus
initiatives are being proposed in the form of financial incentives and tax breaks.
An H.R.3539 Reinvigorating Antibiotic and Diagnostic Innovation Act of 2015
was introduced to the House Committee on Ways and Means in September 2015,
Sponsored by Rep. Boustany, Charles W., Jr. (See Appendix F, Figure F.1). This bill
amends the Internal Revenue Code to allow tax credits for 50% of the clinical testing
expenses for infectious disease products that are intended to treat a serious or lifethreatening infection, including one caused by an antibacterial or antifungal resistant
pathogen, and in-vitro diagnostic devices that identify in less than four hours the
presence, concentration, or characteristics of a serious or life-threatening infection
(Boustany, 2015)
In March 2015, the White House released an initiative on combating antibioticresistant bacteria. This initiative encourages new antibiotic use protocols, antibiotic
stewardship programs implementation across healthcare facilities, and better diagnostics
that can quickly detect bacterial infections and multiple antibiotic resistance genes. The
National Action Plan for Combating Antibiotic-Resistant Bacteria was issued and
provides guidelines for this initiative. The goals are to advance the development and use
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of rapid and innovative diagnostic tests for identification and characterization of resistant
bacteria, accelerate basic and applied research, and development for new antibiotics (The
White House, United States Government, 2015).
Summary
Despite some differences, overall there is an agreement in the literature regarding
a core sepsis approach. To reduce mortality rates, sepsis must be identified and treated as
early as possible so that patients can receive optimal aggressive treatment (LopezBushnell, Demaray, & Jaco, 2014). As specific recommendations evolve and change
with advancing knowledge, and technology, and with emerging new evidence, the most
critical aspects and the underpinning of sepsis care remains early recognition of
symptoms and prompt initiation of aggressive measures with antibiotics (D’Amore, et al.,
2015). The following chapter contains a description of methods utilized for this project.
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CHAPTER III
METHODOLOGY
Methods
Objectives of this project were to review scientific literature for the effects of
sepsis protocols on health outcomes, then conduct data analysis and compare results of
two groups of patients who were hospitalized in a community hospital with the diagnosis
of sepsis before and after implementation of new sepsis guidelines. The purpose of this
project was to evaluate interventions in terms of utilization and effectiveness of current
sepsis protocols on health outcomes, specifically on hospital length of stay, mortality,
morbidity, readmissions, and appropriate antibiotics utilization; also, to assess whether
implementing the mandated protocol actually influenced the timing of initiating early
interventions. Further, additional goals were to examine whether recommendations for
improvements are indicated, explore evidence to guide practice change, and based on the
project’s outcomes to validate best practice recommendation. Ultimately, the
prospective, indirect aim was to determine if a change in practice is necessary.
Project Design
This evidence-based project is a descriptive, retrospective, and a pre and post
measure of an intervention identified as the Sepsis Bundle protocol (SEP-1). This DNP
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scholarly project was conducted at a 100-bed community hospital located in the coastal
South Carolina region, which implemented the new sepsis protocol in October 2015.
Through data collection and analysis, the focus of this quality improvement project was
to evaluate the efficiency of interventions of current sepsis protocols and their effects on
health outcomes, such as mortality, hospital length of stay (LOS), utilization of
antibiotics, and morbidity among septic patients in pre- and post-implementation groups.
The pre-implementation data was collected from September 1, 2014, through
September 31, 2015, and compared to the post-implementation period from October 1,
2015, through March 31, 2016. The elements of data collection were organized into
objectives one to six, measured in both pre- and post-intervention groups.
(1) Objective One: Collect data and demonstrate descriptive statistics.
(2) Objective Two: Summarize findings and compare outcomes: mortality,
morbidity, health outcomes, antibiotics utilization, LOS, readmission rates.
(3) Objective Three: Analyze outcomes between groups looking at selected
individual variables and based on compliance with guidelines.
(4) Objective Four: Evaluate relationship between variables.
(5) Objective Five: Determine if there is a need for practice change.
(6) Objective Six: Make appropriate recommendations based on current evidence.
Sample
The unit of analysis in this project is the patient and her or his health record data.
One hundred fifty-eight electronic charts of patients admitted between September 1,
2014, and March 31, 2016, were reviewed. The sample population included two groups
of patients, 86 prior, and 72 after implementation of new Sepsis Bundles.
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Inclusion and exclusion criteria. Inclusion criteria were comprised of adults of
both genders, 18 years of age or above who had an active sepsis diagnosis at the time of
presentation to the hospital, or at any time during the hospitalization, and were
hospitalized within the specified time frame. To be included patients must have met the
severe sepsis and sepsis shock criteria as per SEP-1 guidelines (Figure II.2).
Included were those patients with the following ICD diagnostic codes: from ICD9 codes: 038.9 (unspecified septicemia), 995.91 (sepsis), 995.92 (severe sepsis), and
785.52 (septic shock). The ICD-10-CM codes ranged from A22 to A54 and B00.7 to
B37.7, with additional multiple extension as applicable, also A41 (for other sepsis, with
extensions from A41.0 to A41.9 for specific types of sepsis and due to particular or
unspecified organisms). In addition, the following ICD-10-CM codes: T81.4, T88.0;
T80.2 were used to generate reports for completeness. These included postprocedural
sepsis, sepsis following immunization or infusion, or transfusion of therapeutic injection.
Not included were codes describing bacteremia without sepsis, sepsis during labor, sepsis
following abortion, neonatal sepsis and sepsis in children of any age below 18 since the
target population did not include these aggregates. Appendix I lists all the ICD-10-CM
codes included for the purpose of generating accurate reports. Since the new protocols
were implemented on October 1, 2015, for the pre-implementation sample the case
selection was from September 1, 2014, through September 31, 2015 (13 months) and for
the post-implementation sample, the case selection was from October 1, 2015, through
March 31, 2016 (6 months). Patients who were admitted to ACU, PCU, or ICU, were
included but admitted to L&D and all neonatal and pediatric patients were excluded from
the sample because they could influence or potentially introduce confounding variables.
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Setting
The setting for this project was a small, community hospital located in the coastal
area of South Carolina. The hospital opened its doors in 1975 as a private, 40-bed,
accredited medical facility serving a small rural population. Over the years with the
growing demands of the region, the hospital transitioned to a larger facility, expanded its
services, and is currently certified for nearly 100 acute care beds serving the local
population and visitors.
Data Collection
With the intention to accomplish the project objectives, permission for data
collection, extraction from electronic medical records (EMR), and analysis was requested
from the Safety Officer /Director of Risk Management of the hospital, who presented the
proposal before the facility’s Compliance Committee. Once permission was granted by
the Compliance Officer (Appendix G, Figure G.1), a comprehensive, retrospective
electronic chart review and data collection of the electronic medical records was
conducted. The aforementioned facility utilizes Cerner® EMR software. For the
purpose of this project, access was granted to the EMR to selected patient databases to
collect necessary demographics and clinical information. The software has the capability
to generate various reports; therefore, a list of patients was created by Medical Records
director, de-identified and consequently received anonymous in its entirety. The list was
based on diagnosis codes for sepsis using International Classification of Diseases, Ninth
Revision (ICD-9) and Tenth Revision (ICD-10-CM) (Appendix I). Once de-identified
reports were received, all pertinent information was manually entered into an Excel®
worksheet (Appendix J, Figure J.1). For the purpose of this project’s data collection, a
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spreadsheet was developed and designed to fit all data elements. The demographic
information was entered from the Cerner® reports. All subjects were organized in rows
by age and gender.
Unique identifiers were assigned to individual cases to facilitate analysis and to
provide an opportunity for retrieval of any missing or duplicated data. Designs for both
pre- and post-implementation groups data collection Excel® worksheets were identical
(See Appendix J, Figure J.1 for worksheet template). For each item in data collection, a
distinctive name was created, items were organized in column headings, and classified as
either categorical (nominal, ordinal, dichotomous) or continuous variables (interval or
ratio). Based on this classification, a specific number of sub-columns was set up for each
variable to reflect the quantities of values. Some variables were answers to yes-no
questions, others had numerous subcategories with possibilities to pick either only oneout-of-all, or all that apply.
Data coding was performed by establishing a numerical value for each entry
options, thus all values in each subcategory of every variable had a unique number
assigned that was associated with the corresponding category. For example, gender was
coded as 1 = Female and 2 = Male, or number 1= answer Yes, and 2 = No. Consecutive
numbers (1, 2, 3 …) were assigned to items with multiple subcategories, such as
antibiotic class: 1 = antibiotic A, 2 = antibiotic B, 3 = antibiotic C, respectively. Please
refer to Appendix J, Table J.1 that illustrates the template of the spreadsheet. Table III.1
below lists categories created on the worksheet for data collection, and Table III.2 shows
the list of categories and subcategories of variables and outcomes measured.
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Encryption of categories was conducted in a particular manner where each
category had assigned a unique combination of letters that reflected in corresponding
subcategory code along with previously established numerical values. For example, the
category “Race” was coded Race1-6, and corresponding variables had numbers assigned
to them as follows: 1=Caucasian (Race1); 2=African American: (Race2); 3=Asian:
(Race3), 4 = Hispanic (Race4) et cetera. The category: “Functional status at discharge”
was coded: OutcFS 0-3, and the corresponding subcategories received the following
codes: No change from pre-hospitalization = 0: (OutcFS0); Worse, lost independence,
declined = 1 (OutcFS1); Better then prior to hospitalization = 2 (OutcFS2); Deceased = 3
(OutcFS3). Please refer to Appendix K, table K.1 for examples of the variables’ coding
system, Appendix E, Table E.1 for a list of data collection elements with corresponding
codes and Appendix M, Table M.6 for the coding legend.
Table III.1.5List of Variable Categories for Data Collection
Variable Categories

Variable Categories

Age
Gender
Race
LOS
Outcomes
Mortality
Functional status at discharge
Discharge destination
Immune status impairing diagnoses
Comorbidities
Sepsis cause
Hospital course
Progression of sepsis
Treatment with initial Antibiotics
Number of days on empiric antibiotics
Number of empiric antibiotics
Deescalation of antibiotics

Appropriateness of antibiotics
Bundle compliance
IV fluids timing and rate
First lactic acid measurement
Second lactic acid measurement
Blood cultures sampling
Duration waiting time for results
Culture results
C-diff
Site of positive cultures
Identified pathogen
Multi-drug resistant organisms
Antimicrobial class
Healthcare-acquired infection
Nosocomial complications
Potential costs savings
Readmitted w/in 30 days
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Data were collected over 19 months from September 1, 2014, to March 31, 2016,
and a total of 158 subjects were included in raw data batch, which consisted of two
separate, independent samples of patients hospitalized before and after launching the new
sepsis protocols. The first sample (n=86) was collected prior to the sepsis guideline
implementation on October 1, 2015, and the second sample (n=72) was collected from
October 1, 2015, after guideline inauguration. Only patients meeting the inclusion
criteria were included in data collection and outcome measures.
Measured Variables and Outcomes
The primary goal relevant to this project was to compare health outcomes before
and after implementation of new sepsis management protocols. With the intention of
producing a meaningful final report, outcomes of several data elements were collected
and measured in both samples (Table III.1).
Selected outcomes measured were those patients results that were expected to
change after sepsis protocols were implemented. The main variables included death and
survival rates, the difference in mortality between patients with sepsis and septic shock,
the proportion of sepsis progressing to septic shock while hospitalized, hospital length of
stay, outcomes such as patients’ functional status at the time of discharge, discharge
destination and readmission. These variables were arranged in categories and supporting
subcategories were added as shown in Table III.2. The role of several different
subcategories was to aid in explaining relationships and differences.
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Table III.2.6Categories and Subcategories of Variables and Outcomes Measured
Categories and Subcategories Of

Categories and Subcategories Of Variables

Variables And Outcomes Measured

And Outcomes Measured












The number of days patient
stayed in hospital (LOS)
Patient survival (Mortality)
Overall functional status at
discharge (Declined, no change,
improved)
Final discharge destination
o Deceased while
hospitalized
o Returned home with
home health, or more
help than prior
o Went to a nursing
facility, long or short
term
o Admitted to Hospice
Care and Deceased
o Prior living
arrangements without
change
Immune status (impaired,
normal)
Diagnosis or conditions
affecting immune status
o None
o Cancer (Ca)
o Status post organ
transplant or
splenectomy
o Chronic Obstructive
Lung Disease (COPD)
o Diabetes Mellitus (DM)
o Rheumatoid arthritis or
on steroids for other
reasons
o On chemotherapy
Comorbidities
o 0 None
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o Vasopressors
o Focused exam
Fluid status reassessment
Number of hours pathogen was first
identified as Gram-negative or Positive
(preliminary results)
Number of hours final culture results
available including sensitivity (MIC)
Site of original infection, port of entry
o Blood
o Urine
o Wound
o Sputum
o Stool
o CNS fluid
o C-diff infection
o Pleural fluid
o Peritoneal fluid
o Other intraabdominal infection
Identified pathogen or pathogens
o Gram-negative pathogen
 Escherichia coli
 Klebsiella pneumonia
 Enterobacter
 Acinetobacter
 Pseudomonas aeruginosa
 Proteus
 Serratia
 Morganella
 Haemophilus influenzae
 Campylobacter
 Neisseria
 Other
o Gram-positive pathogen
 Staph aureus MSSA
 Staph aureus MRSA
 Staph coagulase (-)
epidermidis



o
o
o
o






Ca
COPD
DM
Coronary Artery
Disease (CAD)
o Malnutrition
o Alcohol (ETOH) abuse,
chronic
o Readmitted, recurrent
infection
o History of previous
sepsis
o History of multi-drug
resistant infection
o Underlying dementia
o End Stage Renal
Disease (ESRD), on
dialysis
o Obesity
o Congestive Heart
Failure (CHF)
o Peripheral Vascular
Disease (PVD)
o Other
Initial presentation
o Sepsis
o Severe sepsis
o Septic shock
Acute mental status change
(AMS)
Sepsis cause
o Pneumonia
o Urinary tract infection
(UTI)
o Pyelonephritis
o GI/intraabdominal
o Skin (cellulitis)
o Post-surgery
complications
o Wound infection
o Meningitis
o Neutropenic fever
o Fever of unknown
origin (FUO)
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Streptococcus
pneumococcus
 Strep viridians
 Strep group A pyrogens
 Corynebacterium
 Enterococcus faecium
 Enterococcus faecalis
 Clostridium
 Corynobacterium
 Bacillus
 Other
o Atypicals
 Mycoplasma
 Chlamydia
 Ricketts
o Viral
o Fungal
o MDR Organisms
 MRSA
 VRE
 CRE
 C-diff
 ESBL
 Other
Antimicrobial class
o Penicillin (PCN)
o Extended PCN (Zosyn)
o B-lactamase inhibitor PCN
(Unasyn)
o Cephalosporin 1st generation
o Cephalosporin 2nd generation
o Cephalosporin 3rd generation
o Cephalosporin 4th generation
o Cephalosporin 5th generation
(Ceftaroline)
o Fluoroquinolone 2nd generation
(Cipro)
o Quinolone 3rd generation
(Levaquin/Moxifloxacin)
o Macrolides
o Tetracycline
o Sulfonamides
o Carbapenems
o Monobactam (Aztreonam)

o









Bacteremia without
identified source
o Osteomyelitis
Hospital course
o ICU with vasopressors
o Mechanical ventilation
Progression of sepsis
o Severe sepsis
progressed to septic
shock despite treatment
o Better, status did not
deteriorate during
hospitalization
Antimicrobial stewardship
o Deescalation of
antibiotics
o Number of antibiotics
o Number of days on
antibiotics
Sepsis protocol compliance
o Initiation of treatment
with antibiotics, timing
o IV fluids infusion rate
and timing
o Lactic acid sampling,
results and timing
o Blood culture sampling,
results and timing
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o Glycopeptide (Vanc)
o Liptopeptide (Cubicin/Dapto)
o Oxazolidinone (Zyvox/linezolid)
o Lincosamide (Clindamycin)
o Other antibiotics (Tigecycline)
o Nitroimidazole (Flagyl)
Other Treatment
o Antifungal (fluconazole)
o Antiviral
o Other atypical
Appropriate antibiotic for culture results
Healthcare-acquired infection
Hospital complications
o C-diff
o MDR organism
o Surgery
o Neutropenia
o Coagulopathy
o Abscess
o Renal failure
o Respiratory failure
o Multisystem failure
o Cardiac complications
Potential costs savings
o On LOS
o On antibiotics
Readmitted within 30 days

Strategies to Reduce Barriers
Facilitators and barriers were identified and examined. No major impediments
were identified to data collection and analysis with the exception of the time required to
complete this project. Elements that could have affected outcomes of this project may be
possible flaws in data based on inaccurate documenting of clinical findings in EMR.
Other issues affecting outcomes are noncompliance with guidelines, infeasible
approaches, and ineffectiveness of some components of the guidelines along with long
waiting time for culture results possibly leading to inappropriate antibiotic prescribing.
Managers, as well as staff in general, are often wary of challenges and risk averse,
therefore resistant to change.
A number of barriers exist to the adoption of recommendations resulting from the
data analysis and evidence review, including the absence of an innovation culture in the
organization, lack of abundance of supportive evidence, financial constraints, and a
budget that does not allow additional spending and administration that does not
encourage innovation or change. To overcome barriers, the project’s findings have to be
integrated with collaborative sepsis team efforts to improve sepsis outcomes in this
setting, and use data to validate best practice recommendations. To help reduce barriers
to change, forming a team of supportive colleagues who take ownership of quality and
safety initiatives is critical to successful implementation of evidence-based practice and
ongoing quality improvement.
Instruments
Data was collected retrospectively in a systematic fashion as described above
utilizing electronic tools. Three major instruments were used including EMR Cerner®,
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Microsoft® Office Excel® 2007 program, and Statistical Analysis Software (SAS®)
statistical software. The Cerner® was utilized for generating reports, access to clinical
records, review and collection of pertinent information for this project.
Data was organized, sorted and statistically described using Excel® worksheet for
editing, formatting, developing graphs and charts, also its spreadsheet functionality such
as descriptive statistics and basic mathematical and sorting tools and formulas. Finally
SAS® was used for statistical data analysis of both the pre-implementation and the postimplementation samples.
Procedure
The purpose of this comprehensive retrospective records review and data
collection for this project was to analyze differences in outcomes before and after the
introduction of the new sepsis protocol. Eighty-six electronic charts were reviewed in the
pre-implementation data set (n = 86), and 72 in the post-implementation data set (n = 72)
Charts were reviewed in the context of septic patients’ outcomes based on timely
approaches and administration of mandated treatments as opposed to the standard
practice. Variables such as mortality, LOS, morbidity, patients’ outcomes including loss
of function, hospital complications, AAT, MDR infections, and readmissions strongly
affect outcomes, and were the principal aspects analyzed in this project. In addition,
compliance with each component of the new Sepsis Bundle protocol is now a benchmark
for the quality measure and mandated by Medicare.
After data entry was completed, data quality and reliability were examined
through a series of procedures including random re-checks of all the records, and
inspection of each element for the accuracy of data entry and correct coding utilizing
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spreadsheet’s sorting functionality. Data was double-checked for errors and omissions by
hand, also using the spreadsheet functionality all numerical values were sorted and
checked for accuracy of data entry. Less than 1% of records within the entire collection
were found to be missing or incorrectly coded, and errors were corrected and re-checked
for accuracy based on expected ranges of values in each category before data was
analyzed.
Data Analysis Methods. This post-hoc analysis consisted of comprehensive
literature review, retrospective data collection and analytical approach to data. Initial
descriptive statistics were run using Excel® functions within the spreadsheet such as
AVERAGE (arithmetic mean), RANK (list of values ranked by order relative to other
values), STDEV (sample standard deviation), SUM (sum of numbers in a range of cells),
COUNTIF (count of numbers that meets given conditions), MAX, MIN (largest and
smallest values), MEDIAN (middle number), MODE (most frequently occurring value),
QUARTILE, SUMIF (sum given specified condition), CORREL (correlation coefficient
between two data sets), PEARSON (Pearson correlation coefficient), PERCENTILE, and
T.TEST.
Sorting and calculations performed on the raw data allowed formatting of data
elements for appropriate entry into the statistical software for data analysis. Data from
the two groups (pre-implementation and post-implementation) were arranged and
organized in sets by age, gender, LOS, mortality, hospital course, discharge status and
other outcomes, then ranked accordingly, thus prepared for processing by statistical
software. Subsequently, preliminary descriptive statistical values obtained using Excel®
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functions were plugged into the Statistical Analysis Software (SAS®) for detailed
analysis.
The frequency tables were developed, the t-test, and means procedures were used
for descriptive statistical analysis and data distribution analysis. Pearson’s Correlation
Coefficient and Spearman’s Correlation Coefficient procedures were used for comparison
of outcomes.
Figures are presented in the following chapter illustrating the descriptive statistics
and data analysis; further, data analysis outcomes are shown and demonstrate whether
there was a statistical difference in comparing variables in categories and subcategories
between pre-implementation and post-implementation groups. Inferential data is
presented in tables and graphs in the following chapter. P value at the level of p < 0.05 is
used to indicate a statistically significant difference.
Human Subject Protection
The purpose of this scholarly project was to evaluate the effectiveness of current
sepsis protocols on patients’ outcomes. This project included health data of human
beings, which involved electronic chart reviews, health record information extraction,
and analysis; however, as a Quality Improvement project specific to the setting and
without intent to produce generalizable results, no Institutional Review Board review was
necessary. A request for permission to use data from EMR was filed with the Safety
Officer /Director of Risk Management and granted by the Compliance Officer of the
hospital (Appendix G, Figure G.1).
The collection of data required to some degree participant identification, but only
available to the author, an employee of the institution, in the form of raw data. No
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identifying data was collected or stored and individual cases were assigned unique
identifiers for purposes of data analysis. Data was located on a password-protected
computer and the access to this information was only through the secure passwordprotected server.
This Quality Improvement project does not involve any known risks to subjects.
The outcomes of this project or the entire process of data collection and analysis do not
affect the rights or welfare of the subject. All evaluation information was kept
anonymous and was disseminated by aggregate data only. Obtaining consents was not
indicated and it would be impractical to carry out this project if consents were required;
further, having written consents would risk potentially linking participants with records
in the final project. There were no known physical, psychological, or social risks
involved during the implementation of this intervention. The project involves a
considerably small sample; however, data was only reported in aggregate, thus
identification of individual subjects is implausible
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CHAPTER IV
RESULTS
Project Findings
Description of Sample
This project was designed to compare outcomes of patients with sepsis treated in
a hospital before and after the launching of the newest sepsis guidelines, to evaluate the
effectiveness of the guidelines, and based on results, to assess the need for improvement
and practicability of recommending practice change. The study was completed at a
medical center located in the coastal South Carolina region, and utilized the EMR for
retrospective data collection. A total of 158 electronic charts were reviewed, which
included charts of 86 patients with sepsis who were treated prior to the newest mandatory
Sepsis Bundles were made a part of the hospital protocol (pre n=86), and 72 charts of
septic patients who were treated after the protocols were implemented (post n=72).
Data including descriptive statistics for the relevant variables and outcomes are
displayed below in tables, charts and graphs. Table IV.1 shows percentages of all
patients admitted with sepsis, patients who developed septic shock, and those who had
severe sepsis in the pre-implementation group as compared to the post-implementation
group.
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Table IV.1.7Incidence of Sepsis, Severe Sepsis and Septic Shock

Sepsis, incidence

Pre (n=86)

Post (n=72)

%

%

Septic Shock

41

31

Severe Sepsis

42

58

Sepsis NOS

17

11

* Note: some patients had more than one diagnoses

The major finding in this data set is that while 16% more patients with severe
sepsis were treated in this hospital prior to Sepsis Bundle implementation than after, 10%
fewer patient presented with or developed septic shock.
Demographic Data
Demographic data is displayed below in Table IV.2. In the pre-implementation
sample, there were 42% females and 58% males, 91% of Caucasians, and 7% African
Americans, as opposed to the post-implementation sample of 44% females and 56%
males, 86% Caucasians and 8% African Americans. The average age of all participants
was 74.45 years. Data shows that 43% of patients were female and 57% were male, and
the majority of patients in both groups were Caucasian (88.5%).
The mean age of the entire sample was 74.42 years, and the overall range was 23
to 97 years. The age range in the pre-implementation group was from 23 to 97 years, and
in the post-implementation group, it was 33-97 years. The mean age in the preimplementation group was 72.14, and post-implementation was 76.71 years. The
difference in age between the two groups was 4.57 years (p<0.05).
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Table IV.2.8Demographics. Distribution of Age, Gender and Race by Group
Demographics

Pre (n=86)

Post (n=72)

%

%

Female

42

44

Male

58

56

Caucasian

91

86

African American

7

8

Hispanic

2

6

Asian

0

0

Other

0

0

years

years

72.1

76.8

Gender

Race

Age
Age, average

Distribution among genders is not equal among males and females in both groups.
The male gender predominance is observed in both groups. Sixteen percent more men
than women were treated for sepsis in the pre-implementation group, and 12% more men
than women were treated in the post-implementation group. A disproportional
percentage of Caucasians is noted in both groups as compared to other races. Ninety-one
percent of patients hospitalized with sepsis in the first group were Caucasians, as
compared to 9% of all other races combined in the same group. Similarly, 86% of
patients were Caucasians, as compared to 14% of all other races combined in the second
group
Figure IV.1 shows two histograms displaying the distribution of ages of the patients
hospitalized with sepsis in each implementation group.
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Figure IV.1.5Distribution of Age by Group

Both groups’ characteristics in reference to age distribution are similar and representative
of the known population in this setting; however, what stands out in this figure is that the
post-implementation group was older.
Descriptive data consisted of individual observations collected for the project
objective (Objective One) also included mortality, LOS, most common antibiotic
prescribed, antibiotic treatment duration and most frequently occurring causative
pathogens.
Mortality Rate and Length of Stay
Overall hospital mortality rate for patient population carrying sepsis diagnosis and
hospitalized within the specified time period from September 1, 2014, to March 31, 2016,
was 31.65% (Table IV.3).
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Table IV.3.9Mortality by Group
Pre (n=86)

Mortality
Mortality by group

Post (n=72)

Frequency

%

Frequency

%

Alive

51

59.3

57

79.17

Deceased

35

40.7

15

20.83

Mortality, overall, both groups
Outcome

Frequency

Percent

Alive

108

68.35

Deceased

50

31.65

The mortality rate for the pre-implementation group was 40.7% with a survival rate of
59.3%, and in the post-implementation group, the mortality rate was 20.83% with a
survival rate of 79.17%. A difference of 19.87% in mortality rate was noted between the
two groups.
Table IV.4 shows septic patients’ mortality in relation to age and LOS. A t-test of
mortality with regard to age in both pre- and post-implementation groups (Table IV.4)
showed that the average age of patients who were deceased was 78.16 years and the
average age of survivors was 72.4 years (p<0.05).
Table IV.4.10Mortality by Age and LOS

N

Mean

SD

N

Mean

SD

T-test
pvalue

Mortality by age

108

72.40

14.8103

50

78.16

13.25

<0.05

Mortality by length of stay

108

7.06

4.89

50

7.08

5.83

0.9

Alive
Variable

88

Deceased

The difference in the LOS between the patients who survived and who were deceased
(0.024 days) was not statistically significant (p=0.9). More details regarding mortality
and LOS are shown in the Appendix M. Table M.1 and M.2 and Figures M.1 and M.2 in
Appendix M. Data in charts graphically demonstrate the distribution of mortality by LOS
and LOS by age between groups.
Table IV.5 shows the difference between means of ages of septic patients
hospitalized before and after implementation of the sepsis protocol. The mean age in the
pre-implementation group was 72.14 years and in the post-implementation was 76.71
years; resulting in a statistically significant age difference of 4.57 years between the two
groups (p <0.05).
Table IV.5. T-Test: Difference Between Groups
11

Pre-implementation

Post-implementation

N

Mean

SD

N

Mean

SD

p
value

Age

86

72.14

15.17

72

76.71

13.44

<0.05

LOS

86

7.38

5.46

72

6.68

4.85

0.4

Number of prescribed empiric
IV antibiotics per patient per
stay

86

3.03

1.17

72

3.17

1.41

0.5

Number of days on empiric IV
antibiotics

86

6.62

4.33

72

6.94

5.02

0.66

Number of hours until pathogen
was identified

82

33.70

12.63

71

31.59

12.00

0.3

Number of hours final results of
cultures are known

82

64.68

19.97

71

69.59

13.33

<0.05

Variable
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The average LOS for the pre-implementation group was 7.38 days and postimplementation was 6.68 days. A minimum number of days patients were hospitalized
was one day for both groups. The maximum number of days for the pre-implementation
group was 26 days, and for the post-implementation group was 27 days. The difference
in LOS between the two groups was 0.7 day (p=0.4), which while statistically
insignificant, may represent a considerable difference in resource consumption for
hospitals (Table IV.5). The average number of empiric antibiotics prescribed before the
launch of new guidelines was 3.03 with minimum 0 and maximum 5, as opposed to the
average number 3.17, minimum 1 and maximum 7 after guidelines were in place, and the
difference was 0.13 (p=0.5), (Table IV.5). The average number of days each patient
received empiric antibiotics in the first group was 6.62 and in the second group 6.94. The
minimum number of days was 0 and maximum 22 for the pre-implementation group; for
the post-implementation, 1 and 27 days, respectively. With a 0.33 day difference, this
finding is also not significant (p=0.66), (Table IV.5).
Waiting Time for Blood Cultures
The number of hours of waiting time before the causative pathogen was first
identified in a cultured specimen, and the number of hours before the final results for
culture and sensitivity were available are shown in Table IV.5. The average waiting time
for the initial identification was 33.7 hours for the first group and 31.59 hours for the
second group, with a minimum of 2 hours, and a maximum of 72 hours respectively. The
difference was 2.1 hours (p=0.3).
The final culture results were available, on average, 64.68 hours after specimen
collection before guidelines implementation, and 69.59 hours in the post-implementation
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group, with a minimum of 2 hours and a maximum of 100 hours in the first group, and a
minimum of 40 and a maximum of 92 hours in the second group. The calculated
difference for this measure between the two groups was 4.91 hours and the difference
was statistically significant (p=0.05, Table IV.5). Additional data regarding the most
frequently used antibiotics and their utilization in sepsis is presented in Appendix M,
Figure M.3, and Table M.3.
For supplementary and supportive purposes to aid with the explanation of results,
ancillary data was collected regarding sepsis-related conditions, including the most
frequently occurring disease associated with sepsis as well as the most frequent causative
organisms, including C. diff. and MDR organisms. Pneumonia and urinary tract infection
(UTI) were the most frequently occurring conditions for both groups. Escherichia coli
(E. coli) bacterium and Candida fungus were the most often identified pathogens isolated
in septic patients (Appendix M, Figure M.4, Table M.4 and Table M.5).
For Objectives Two and Three, outcomes were summarized, and then analysis
was conducted while the pre-implementation and post-implementation groups’ outcomes
were compared. Compliance with each element of the new sepsis guidelines was
measured in the post-intervention group and compared to prior performance.
To achieve a clearer picture of the Sepsis Bundle’s impact on health outcomes,
additional data were gathered, including patient’s condition upon discharge from the
hospital, discharge destination, and readmission rates. For Objectives Four and Five,
results were examined for relationships, similarities, and differences, and conclusions
were made in efforts to answer the PICO question guiding this scholarly project.
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An additional secondary, but noteworthy, finding was the occurrence of a mental
status change in older patients with sepsis. Seventy-six percent of patients with sepsis
experienced mental status changes. The average age of those with acute delirium was 79
years as opposed to 69 years among those without acute confusion in the postimplementation group. Similarly, 7.9 years difference in age between patients with and
without mental status change associated with sepsis was noted in the pre-implementation
group.
Health Outcomes
This project aimed to answer the PICO question: In adult patients presenting with
sepsis before and after October 1, 2015, does implementation of a new sepsis protocol
reflect in improved outcomes such as reduced hospital LOS, decreased mortality,
morbidity, readmissions, and appropriate antibiotics utilization, and does it result in
initiating early treatments as compared to previous approaches?
Morbidity. Table IV.6 shows outcome variations between both groups in
patients’ mortality, functional status change at the time of discharge, the difference in
required level of care at discharge, as well as hospital course, in-hospital complications,
and readmissions. Additionally, differences in means of patients’ ages in each group in
relation to functional status at discharge and required level of care at discharge were
taken into consideration.
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Table IV.6. Outcomes of Patients with Sepsis
12

Sepsis Outcomes

Functional status at discharge
Better
Same
Worse
Deceased
Discharged destination
Prior living arrangements
SNF
Higher level of care/ transfer to tertiary hospital
Home Health
Hospice
Hospital course
Nosocomial/healthcare acquired infection
ICU, intubated
ICU, pressors
PCU
Of all pneumonia cases, HAP
Of all pneumonia cases, readmitted
Readmission among patients with sepsis
Sepsis progressed, worsened during treatment
Septic shock-only mortality
Sepsis mortality
Average age of those with functional status change
Better
Same
Worse
Deceased
Average age of those discharged to other settings
Prior living arrangements
SNF
Deceased
Higher level of care/ transfer to tertiary care
Home Health
Hospice
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Pre (n=86)

Post (n=72)

%
2
19
38
40.7
%
23
12
5
20
9

%
0
15
64
20.83
%
21
19
1
32
6

13
38
35
50
13
15
17
46
57
40.7

36
10
43
47
47
56
47
28
36
20.83

years
71.5
71.1
64.6
77.6
62.3
78.4
75.3
58.3
74.1
81.1

years
n/a
61.8
78.6
81.7
65.1
81.8
81.7
72.0
76.7
85.0

Figures in Table IV.6 show differences in patient outcomes prior to and following
implementation of the sepsis protocol. Sixty-four percent of sepsis survivors in the postimplementation group experienced worsening of their functional status, as compared to
38% in the pre-implementation group, at the same time observing 20.83% mortality in
the post-implementation group and 40.7% in the post-implementation group. This is in
the context of 57% and 36% mortality rate of patients with septic shock for preimplementation and post-implementation groups and respectively.
The average age of patients experiencing worsening of their functional status in
pre- and post-implementation groups was 64.6 and 78.6 years, respectively. Other
noteworthy findings include a higher percentage of patients who lost or had a decrease in
independence after hospitalization (26%) and a higher nosocomial (hospital acquired)
infection rate (23%) in the post-implementation group. In addition, a much lower
percentage of patients requiring intubation and ventilator support (28%) and a higher
incidence of sepsis associated with pneumonia were observed in the post-implementation
group. A substantial increase in nosocomial complications was noted (13%), and the
leading cause was healthcare-acquired pneumonia, which increased from 13% to 47%.
Of all deceased patients, over 70% had sepsis caused by pneumonia. The readmission
rate increased 30% with an increase in pneumonia cases as a major cause for
readmissions. While the readmission rate went up from 17% to 47% in the postimplementation group, the mortality rate among those who were readmitted decreased
from 78% to 29.4%. Protocol compliance and antibiotic utilization are addressed in
Tables IV.7, IV.8, and IV.9.
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Utilization of Antibiotics and the Sepsis Protocol Data
Table IV.7 shows the percentage of patients who had antibiotics administered
within the first three hours from the onset of sepsis, the percentage of the number of
antibiotics deescalated during hospitalization, as well as the percentage of the times that
the initially prescribed antibiotic turned out to be inappropriate based on culture results.
Table IV.7. Antibiotics Prescribing Trends
13

Prescribing trends

Pre (n=86)

Post (n=72)

Antibiotics deescalated

%
43

%
65

Inappropriate antibiotic choice for culture results

31

58

Antibiotic administered within 3 hrs

72

58

In the post-intervention group, there was a 22% increase of antibiotics which had
been deescalated from empiric to a narrower spectrum antibiotics. There was also a 27%
increase in inappropriate antibiotic choice for culture results, and a 14% greater delay in
antibiotics administered within three hours in the post-implementation group as compared
to the pre-implementation group.
The mean LOS for patients’ who received appropriate antibiotic therapy (AAT)
was 5.8 days and patients who received inappropriate antibiotics had an average hospital
stay of 9.1 days (p<0.0001). Among those who received AAT, the difference in LOS
between the two groups is 3.33 days (Table IV.8).
Patients who received AAT on time received empiric IV antibiotics on average
for 5.84 days, but those who had antibiotics prescribed inappropriately received empiric
IV antibiotics on average for 8.33 days(p<0.001). Patients who were treated for sepsis
with inappropriate antibiotics received on average 3.82 empiric antibiotics during the
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hospitalization, and those on AAT received on average 2.67 empiric antibiotics
(p<0.0001). The inappropriateness of antibiotics was determined based on final culture
results if shown the treatment was ineffective or inappropriate against causative
organisms The difference in days on empiric antibiotics was 2.48 day between groups
(Table IV.8).
Table IV.8. Antibiotic utilization
14

Yes

No
p-value

Variable

N

Mean

SD

N

Mean

SD

Received AAT (yes, no)/
LOS

96

5.80

4.14

61

9.13

5.99 <0.0001

Received AAT (yes, no)/
Number of days on
empiric IV antibiotics

96

5.84

3.82

61

8.33

5.36

Received AAT (yes, no)/
Number of prescribed
empiric IV antibiotics

96

2.67

1.00

61

3.82

1.32 <0.0001

<0.001

The difference in an average number of empiric antibiotics prescribed per patient
between two groups was 1.15 (Table IV.8). Additional data regarding distribution and
frequency of individual antibiotic utilization for both groups can be found in Appendix
M, Figure M.3, and Table M.3.
Sepsis protocol utilization. Utilization of the new sepsis protocol was measured
using the elements of the Sepsis Bundle guidelines for early management, as shown in
Table IV.9. The percentages of patients receiving treatments on time according to the
protocol were measured in both pre- and post-implementation groups.
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Table IV.9. Sepsis Protocol Compliance: Early Interventions
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Sepsis Protocol Compliance: Early Interventions

Pre (n=86)

Post (n=72)

%

%

1st Lactic Acid measures within 3 hrs

73

90

2nd Lactic Acid measured within 6 hrs when indicated

11

49

Lactic Acid results > 2

60

65

IVF initiated per protocol

58

65

Blood cultures drawn before antibiotic and within 3 hrs

80

80

Antibiotic administered within 3 hrs

72

58

Vasopressors per protocol

78

81

Focused exam

n/a

45

.
Noteworthy is the change in the collection of the lactic acid performance measure
between the two groups from 73% to 90% compliance obtaining the first specimen and
from 11% to 49% compliance obtaining the second lactic acid specimen. There was no
change in drawing blood cultures before and after implementation of sepsis protocols, but
the administration of antibiotics within the first three hours from sepsis onset dropped
from 72% to 58%.
Figure IV.2 is a graphical display demonstrating utilization of the sepsis protocols
including the early interventions: receiving antibiotics within three hours from initial
sepsis onset, having blood specimen drawn for blood cultures, first lactic acid level
within three hours, and second lactic acid level within six hours of sepsis presentation.
The chart shows a comparison of those elements between both groups.
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100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
Abt<3h

Pre
Post

Yes
No
Yes
No

LA1_3h

LA2_6h

Abt<3h

LA1_3h

LA2_6h

Cult<3h

%

%
73
27
90
10

%
11
89
49
51

%
80
20
80
20

72
28
58
42

Cult<3h

Figure IV.2.6Sepsis Guidelines Compliance.
*(Abt<3h: antibiotic administered within three hours from presentation; LA1_3h and LA2_6:
lactic acid collected within three and six hours respectively; Cult<3h: blood cultures were drawn
within three hours).

The first set of columns in Figure IV.2 represents the percentage of patients who
either received or did not receive antibiotics within three hours from sepsis presentation
in the pre-implementation group, followed by columns representing the postimplementation group. This distribution demonstrates a decrease in the percentage of
patients who received antibiotics on time after implementation of the sepsis protocol. On
the contrary, the percentage of patients having lactic acid drawn within the first three and
six hours increased after the new sepsis guidelines were put in place. The timing of
obtaining blood culture specimen did not change between groups.
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Summary of outcomes. Figure IV.3 is a graphical display demonstrating
patients’ outcomes, specifically patients’ condition and functional status at the time of
discharge, as well as discharge destination. The chart shows a comparison of those
elements between both groups.
70%
60%
50%
40%
30%
20%
10%
0%

Figure IV.3.7Patients’ Outcomes After Discharge Chart – Comparing Both Groups.
*(Dark gray bar = pre-implementation group; light gray = post-implementation group)

The most important differences within Figure IV.3 are the variations between groups in
patients’ mortality and health at the time of discharge from the hospital. While mortality
improved in the post-implementation group, there were considerably more patients whose
health status worsened and who were consequently discharged to higher levels of care
than before admission, whether it was a skilled nursing facility or home health agency
assistance at home.
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Relationships between variables. Multiple variables including age, LOS,
patients’ outcomes at discharge, initial presentation, empiric antibiotic utilization, and
waiting time for culture results were compared to each other to investigate the
dependence between them. The table below shows the matrix containing correlation
coefficients between the possible pairs of variables (Table IV.10) accompanied by the
scatter plot for visualization of the matrix (Figure IV.4).
Table IV.10. Correlation Coefficients among Both Groups Outcomes
16

Age

LOS

OutcmFS

IniPre

AbtEmpD

AbtEmp

CulthrID

Age

1

LOS

-0.0245

1

0.2363

0.1369

1

IniPres

-0.0847

0.1153

0.3524

1

AbtEmp#D

-0.0924

0.8797

0.0385

0.0806

1

AbtEmp#

-0.0434

0.4931

0.0821

0.1367

0.5192

1

Cult#hrID

-0.0749

0.1005

0.1785

-0.0093

0.0835

0.1071

1

Cltr#hrFIN

-0.0320

-0.0549

0.0152

-0.0170

-0.0145

0.0716

0.4358

OutcmFS

100

CulFIN

1

30
25
20
LOS
15

AbtEmp#D
AbtEmp#

10
5
0
0

20

40

60

80

100

Figure IV.4.8Correlation Coefficients among Both Groups Outcomes Scatter Plot.

The scatter plot above (Figure IV.4) corresponds to items included in the
correlation coefficient matrix in Table IV.10. It demonstrates the strongest relationship
between the LOS and the number of days empiric antibiotics were prescribed and
between the LOS and the number of antibiotics prescribed. The correlation between
these variables is positive, meaning that the longer the LOS, the more empiric antibiotics
were prescribed, and empiric antibiotics were received for a greater number of days.
Table IV.10 shows a very strong positive correlation between the duration of treatment
with antibiotics (AbtEmp#D) (0.8797) and the number of empiric antibiotics prescribed
(AbtEmp) and the patient’s LOS (0.4931). A positive but weaker relationship exists
between patients’ ages and declined functional status (OutcmFS) at the time of discharge
(0.2363), as well as patients’ condition at the time of initial presentation and discharge
(0.3524). The correlation between age and LOS is negative and extremely weak, almost
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negligible. (-0.0245). A strong positive correlation exists between the number of empiric
antibiotics prescribed and the duration of treatment with antibiotics (0.5192).
Summary
The focus of this project was retrospectively evaluating outcomes of patients with
severe sepsis before and after implementing the Sepsis Bundle. The results of this
analysis apply to a predominantly Caucasian population sample in a treatment setting
whose average age is 74 years old. In this sample population, the impact of the
mandatory sepsis protocol utilization on health outcomes was measured. While
substantial improvements were noted in some areas, a decline or no differences were
noted in others.
Mortality, the length of stay and health outcomes. The mortality rate
unsurprisingly has consistently been higher in the older population in both groups, but an
overall considerable improvement in the mortality rate was noted after the sepsis
protocols were implemented. The duration of hospitalization for patients with sepsis, on
average, was 0.7 days shorter. Although the improved mortality rate could have been
anticipated with new protocols, a decline of health outcomes of sepsis survivors was
noted in the post-implementation group. While LOS shortened after new guidelines were
implemented, patients were discharged in a generally worse condition than those
discharged prior to implementation. An increased number of patients who survived
sepsis were unable to return to their prior living arrangements, were discharged to nursing
facilities instead, or required additional help at home. Nevertheless, a substantial number
of lives had possibly been saved, and the average length of hospital stay reduced.
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Notably, among sepsis survivors, a considerably higher rate of readmission was recorded
in the post-implementation group.
Utilization of antibiotics and the protocol. There was no noteworthy difference
in antibiotic prescribing behaviors despite the fact that the post-implementation group’s
average duration of hospitalization was shorter, and there were fewer patients in septic
shock. Whereas a higher percentage of patients had blood samples collected for lactic
acid on time, unexpectedly fewer patients received timely initial antibiotics, and
considerably fewer patients received AAT after the new Sepsis Bundle was initiated. The
blood culture collection times and wait time for blood culture results were not affected by
the bundles.
Other secondary findings. While a decrease in MDR infections was noted, a
major increase in healthcare acquired infections was seen, which occurred in the context
of a higher readmission rate, with pneumonia being a leading cause for both readmissions
and healthcare acquired infections. An expected change in mental status often associated
with sepsis was noted in a higher percentage among older patients in both groups.
Finally, the results show a negligible relationship between age and LOS, a weak
correlation between patients’ outcomes at discharge and age, and a weak correlation
between LOS and outcomes at discharge, but a strong relationship between LOS and the
number of antibiotics prescribed.
The following chapter presents the discussion of findings outlined in this section,
and implications of these findings for nursing practice, research, and policy.
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CHAPTER V
DISCUSSION
Sepsis is a serious and often fatal condition affecting millions of people nationally
and across the globe, and despite advances in medicine and technology, the outcomes of
patients affected with sepsis remain poor. Patient outcomes not only depend on targeting
the pathogen but on controlling the host response and reducing collateral organ and tissue
damage.
The incidence of sepsis has been increasing over past decades, primarily as a
result of an aging population and a milieu of antimicrobial resistance and growing
numbers of drug-resistant pathogens. Wider use of immunosuppressive therapies, more
accessible medical technology and interventions, and improved recognition of sepsis are
other factors contributing to increased incidence and diagnosis of sepsis. Sepsis
guidelines have been evolving with changing recommendations derived from emerging
trials and evidence-based research. Efforts by healthcare organizations, government
officials, and researchers to improve sepsis outcomes have been put forth in attempts to
improve short-term and long-term survival. While there is a general consensus that the
optimal approach to sepsis management is early recognition and rapid interventions, the
methods of initial resuscitation and hemodynamic monitoring remain controversial.
This evidence-based project’s focus was to evaluate the effectiveness of the
newest sepsis protocol on patients’ health outcomes and compare mortality, morbidity,
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LOS, antibiotic utilization, and readmission rates before and after the protocol
implementation in a community hospital in the coastal region of South Carolina. In
addition, this project’s goal was to assess whether implementing the mandated protocol
actually influenced the timing of initiating early interventions. The protocol is a
mandatory quality improvement measure known as the Sepsis Early Management Bundle
(SEP-1) that went into effect on October 1, 2015, to monitor the quality of sepsis care in
hospitals nationwide. The Sepsis Bundle is enforced by Medicare and adherence is
measured by the timeliness of interventions.
A retrospective data analysis was performed that included 158 patients’ medical
records and compared patients’ outcome before and after implementation of the sepsis
protocols. The results presented in this paper apply to a population sample whose average
age is 74 years, predominantly Caucasian, and hospitalized with sepsis in the setting
noted above. In this sample population, the impact of mandatory sepsis protocol
utilization on health outcomes was measured.
The expectations for this project’s results were that outcomes of all aspects of
sepsis care would improve with the use of the new sepsis protocols, including hospital
length of stay (LOS) mortality, morbidity, and readmissions. Additionally, it was
anticipated that having introduced the mandated protocol for timely carrying out specific
therapeutic approaches to sepsis management would improve the timeliness to initiation
of these interventions. The outcomes of this project showed that uniform improvement
was not achieved. Given the results of this project, it can be assumed that the guidelines
have made an impact on some aspects of sepsis management and care and outcomes but
not others.
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Evaluation of Findings
While results of this project do not necessarily infer causality, since the new
protocol was made mandatory, considerably decreased mortality and reduced LOS were
reflected in the post-implementation group as compared to the pre-implementation group.
However, overall patients’ outcomes, including long-term morbidity such as a functional
status at the time of discharge and readmissions rates had worsened. Increased sepsis
survival rates and shorter hospital stay after implementation of the sepsis protocol may, in
fact, have contributed to these phenomena, because patients who would have otherwise
died did survive, but did so with multiple negative health consequences.
Results of this project are consistent with evidence in literature (Delaney et al.,
2013; Mouncey et al., 2015; Yealy et al., 2014) in which no significant decrease in sepsis
morbidity or mortality was demonstrated when patients were treated with a strict
protocol-based resuscitation strategy over individualized care at the discretion of the
treating physician. Results showed a marked improvement in mortality, but overall
worse health outcomes of those who survived sepsis.
Mortality. Major findings of this project included a considerably increased
overall incidence of sepsis and septic shock survival rates after the new sepsis protocol
was implemented. In reviewed literature, one study since Rivers et al. (2001) EGDT
trial, showed a marked reduction of mortality (Chelkeba, 2015). This project showed a
20 % decrease in mortality rates after the Sepsis Bundle protocol was in place (41%
mortality in the pre-implementation group and 21% in the post-implementation group).
Proportionally 10% fewer patients went into a septic shock and were critically ill, but
16% more severe sepsis cases were recognized in the post-implementation group
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compared to the pre-implementation group. These findings can be attributed to the EMR
alert module and mandated measures. A substantial 28% decrease in the number of
patients who were treated in the ICU, intubated and on a ventilator requiring respiratory
support were recorded in the second group. It can be speculated that faster recognition of
sepsis by providers may have improved the mortality outcome by preventing more
patients from progressing to septic shock and death. Aside from the availability of more
sophisticated treatments, the software generated sepsis alert, and the mandated measures,
the potential explanation for the decreased mortality rate seen in this project’s outcomes,
which is supported by the literature, may be multifactorial (Vincent et al., 2013).
Uniformly increased incidence of sepsis observed nationwide might be attributed to
increased awareness of sepsis, but also overdiagnosis. Outcomes of this project show
that after implementation of the new sepsis protocols in the community hospital,
mortality rates were reduced and LOS shortened.
The length of stay. There are conflicting results in the literature that include
questionable benefits of components of EGDT on LOS (Zhang et al., 2015); however,
this project’s findings did not reflect it. The average LOS for patients in this project
decreased by a 0.7 day from pre-implementation to post-implementation time. Although
the 0.7-day reduction in hospital LOS seems trivial, it is substantial for quality and costeffectiveness of care. Such a difference can contribute to lower patients' exposure to
iatrogenic complications. Furthermore, given the estimated costs associated with a day in
the hospital, a 0.7-day reduction would translate into approximately $1,500 in savings for
every inpatient admission (Gryczynski et al., 2016).
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These findings can be associated with more efficient resource utilization and costeffectiveness of sepsis care. This is likely to be attributed to improved sepsis awareness,
earlier recognition, and prompt treatment. Interestingly, on average, patients in the postimplementation group were 4.7 years older and, hypothetically, the final results might
show greater improvement if adjusted for age. These findings alone are optimistic and
encouraging, and if accurately owed to the protocol and enduring, they will likely
contribute to substantial cost savings on the utilization of healthcare resources. However,
while mortality and LOS were substantially lower in the post-implementation group, the
health outcomes of survivors were generally worse.
Morbidity. Although more patients survived sepsis, they often lost their
independence and required long-term care or assistance at home. A large percentage of
sepsis survivors were unable to return home and were discharged to rehabilitation nursing
facilities. They were also more likely to be rehospitalized with recurrent infections.
Older age and multiple comorbidities, disabling consequences of sepsis, as well as
possible premature discharges (shorter LOS) may be attributed to sepsis survivors’ poorer
health at the time of discharge preventing them from returning to their previous
functional status.
Sepsis has been associated with the development of at least one new physical
limitation for survivors and with a 3-fold risk of developing moderate to severe cognitive
impairment (Iwashyna et al., 2010). Sepsis survivors report deterioration in the quality of
life related to poor physical function and overall declined health (Turi & Ah, 2013). In
regards to morbidity, this project’s finding is consistent with the evidence in the literature
(Turi & Ah, 2013; Wang et al., 2014). Among patients in the post-implementation group,
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treated for sepsis after protocols were put in place, as many as 64% of those who
survived were discharged in lower functional status than prior to hospitalization, as
compared to a 38% in the pre-implementation group. Overall, this accounts for a 26%
difference. The decreased functional status in the second group appears to be explainable
by higher survival rates. While mortality in the same group was reduced by 20%, the
survivors were likely left with more severe comorbidities as a result of sepsis.
Interestingly, among the sepsis survivors in the post-implementation group whose
functional status was worse at the time of discharge as compared to their functional status
prior to admission, were on average 17 years older from those in the same group but
whose status did not change. There was an average 14 years difference in age between
those patients with worse outcomes at the time of discharge in the post-implementation
group than in the pre-implementation group was 14 years. Age seems to be playing an
important role not only in the incidence and mortality but also in the sepsis morbidity.
Evidence in literature also shows that older age is an independent predictor of poor
outcomes of sepsis (Martinal, 2006). Persons older than 65 years of age with multiple
comorbidities are at a higher risk for complications from infections than the general
population. Therefore, since worse outcomes in the post-implementation group could be
explained by the higher survival rates as well as the overall older age, in the future, it
could be useful to adjust for these differences in evaluating outcomes.
Only 21% of patients in the post-implementation group were discharged to prior
living arrangements compared to 23% in the pre-implementation group. Patients in the
post-implementation group were more frequently discharged to nursing facilities (19% in
contrast to 12% in the pre-implementation group), and considerably more frequently
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required home health or higher level of care (32% in contrast to 20% in the preimplementation group). These patients were at higher risk of developing recurrent
infections and further complications and were consequently more prone to
rehospitalizations.
Readmissions. Hospitals are paid by Medicare, Medicaid and third party payers
based on a formula that is specific to categories of diagnoses referred to as Diagnosis
Related Groups (DRG’s) (Case Management Innovations, 2016). The payments for the
DRGs are predetermined, and the amount does not change regardless of the cost of care.
Hospitals make profits by providing medically appropriate care and discharging patients
in a timely manner, but at the same time keeping the costs below the amount of the DRG
payment. If the cost exceeds the payment, then the hospital will lose money in that case
(Case Management Innovations, 2016). Early discharges may be driven by high costs of
acute care hospitalization, especially in intensive care units, and diagnosis- related
recommended average LOS. This project demonstrated disproportionally higher (47%)
readmission rates in the post-implementation group as compared to the preimplementation group (17%). This finding could be explained by patients being
discharged too soon in an effort to control costs based on DRGs as indicated by the
finding of a 9% reduction in LOS following implementation of protocols.
Readmission rates among sepsis survivors increased substantially in the period
measured after implementation of the sepsis protocol, from 17% to 47%. High
readmission rates are also documented in the literature. A retrospective cohort study of
adults hospitalized with severe sepsis showed that 26% of severe sepsis survivors were
readmitted within 30 days of discharge, 48% were readmitted within 180 days, and the

110

mean cost of each readmission was $25,505 (Goodwin, Rice, Simpson, & Ford, 2015).
In this project, of the 34 of the 72 patients with sepsis in the post-implementation group
were readmitted. These high readmission rates can lead to significant health care
expenditures. Based on the average cost of readmissions, an estimated cost for
readmissions in this setting could reach $870,000 including only those rehospitalized
patients from the post-implementation group, as compared to an estimated $380,000 prior
to the protocols being in place. It should be taken into consideration, however, that the
sepsis survivors in the second group were on average 4.7 years older and generally in
poorer health.
Patients presenting with sepsis often are also burdened with multiple
comorbidities that may contribute to readmissions. Under the Hospital Readmissions
Reduction Program (HRRP), hospitals with excess readmissions for selected common
diagnoses such as heart failure, myocardial infarction, pneumonia, chronic obstructive
lung disease, and total hip or knee procedures are penalized up to 3% of all DiagnosisRelated Group payments (Adamson, Bharmi, Dalal, & Abraham, 2015). Severe sepsis
readmission places a substantial burden on the healthcare system, with one in 15 and one
in five severe sepsis discharges readmitted within 7 and 30 days, respectively (Donnelly,
Hohmann, & Wang, 2015). Hospitals pay a high price in penalties for readmissions.
Hospitals and clinicians should be aware of this important sequela of severe sepsis
(Donnelly, Hohmann, & Wang, 2015).
Impact on protocol utilization. Uniform improvement in utilization of the
elements of the sepsis protocol and timeliness in initiating treatments were expected since
the Sepsis Bundle protocol became mandatory, especially in the context of associated
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preceding staff education and EMR updates to include sepsis alerts and prompts for
protocol exploitation. However, in this particular hospital, implementation of mandatory
sepsis protocols did not improve intervention processes when the interventions were
bundled together. While individual elements of the bundle, such as drawing lactic acid,
improved (on average, the first lactic acid sample collection within three hours of
presentation improved 17%, and obtaining repeat lactate within six hours improved
38%), unfortunately the timeliness of initiating antibiotics and the appropriateness of
antimicrobial agent choice substantially deteriorated. Moreover, with the new protocol in
place, 49% of qualifying patients had the second lactic acid collected, which is a major
improvement from 11% in the pre-implementation group, but still short of meeting
standard protocol. Initiation of appropriate IV fluids improved 7% in the postimplementation group, and there was no difference (80% for both groups) between
groups in drawing blood samples for cultures within three hours and prior to initiation of
antibiotics.
No clear explanation for these phenomena or associations with other variables
could be established based on the results of data analysis in this project. This protocol is
positively influencing some aspects of sepsis care that could continue to improve with
consistent use, but did not have much of an impact on the other aspects, such as the
antibiotics utilization warranting the necessity for continued attention to this issue.
Potentially, if better antibiotic utilization was possible in combination with the protocol,
improvements in both mortality and morbidity could be achieved.
Appropriateness of antibiotics utilization. No significant change was seen in
timeliness of obtaining blood cultures before and after implementation of protocols,
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therefore there was no difference in the time until pathogens were identified. No change
in the current long waiting time for the culture results was anticipated since this is
dependent on the hospital microbiology techniques and currently available technology,
not on the new protocols. A long waiting time for cultures results in a greater period of
time that empiric, broad-spectrum antibiotics are utilized. Moreover, the necessity to
treat unidentified pathogens probably contributes to inappropriate antibiotic choices,
which in turn encourages breeding resistant microbes and leads to an increase in multidrug resistant organisms. The proportion of patients receiving AAT within the first three
hours of sepsis onset decreased from 72% in the pre-implementation group to 58% in the
post-implementation group. Nearly 60% of patients in the post-implementation group
received inappropriate antibiotics based on subsequent cultures results.
This problem occurs similarly in this facility and across the nation in facilities that
still use traditional methods to obtaining blood cultures results. Current standard blood
culture procedures consist of inoculating blood cultures bottles and monitoring for the
growth of microorganisms. Cultures are allowed to grow for 24 to 72 hours or longer,
with subsequent subcultures and susceptibility to antibiotics testing results (Dekmezian,
Beal, Damashek, Benavides, & Dhiman, 2015). This process creates a considerable
delay in initiating AAT from the initial collection of blood sample from the patient to
delivery of the most appropriate antimicrobial treatment. Newer technologies such as
molecular diagnostics offer rapid identification and might be more efficient diagnostic
tool for the treatment of infections.
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Additional Findings
The most common source of infection among adults is the lung or lungs, and
pneumonia is the leading cause of sepsis nationwide. While community-acquired
pneumonia is the most frequently seen cause of sepsis, pneumonia can also be caused by
a healthcare-associated infection that affects 1.7 million hospitalizations in the United
States every year (Sepsis Alliance, 2016). In this setting, the incidence of pneumonia in
septic patients accounted for 50% of all sepsis causes in both groups, followed by urinary
tract infections. While a trivial decline in the incidence of MDR infection was recorded
in the post-implementation group, there was a major increase in nosocomial infections,
from 13% in the pre-implementation group to 36% in the post-implementation group.
Pneumonia was seen as the most frequent reason for readmissions (56% in the postimplementation group, compared to 15% in pre-implementation group), and 47% of those
readmitted cases in the post-implementation group were associated with healthcareacquired pneumonia compared to 13% in the pre-implementation group. Furthermore, of
all deceased patients in both the pre-intervention and post -intervention groups, over 70%
had a diagnosis of sepsis related to pneumonia. These findings may be associated with
increased survival rate but a poorer health status of survivors. As more people survive
sepsis, survivors are frequently struggling with serious health issues and they are prone to
recurrent infections including pneumonia and sepsis.
Another noteworthy unexpected finding was that 76% of septic patients also
experienced a mental status change and those patients were on average 9.8 years older
than those who did not experience acute mental status change associated with sepsis.
This finding may be important in diagnosing sepsis in elderly patients. In addition, there
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was an association found between the number of empiric antibiotics prescribed and the
LOS. While the results cannot demonstrate causality, an assumption can be made that
sicker patients did not respond to treatments as expected. This is likely due to their more
severe presentation, multiple comorbidities or immunocompromised status, thus the
necessity to use a greater number of broad-spectrum antibiotics and longer
hospitalization.
Limitations
One of the limitations of this study was that the overall sample size was small.
This project involved patients with a mean age of 74. In addition, patients in Labor and
Delivery, Gynecology, Neonatal, and Pediatric wards were not included in this study,
which could have influenced the results consequently yield different results as these
individuals are very likely different from the participants chosen for this project.
Post-implementation group participants were on average 4.7 years older which
should be taken into consideration when comparing both groups. Other confounding
variables such as comorbidities may have also affected patients’ outcomes. Since
comorbidities were not included in the analysis, it is important to acknowledge that
certain aspects of the participants’ health history may have affected the outcomes.
With objectivity in data collection, potential measuring bias is low. The access to
the data in a retrospective review reduces the possibility of data collection, calculation or
transcription errors. Reliability can be established with accuracy of the tools used for
data analysis that produces stable and consistent results, and validity with concepts
accurately measured, although clinicians’ judgments and charting error cannot be
completely excluded.
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Recommendations
Recommendations for Practice. Results of this project suggest the need for
improvement and innovative approaches to therapeutic and diagnostic methods that could
facilitate earlier and more targeted interventions in this acute care hospital setting.
Methods such as an antimicrobial stewardship program and rapid diagnostic technology
can generate a better response to treatment, and potentially improve sepsis outcomes,
save resources, and help to reduce MDR organisms. Utilization of antimicrobial
stewardship programs in inpatient settings has many benefits including improved patient
outcomes, reduced adverse events such as Clostridium difficile infection, improvement in
rates of antibiotic susceptibilities to targeted antibiotics, and optimization of resource
utilization across the continuum of care (Calderwood et al., 2015). Antibiotic
stewardship programs are designed to implement guidelines and strategies to reduce
antibiotic therapy to the shortest effective duration and increase both appropriate uses of
oral antibiotics and the timely transition of patients from empiric to narrow spectrum
targeted treatment. The rising threat of antimicrobial resistance calls for rapid
interventions with appropriate antimicrobial choices in sepsis treatment.
In this setting, an interdisciplinary team dedicated to improving sepsis outcomes
has been functioning, but a more robust, dedicated antimicrobial stewardship program
would be beneficial in sepsis treatment as well as in attempts to combat antibiotic
resistance, reinfections, and superinfections. This stewardship program should be formed
by a multidisciplinary team consisting of practicing clinicians, such as a hospitalist
physician or a nurse practitioner, in collaboration with clinical pharmacists, clinical
microbiology staff, the infectious disease specialist and the infection control staff. The
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team should implement local strategies aimed at timely delivery of appropriate antibiotic
therapy and timely de-escalation of empiric antimicrobials to narrower spectrum agents
to improve outcomes and reduce the length of stay (Zhang Micek & Kollef, 2015). Local
strategies include collaboration between prescribers, pharmacists, and the entire team,
and knowledge of antimicrobial susceptibilities of local bacterial isolates and resistance
patterns to aid inappropriate empiric antibiotic selection. The team should focus on
prompt de-escalation of antibiotics based on cultures and sensitivities, and continue to
explore innovative diagnostic technologies to allow earlier identification of pathogens.
Rapid diagnostic testing in addition to conventional cultures combined with active
antimicrobial stewardship program support has the potential for considerable
improvement of sepsis management and patients’ outcomes (Barlam et al., 2016).
Advantages to transition to rapid diagnostic technology such as molecular diagnostics
would far outweigh any disadvantages including cost because this technology has the
potential to have readily available, objective, and reproducible tests that guide specific
treatment of infections (Wilson, 2015). This project’s findings have to be integrated with
collaborative sepsis team efforts to improve sepsis outcomes in this setting, and use data
to validate best practice recommendation.
Not all sepsis is created equal and a cookie cutter approach should not be used in
the treatment approach. Sepsis does not follow any algorithm and does not always
progress in a predicted direction. It is a misconception that sepsis always progresses
gradually from sepsis to severe sepsis to septic shock; therefore, applying treatment
templates would not always yield desired results. There are no specific thresholds to
sepsis, and applying standard measures to such a complex and rapidly progressing
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condition is likely to fail in achieving uniform improvement in outcomes. Enforcing
obligatory standardized measures as templates to combat sepsis proved unsuccessful in
many aspects of health outcomes, as shown in this project’s results and supported by the
evidence-based literature. Therefore, applying individualized clinical judgments to
treatments such as aggressive fluid resuscitation and empiric antibiotic use, utilization of
knowledge of individual patient’s history and local antibiogram make-up, in addition to
evidence-based guidelines and protocols could result in the most favorable outcomes.
Recommendation for Future Research. Healthcare providers should anticipate
seeing more sepsis cases in the future, partially as a result of better recognition of the
condition, but primarily because people are now living longer with multiple
comorbidities that are currently treatable. Future studies are needed to identify
approaches that can help the increasing older population of sepsis survivors to regain
independence, return to prior living arrangements, and avoid rehospitalizations. Again, a
possible assumption can be drawn that a relationship exists between the rate of patients
experiencing worse outcomes and readmissions. Further analysis to estimate these
associations and an intervention research related to discharge planning and prevention of
readmissions would be beneficial to approaches to sepsis care.
Whereas early diagnosis of sepsis and prompt initiation of antibiotic treatment
improve survival, methods of initial resuscitation and hemodynamic monitoring remain
controversial. The nuances of aggressive fluid administration to all septic patients, and
using vasopressors in early septic shock are divisive and not completely defined;
therefore, more research is needed to further validate the most practical methods for
optimal sepsis treatment. Further investigation would also be beneficial to establish
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direct evidence regarding safety and efficacy of early de-escalation of antimicrobial
agents for adults with sepsis, severe sepsis or septic shock (Silva, Andriolo, Atallah, &
Salomão, 2013).
Sepsis in the elderly population is a common problem associated with
considerable mortality and major consumption of healthcare resources. These findings
have implications for resource prioritization and provide insights for expanded scientific
investigation (Martin et al., 2006). A separate study utilizing sepsis data would be useful
to evaluate sepsis outcomes given advanced age and pre-existing conditions. In addition,
a study researching altered mental status in elderly patients as a sign of impending sepsis
would be helpful for healthcare providers in recognizing sepsis in this vulnerable
population. Since pneumonia was the leading cause of sepsis and death from sepsis, it
could be beneficial to further investigate this problem, including for example
investigation of pneumonia occurrences, preventative measures, and vaccination rates.
Despite extensive research, advances in medicine and technology, knowledge of
sepsis pathophysiology and complexity of its mechanisms is still limited, and finding
optimal sepsis management strategies is challenging. More research is needed addressing
best evidence practice, as currently available therapies do not provide a cure. Future
study on more individualized approaches for better therapeutic response is needed
(Iskander, et al., 2013).
Recommendation for Policy. Given the limitations to current guidelines as
outlined in this project, recommendation for the general policy is to consider updating
sepsis definitions; specifically, clarifying SIRS and severe sepsis definitions before
mandating sepsis measures. Today, diagnosis of sepsis relies on nonspecific
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physiological criteria and causative microorganism detection based on culture assays.
This results in diagnosis and treatment delays, and improper use of antibiotics. Since
symptoms of sepsis can be vague especially in its early stage, it is difficult, if not
impossible to denote the exact time of initial sepsis onset, which is an important point of
reference in current treatment guidelines and a marker for quality measures. This may
lead to inappropriate prescribing of antibiotics in order to comply with the measure.
The key to effective treatment of sepsis is fast detection and rapid initiation of
treatment. Recommendations for policy improvement for this hospital include
consideration to establishing a Code Sepsis call in addition to current sepsis guidelines,
and a medical sepsis team dedicated to the rapid recognition and timely initiation of
appropriate treatments. Ongoing staff education is fundamental because tight
coordination and communication are needed among the entire team. The risk of having
Code Sepsis is that the code can inadvertently be called to patients who do not have
sepsis but meet severe sepsis criteria, and unintentionally captured by the sepsis measure
matrix. Consequently, this raises concerns about antibiotic overuse. Therefore, other than
simply accepting the risk, it is imperative to have a policy in place regarding appropriate
antibiotic use and de-escalation once deemed safe for patients and coordinated by
designated antimicrobial stewardship program team.
Despite an emphasis on the appropriateness of antibiotic administration,
measuring effects of antibiotics’ appropriateness and effectiveness against pathogens is
only possible with known culture and sensitivity data, is not usually available for 24 to 96
hours (Puskarich et al., 2011). Therefore, the antimicrobial stewardship team needs to be
focused on providing evidence to influence the hospital administration to consider
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investing in the innovative diagnostic technology to allow earlier identification of
pathogens and, in the spirit of antimicrobial stewardship, better-targeted antibiotic
treatment.
Hospital administration should also consider assessing discharge practices to
evaluate for potential premature discharges. While each additional day of hospital stay
over the recommended LOS based on DRG is not cost effective as it falls outside of the
bundle payments for the hospital, readmissions can be much more expensive and
premature discharges can have serious negative health consequences for patients.
Based on results of this project, drawing the second lactic acid was especially
deficient in both the pre- and post-implementation measures. Therefore, another
recommended innovation, in order to improve compliance with sepsis guidelines,
includes building into the existing sepsis power plan in the EMR software an additional
automated reflux order prompting providers to repeat a lactic acid level for qualified
patients.
Standardizing sepsis care proves to be challenging. Proportionally more
diagnoses of severe sepsis were made after the protocol went into effect. This could be
attributed to overdiagnosis based on the protocol’s controversial criteria for SIRS and
severe sepsis. The concepts of SIRS and severe sepsis with their low specificity and high
sensitivity can lead to misinterpretations and discrepancies in reported incidence and
observed mortality. Therefore, data collected retrospectively for the quality measure
could inadvertently include patients that were perhaps not septic at all, thus incorrectly
showing more survivors among patients labeled with severe sepsis. Hospitals not treating
these patients accordingly as per the protocol can trigger a quality measure deficit based
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on the mandatory quality improvement measure known as the Sepsis Early Management
Bundle (SEP-1). Hospitals will likely be struggling with this measure; therefore, the
severe sepsis definition should be clarified for the purpose of the accuracy of data
collection for quality measures. In the case of severe sepsis (SIRS with infection and
evidence of organ damage), it should be made clear that the organ dysfunction is a new
condition related to current infection, and quality procedures should leave room for
individual clinical judgment. Measures of sepsis guideline effectiveness should focus on
not only immediate results and improved mortality rates, but also long-term debilitating
effects affecting survivors. Both short-term survival and long-term morbidity, including
a return to function, should be considered as important outcomes.
Conclusions
This report summarizes the retrospective review of effects of sepsis protocols on
health outcomes, particularly mortality, hospital LOS, morbidity, readmissions,
antibiotics utilization, and the protocol’s impact on the early initiation of treatment in a
South Carolina community hospital. This project showed that implementation of
mandatory sepsis protocols did not uniformly improve intervention processes. Moreover,
results did not clearly demonstrate that the Sepsis Bundle interventions improved overall
outcomes. The mortality and LOS improved, but health outcomes of survivors did not.
While the utilitarian goal to reduce mortality is reasonable, the increasing numbers of
sepsis survivors are at high risk for worse long-term negative health outcomes. These
patients may be discharged into nursing facilities from the hospital prematurely and in
worse functional status and health than prior to hospitalization. This puts them at risk for
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remaining in long-term care homes and prone to readmissions because of the debilitating
nature of sepsis.
This project is an exploration of a PICO question that addresses a current problem
with sepsis management in the South Carolina’s community hospital, which is relevant to
DNP practice. The methodology described above is an attempt to determine the impact
of the newest Sepsis Management Bundle on patient outcomes and feasibility to
recommend practice change in this facility. Sepsis is common in hospitals and its
outcomes are frequently fatal. Prompt recognition and effective treatment are serious
issues that this and other hospitals are facing across the nation. This project offers the
stakeholders an educational opportunity to gain new knowledge regarding the severity of
the problem of sepsis and its management among inpatient adults in this hospital, and the
effects of the current sepsis protocol on patients’ outcomes.
Evidence in the literature supports the conclusion that enforcing protocols alone is
unlikely to bring anticipated results. An open-minded approach is needed to sepsis
interventions, with criteria and guidelines that allow room for clinical judgment. Sepsis
guidelines should focus not only on survival but also on long-term consequences for
survivors and their return to their prior level of functioning. Administration of
appropriate antibiotics may be the single most important factor in reducing both longand short-term morbidity and mortality from sepsis (Marik, 2014). Antibiotic treatment
efficiency can be best achieved with robust antibiotic stewardship programs and can be
improved with rapid diagnostic technology. Nevertheless, no single sepsis-specific
treatments exist and core management of patients still relies mainly on early recognition,
initiation of treatment, and source control. Accurate and prompt diagnosis of sepsis,
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identification of causative pathogens, and initiation of appropriate antibiotic treatment are
paramount approaches to sepsis, but the protocol’s interventions remain a source of
controversy, and timely recognition remains a challenge for healthcare professionals.
Although the Sepsis Bundles have already been enforced by CMS, new clinical trials are
needed to update sepsis criteria and definitions, to evaluate the effect of interventions on
short and long-term health outcomes and determine best evidence-based approaches.
As the knowledge of sepsis pathobiology improves and technology continues to
advance, the recommendations for sepsis treatment will continue to evolve and change
based on emerging new evidence as they have over past decades (Lopez-Bushnell,
Demaray, & Jaco, 2014). This quality improvement project might serve an introductory
work in developing a research study that can be generalizable to other settings and more
globally address the challenge of sepsis management.
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randomized
controlled trial
IA

A total of 617 patients with
positive blood cultures
were included, randomized
to three groups: control, n
= 207, rmPCR n = 198 and
rmPCR/AS, n = 212.

Threats to
Validity/
Reliability
All RCT scored
high except for lack
of blinding

Relatively small
sample, otherwise
none identified

Findings

EGDT is not superior to
usual care for ED patients
with septic shock, no
effect in primary and 90day mortality

Conclusions

EGDT for
patients
presenting to
ED with early
septic shock
does not
decrease
mortality but
increases ICU
resources
utilization.
Intervention group had
Groups did not
shorter time to microbe
differ in
ID (1.3 hr) vs. control
mortality, LOS,
(22.3 hr) (P < .001) and
or cost. rmPCR
decreased broad-spectrum reduced use of
antibiotic use (control 56 broad-spectrum
hr, rmPCR 44 hrs,
antimicrobials.
rmPCR/AS 45 hr; P =
Addition of
.01) and increased
antimicrobial
narrow-spectrum (control stewardship
42 hr, rmPCR 71 hr,
enhanced
rmPCR/AS 85 hr; P =
antimicrobial
.04) use, control 24 hours, de-escalation.
rmPCR 6 hours, P = .04).

Systematic
review and metaanalysis of RCT
IA

Trial included RCTs, total
of nine trails comprising
4783 patients that
compared EGDT with
usual care

Six studies low risk
of bias, remaining
studies unknown
risk of bias. None of
the these included
nine trials were
double blinded as it
is difficult to blind
the clinicians in
such difficult
situations, and we
believe that such act
did not influence the
outcomes of
interest.

The study found that
EGDT significantly
reduced mortality in a
random-effect model (P =
0.008); significantly
reduced mortality in low
to middle economic
income (P = 0.002)
compared to those in
higher income countries
(P = 0.28).On the other
hand, patients receiving
EGDT had longer length
of hospital stay compared
to the usual care (P =
0.07);

Delaney, A.
P., Peake, S.
L.,
Bellomo,
R.,
Cameron,
P.,
Holdgate,
A., Howe,
B., ... &
Webb, D.
(2013).

ARISE
(Australasian
Resuscitation in
Sepsis
Evaluation)
multicenter
prospective,
randomized trial
IA

Designed to test the EGDT
hypothesis as compared to
usual care, this trial was
conducted at 51 tertiary
care and non-tertiary care
metropolitan and rural
hospitals across Australia
and New Zealand. 796
patients were assigned to
the EGDT group and
received care based on the
original EGDT
resuscitation algorithm, and
804 control patients
received usual care at the
discretion of the treating
physician

Trial could not be
blinded, but risk of
bias minimized
through central
randomization

Study results
demonstrated that
patients in the EGDT
group were more likely to
receive vasopressor
infusion, red-cell
transfusion, and
dobutamine infusion.
However, despite an
increased rate of
aggressive therapy, there
was no significant
difference in 28- and 90day mortality, hospital
mortality, organ support
and LOS between the two
treatment groups
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Chelkeba,
L., Ahmadi,
A.,
Abdollahi,
M., Najafi,
A., &
Mojtahedza
deh, M.
(2015).

The result of
our study
showed that
EGDT reduced
mortality in
patients with
severe sepsis
and septic
shock.
Paradoxically,
EGDT
increased the
length of
hospital stay
compared to
usual routine
care.
Adherence to
the EGDT
algorithm did
not offer a
survival
advantage over
usual care for
patients
presenting to
the emergency
department with
early septic
shock.
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Jones, A.
E., Shapiro,
N. I.,
Trzeciak,
S., Arnold,
R. C.,
Claremont,
H. A.,
Kline, J. A.,
&. (2010).

RCT,
multicenter,
prospective,
randomized,
non-blinded
clinical trial
IA

The study evaluated
whether lactate clearance
could be an equally
effective measure of tissue
oxygen delivery and an
alternative to central
venous oxygen saturation
(ScvO2) measurement.
Included in data analysis
were 294 patients, 147
patients were assigned to
the control ScvO2 group,
and 147 to the lactate
clearance group.

None identified

Study results
demonstrated no
difference in frequency of
any treatments
administered during the
six-hour resuscitation
period and throughout the
initial 72 hours of
hospitalization to
maintain high compliance
with the target goals
(CVP, MAP, and ScvO2,
or lactate clearance)

Mouncey,
P. R.,
Osborn, T.
M., Power,
G. S.,
Harrison, D.
A., Sadique,
M. Z.,
Grieve, R.
D., ... &
Rowan, K.
M. (2015).

(ProMISe)
Multicenter,
pragmatic, open,
parallel group
randomized
controlled trial
with integrated
economic
evaluation
IA

Trial conducted in 56
hospitals in England from
February 16, 2011, to July
24, 2014, enrolled 1260
patients, 630 in EGDT
group and 630 in usual care

Interventions could
not be blinded, but
the risk of bias
minimized through
central
randomization.
Since lower than
anticipated death
rate, this study
outcome may not
apply to settings
with higher
mortality

Mortality was 29.5% in
EGDT group and 29.2%
in the usual care, and no
significant difference in
any other outcomes
including health-related
quality of life, or rated in
serious adverse events.
Moreover, on average,
EGDT was associated
with increased costs.

Measurement of
lactate
clearance, a
quicker and
more noninvasive
measurement,
can be an
equally
effective
alternative to
ScvO2
monitoring in
goal-directed
resuscitation.
EGDT strict
protocol and
addition of
SCVO2
monitoring did
not lead to
improvement in
outcomes. Of
note, decreasing
mortality is a
trend in recent
years, and many
aspects of sepsis
care have
evolved since
Rivers et al.
(2001) study 15
years ago.
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Peake, S.
L., Delaney,
A., Bailey,
M.,
Bellomo,
R.,
Cameron, P.
A., Cooper,
D. J., …&
Williams, P.
(2014).
Sterling, S.
A., Miller,
W. R.,
Pryor, J.,
Puskarich,
M. A., &
Jones, A. E.
(2015).

Prospective,
randomized,
parallel group
trial
IA

From October 5, 2008, to
April 31, 2014, a trial was
conducted in 51 tertiary
and non-tertiary
metropolitan and rural
hospitals

Trial could not be
blinded, but risk of
bias minimized
through central
randomization

In critically ill patients
presenting to the
emergency department
with early septic shock,
EGDT did not reduce allcause mortality at 90 days

The value of
incorporating
EGDT into
international
guidelines as a
standard of care
is questionable

Systematic
review and metaanalysis; IA

11 included studies, 16,178
patients were evaluable for
antibiotic administration
timing from emergency
department triage. The
study sought to determine
the association between
timing of antibiotic
administration and
mortality in severe sepsis
and septic shock.

None identified

Contrary to Kumar et al.
(2006) study, this study
found no increased
mortality in the pooled
odds ratios for each
hourly delay from less
than 1 to more than 5
hours in antibiotic
administration from
severe sepsis/shock
recognition.

No significant
mortality
benefit of
administering
antibiotics
within 3h of ED
triage or within
1 hour of shock
recognition in
severe sepsis
and septic
shock. These
results suggest
that currently
recommended
timing metrics
as measures of
quality of care
are not
supported by
the available
evidence

Yealy, D.
M., Kellum,
J. A.,
Huang, D.
T., Barnato,
A. E.,
Weissfeld,
L. A., Pike,
F., ... &
Angus, D.
C. (2014)

ProCESS
(Protocolized
Care for Early
Septic Shock) A
prospective
multicenter
randomized trial
IA
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The study evaluated
whether all aspects of the
original EGDT protocol
(by Rivers, 2001) were
necessary. 31 academic
EDs across the United
States participated, in this
study. 1,341 patients
meeting criteria for severe
sepsis and septic shock
were included in data
analysis; 439 patients
received EGDT according
to the original protocol,
456 control patients
received standard care, and
446 patients received
protocol-based standard
therapy.

Generalization
across various
healthcare settings
and outside of the
United States is
uncertain, more
evidence is needed.

Despite more aggressive
therapy in the protocolbased groups, there was
no significant difference
in 60- and 90-day
mortality between the
treatment groups; no
significant differences in
the incidence and
duration of
cardiovascular or
respiratory failure, LOS,
in sepsis morbidity or
mortality when patients
were treated with a strict
protocol-based
resuscitation strategy
over usual care at the
discretion of the treating
provider

This study
outlined a
protocol for
administration
of fluid and
vasoactive
agents to reach
goals for
systolic blood
pressure, shock
index, and fluid
status, without
mandating
invasive venous
access,
aggressive
blood
transfusion, and
inotropic
support. A
combination of
EGDT and
protocol based
therapy offers
no survival
benefits as
compared to
not-protocolbased usual
care.

Systematic
review and metaanalysis of RCTs
IA

10 RCTs included from
2001 to 2014 involving
4,157 patients

Among all RCTs,
none of them were
double-blinded.
However, blinding
of patients and
clinicians was
extremely difficult
in these studies to
evaluate a complex
intervention such as
EGDT protocol, and
the authors judged
that the primary
outcome (mortality)
is not likely to be
influenced by lack
of blinding

Gu, W. J.,
Wang, F.,
Bakker, J.,
Tang, L., &
Liu, J. C.
(2014).

Meta-analysis of
RCTs
IB

13 trials involving 2,525
adult patients were
included.

Strong and
definitive
recommendations
cannot be made
given variable
quality of the
studies
.
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Zhang, L.,
Zhu, G.,
Han, L., &
Fu, P.
(2015).

EGDT was associated
with a higher mortality
rate in comparison with
the early lactate clearance
group (P = 0.02). In the
first 6h EGDT received
more inotropic agents
(P = 0.04), fluid
administration (P = 0.05),
and red cell transfusion
(P < 0.01). There were no
significant differences in
length of ICU stay
(P = 0.73) or in-hospital
stay (P = 0.57),
ventilation rate
(P = 0.53), and
vasopressor support
(P = 0.63).
GDT significantly
reduced overall mortality
in the
random-effects model
(P=0.01); mortality
benefit was seen only in
the subgroup of early
GDT within the first 6
hours

No significant
difference in
mortality
between the
EGDT and the
control group

The results of
the present
meta-analysis
suggest that
GDT reduces
overall
mortality in
patients with
sepsis,
especially when
initiated early.

150

Puskarich,
M. A.,
Trzeciak,
S., Shapiro,
N. I.,
Arnold, R.
C., Horton,
J. M.,
Studnek, J.
R., ... &
Jones, A. E.
(2011).
Xu, J.,
Yang, Y., &
Qiu, H.
(2016).

Pre-planned
analysis of a
multicenter
prospective,
parallel group,
randomized
controlled trial of
early sepsis
resuscitation
IB

Study was designed to
assess the non-inferiority of
lactate clearance versus
central venous oxygen
saturation, evaluated adult
septic patients in 3 urban
EDs in the United States

Non-blinded. Only
able to draw
conclusions
regarding
associations and not
causation.

The study found no
increase in mortality with
each hour delay to the
administration of
antibiotics after triage.
However, delay in
antibiotics until after
shock recognition was
associated with increased
mortality.

Among patients
who received
antibiotics after
shock
recognition,
mortality did
not change with
hourly delays in
antibiotic
administration

Meta-analysis of
RCTs
IB

Nine studies compared
EGDT with control care,
and 5202 severe sepsis and
septic shock patients were
included.

More powered,
randomized
controlled trials are
needed to determine
the effects

A non-significant trend
toward reduction in the
longest all-cause
mortality was observed in
the EGDT group
compared with control
care

Trial sequential
analysis
indicated lack
of firm evidence
for a beneficial
effect of EGDT
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Yu, H., Chi,
D., Wang,
S., & Liu,
B. (2016).

Meta-analysis of
RCTs
IB

5 studies enrolled 4303
patients with 2144 in the
EGDT group and 2159 in
the control group. The trial
was conducted to
determine whether patients
with severe sepsis or septic
shock could benefit from
the EGDT protocol
recommended by SSC
Guidelines.

Included trials are
not sufficiently
homogeneous and
potential
confounding factors
in the negative trials
(ProCESS, ARISE,
and ProMISe) might
bias the results and
diminish the
treatment effect of
EGDT

Overall, there were slight
decreases in mortality
within 28 days, 60 days
and 90 days in the
random-effect model in
patients with severe
sepsis or septic shock
receiving EGDT
resuscitation. However,
none of the differences
reached statistical
significance

Rivers E,
Nguyen B,
Havstad S,
Ressler J,
Muzzin A,
Knoblich B,
& Peterson
E. (2001).

Single –center,
prospective,
randomized trial
IC

The study included 263
patients who met criteria
for severe sepsis and septic
shock; 130 subjects
received EGDT and 130
controls received standard
care. Study examined the
effects of Early Goal
Directed Therapy (EGDT)
to evaluate the efficacy of
the therapy prior to
admission to Intensive Care
Unit (ICU)

Small sample,
external validity
threat due to single
center study.
Potential bias
resulting from the
direct influence
of the investigators
on the care of the
patients
in the treatment
group

In-hospital mortality was
30.5% in the group
assigned to EGDT,
compared to 46.5% in the
standard therapy group in
short-term treatment
(p=0.009). Mortality was
33.3% in EGDT group
(p=0.01) compared to and
49.2% in control group in
28 day mortality rate ,
and 44.4% EGDT group
(p=0.03) to 56.9%
standard therapy groups
in 60-day long-term
mortality outcomes

Data from five
RCTs and found
no survival
benefit of
EGDT in
patients with
sepsis. Further
well-designed
studies should
eliminate all
potential source
of bias to
determine if
EGDT has a
mortality
benefit.
This landmark
article
demonstrated
both long and
short-term
mortality
benefit when
EGD was
introduced
within the
earliest possible
stages of sepsis
while patients
are still in ED
and prior to
going to ICU.
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Jones, A.
E., Brown,
M. D.,
Trzeciak,
S., Shapiro,
N. I.,
Garrett, J.
S., Heffner,
A. C., &
Kline, J. A.
(2008).

Systematic
review and metaanalysis of RCT
IIB

The study sought to
measure the treatment
effect of quantitative
resuscitation on mortality
from sepsis. Nine RTCs
were included and total
sample of 1001 subjects

Dettmer,
M.,
Holthaus,
C. V., &
Fuller, B.
M. (2015)*.

Retrospective
observational
cohort study
IIIB

Multivariable model was
used in this study of 243
adult patients with severe
sepsis and septic shock to
assess outcome differences
between the serial lactate
and no serial lactate cohorts
to assess clinical outcomes

No blinding,
limitations of
making inferences
based on betweenstudy rather than
within-study
comparisons.
Potential bias due to
its retrospective
approach, and
possibility of
unreported
cointerventions
influenced results
Small sample. This
is a retrospective
study which limits
causal inference

The study demonstrated a
survival benefit afforded
by quantitative
resuscitation to treat
sepsis at or near the time
of recognition. There is
lost if the intervention is
initiated late. Study
demonstrated support for
the Surviving Sepsis
Campaign
recommendation

Applying an
early
quantitative
resuscitation
strategy to
patients with
sepsis imparts
reduction in
mortality.

Lack of serial lactate
monitoring was
independently associated
with mortality. Serial
lactate monitoring is
associated with an
increase in crystalloid
administration,
resuscitation
interventions, and
improved clinical
outcomes in ED patients
with severe sepsis and
septic shock

Study results
suggest that
serial lactate
monitoring,
targeting a
reduction in
lactate levels to
normal, is a
generalizable
resuscitation
target in the ED.
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Marik, P.,
& Bellomo,
R. (2015).

Retrospective
study IIIB

Article reviews the
haemodynamic
changes associated with
sepsis and provides an
approach to fluid
management

Waechter,
J., Kumar,
A.,
Lapinsky,
S. E.,
Marshall, J.,
Dodek, P.,
Arabi, Y., ...
&
Cooperative
Antimicrobi
al Therapy
of Septic
Shock
Database
Research
Group.
(2014).

Retrospective
analysis, a
multicenter,
observational
study
IIIB

The study sought to
determine how hospital
mortality was influenced
by combined use of these
two treatments, and
retrospectively analyzed
data from 24 ICUs in three
countries.

Potential bias due to
its retrospective
approach, and
possibility of
unreported
cointerventions
influenced results

Sepsis is primarily not a
volume-depleted state
and most septic patients
are poorly responsive to
fluids that are sequestered
in the tissues, resulting in
severe edema. A
physiologic,
haemodynamically
guided conservative
approach to fluid therapy
is prudent, would likely
reduce the morbidity and
improve the outcome
Results showed that
fluids and vasoactive
agents had strong,
interacting associations
with mortality (p <
0.0001).
Mortality was lowest
when vasoactive agents
were begun 1–6 hours
after onset, with more
than 1 L of fluids in the
initial hour after shock
onset, more than 2.4 L
from hours 1–6, and 1.6–
3.5 L from 6 to 24 hours.
The lowest mortality rates
were associated with
starting vasoactive agents
1–6 hours after onset

Aggressive IV
fluid
resuscitation
does not
improve the
outcome of
patients with
severe sepsis
and septic shock

the focus during
the first hour of
resuscitation for
septic shock
should be
aggressive fluid
administration,
only thereafter
starting
vasoactive
agents, while
continuing
aggressive fluid
administration

Zhang, D.,
Micek, S.
T., &
Kollef, M.
H. (2015).

Single-center
retrospective
cohort study
IIIB
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From January 2008 to
December 2012, the study
was conducted to assess the
timing of AAT, included
1058 subjects in 1200-bed
academic hospital. Timing
of appropriate antibiotic
therapy was determined
from blood culture
collection time to the
administration of the first
dose of antibiotic therapy
with documented in vitro
susceptibility against the
identified pathogen

Retrospective study
which limits causal
inference

The median time from
blood culture collection
to the administration of
AAT was 6.7 hours The
time AAT is an
independent determinant
of postinfection ICU
LOS; (p < 0.001) and
postinfection hospital
LOS increased per hr of
time to deliver AAT; (p <
0.001). Other indep.
determinants increasing
ICU hospital LOS were
mechanical ventilation
and leukocytosis

time to
appropriate
antibiotic
therapy in
patients with
sepsis to be an
independent
determinant of
postinfection
ICU and
hospital lengths
of stay.
Clinicians
should
implement local
strategies aimed
at timely
delivery of
appropriate
antibiotic
therapy to
improve
outcomes and
reduce the
length of stay.

Kumar, A.,
Roberts, D.,
Wood, K.
E., Light,
B., Parrillo,
J. E.,
Sharma, S.,
... & Gurka,
D. (2006).

Retrospective
cohort study
IIIB
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Review of medical records Possible
Among 2,154 septic
Effective
of 2,731 adult patients with confounding factors shock patients (78.9%
antimicrobial
septic shock in fourteen
may have played a
total) who received
administration
intensive care units (four
role in outcomes
effective antimicrobial
within the
medical, four surgical, six
Potential bias due to therapy only after the
the first hour of
mixed medical/surgical)
its retrospective
onset of recurrent or
documented
and ten hospitals (four
approach, and
persistent hypotension, a
hypotension
academic, six community)
possibility of
strong relationship
was associated
in Canada and the United
unreported cobetween the delay in
with increased
States. Study sought to
interventions
effective antimicrobial
survival to
determine the prevalence
influenced results
initiation and in-hospital
hospital
and impact on mortality of
mortality was noted
discharge in
delays in initiation of
adult patients
effective AAT from initial
with
onset of hypotension of
septic shock
septic shock
Quality rating as per Evidence table and quality guide by The Johns Hopkins Hospital/The Johns Hopkins University (Dearrholt, 2012);
(Table B.1.).

APPENDIX B: EVIDENCE LEVEL AND QUALITY GUIDE
Table B.1. Evidence Level and Quality Guide
18

Evidence Levels

Quality Guides

Level I
Experimental study, randomized
controlled trial (RCT)
Systematic review of RCTs, with
or without meta-analysis

A High quality: Consistent, generalizable results;
sufficient sample size for the study design; adequate
control; definitive conclusions; consistent
recommendations based on comprehensive literature
review that includes thorough reference to scientific
evidence
B Good quality: Reasonably consistent results;
sufficient sample size for the study design; some control,
fairly definitive conclusions; reasonably consistent
recommendations based on fairly comprehensive
literature review that includes some reference to
scientific evidence
C Low quality or major flaws: Little evidence with
inconsistent results; insufficient sample size for the study
design; conclusions cannot be drawn

Level II
Quasi-experimental study.
Systematic review of a
combination of RCTs and quasiexperimental, or quasiexperimental studies only, with or
without meta-analysis
Level III
Non-experimental study
Systematic review of a
combination of RCTs, quasiexperimental and nonexperimental studies, or nonexperimental studies only, with or
without meta-analysis
Qualitative study or systematic
review with or without a metasynthesis
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A High quality: Material officially sponsored by a
professional, public, private organization, or government
agency; documentation of a systematic literature search
strategy; consistent results with sufficient numbers of
well-designed studies; criteria-based evaluation of overall
scientific strength and quality of included studies and
definitive conclusions; national expertise is clearly
evident; developed or revised within the last 5 years
B Good quality: Material officially sponsored by a
professional, public, private organization, or government
agency; reasonably thorough and appropriate systematic
literature search strategy; reasonably consistent results,
sufficient numbers of well-designed studies; evaluation of
strengths and limitations of included studies with fairly
definitive conclusions; national expertise is clearly
evident; developed or revised within the last 5 years
C Low quality or major flaws: Material not sponsored
by an official organization or agency; undefined, poorly
defined, or limited literature search strategy; no evaluation
of strengths and limitations of included studies,
insufficient evidence with inconsistent results, conclusions
cannot be drawn; not revised within the last 5 years.
Level V
Organizational Experience:
Based on experiential and nonA High quality: Clear aims and objectives; consistent
research evidence
results across multiple settings; formal quality
Includes:
improvement, financial or program evaluation methods
Literature reviews
used; definitive conclusions; consistent recommendations
Quality improvement,
with thorough reference to scientific evidence
program or financial evaluation
B Good quality: Clear aims and objectives; consistent
Case reports
results in a single setting; formal quality improvement or
Opinion of nationally
financial or program evaluation methods used; reasonably
recognized experts(s) based on
consistent recommendations with some reference to
experiential evidence
scientific evidence
C Low quality or major flaws: Unclear or missing aims
and objectives; inconsistent results; poorly defined quality
improvement, financial or program evaluation methods;
recommendations cannot be made
Literature Review, Expert Opinion, Case Report,
Community Standard,
Clinician Experience, Consumer Preference:
A High quality: Expertise is clearly evident; draws
definitive conclusions; provides scientific rationale;
thought leader(s) in the field
B Good quality: Expertise appears to be credible; draws
fairly definitive conclusions; provides logical argument
for opinions
C Low quality or major flaws: Expertise is not
discernable or is dubious; conclusions cannot be drawn
© The Johns Hopkins Hospital/The Johns Hopkins University
(Dearrholt, 2012)
Level IV
Opinion of respected authorities
and/or nationally recognized
expert committees/consensus
panels based on scientific
evidence
Includes:
Clinical practice guidelines
Consensus panels
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APPENDIX C: MICROORGANISMS ASSOCIATED WITH RISK OF MORTALITY
Table C.1. Type of Organisms Associated with Risk of Mortality
19

Organism
Gram-positive

Frequency (%)
46.8

OR (95% CI)

Staphylococcus aureus

20.5

0.8 (0.6–1.1)

MRSA

10.2

1.3 (0.9–1.8)

Enterococcus

10.9

1.6 (1.1–2.3)

S. epidermidis

10.8

0.9 (0.7–1.1)

S. pneumonia

4.1

0.8 (0.5–1.4)

Other

6.4

0.9 (0.7–1.2)

Gram-negative

62.2

Pseudomonas species

19.9

1.4 (1.2–1.6)

Escherichia coli

16.0

0.9 (0.7–1.1)

Klebsiella species

12.7

1.0 (0.8–1.2)

Acinetobacter species

8.8

1.5 (1.2–2.0)

Enterobacter

7.0

1.2 (0.9–1.6)

Other

17.0

0.9 (0.7–1.3)

Anaerobes

4.5

0.9 (0.7–1.3)

Other bacteria

1.5

1.1 (0.6–2.0)

Candida

17.0

1.1 (0.9–1.3)

Aspergillus

1.4

1.7 (1.0–3.1)

Other

1.0

1.9 (1.0–3.8)

Parasites

0.7

1.3 (0.5–3.3)

Other organisms

3.9

0.9 (0.6–1.3)

Fungi

OR, odds ratio; CI, confidence interval; MRSA, methicillin-resistant S. aureus (Mayr, Yende, &

Angus, 2014).

158

APPENDIX D: PDCA TEMPLATE AND PDSA WORKSHEET

Figure D.1.9PDCA Template

Source: Free resources, East West Manufacturing Company
http://www.ewmfg.com/resources
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Figure D.2. PDSA Worksheet
(Institute for Healthcare Improvement, 2014).
10
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APPENDIX E: DATA COLLECTION ITEMS
Table E.1. Data Collection Items
20

Patient’s unique # (PtID)
1,2,3,4,5,6,7,8,9…

Appropriate ABT for Dx (AbtAppr)
1 yes;
2 no

Age:
# number of years

IVF (IVF1-3)
1 yes 30 ml/hr;
2: no;
3: contraindicated

Gender
1 male
2 female

Lactic Acid 1st drawn w/in 3 hrs (LA1_3h)
1-yes,
2 - no

Race (Race1-6)
1 Caucasian
2 African American
3 Asian
4 Hispanic
5 Native American;
6 Other

Lactic Acid sample #1 > 2 (LA1>2)
1 yes
2 no
0 not done
Repeat Lactic Acid 6 hrs (LA2_6h)
1 yes
2 no;
0 N/A, not indicated

LOS (Length of stay in # of days)
# number of days spent in hospital
Outcomes
Mortality (OutcMort)
1 yes - Alive
2 no - Deceased

Blood Cultures (Cult<3h) (0-2)
1 yes <3h cultures drawn prior to
administration of antibiotics
2 no >3h blood cultures drawn/ or not before
antibiotics
0 -- Blood cultures were not done

Functional status at discharge (OutcFS 0-3)
0 same as pre-hospitalization
1 worse, lost independence, needs more help,
declined
2 better than prior to hospitalization
3 Deceased

Cultures (Cult#hrID)
# number of hr pathogen group described or
identified in sample
Cultures (Cult#hrFIN)
# number of hours final results of cultures
known, including MIC
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Discharge (D/C1-6) Discharge to:
1 Prior living situation/home, independent
2 Extended care facility/ SNF (new)
3 Deceased
4 Higher level of care (transfer to another
hosp)
5 Home w/ Home Health/caregivers/more
help
6 Discharged to Hospice

Immune status impairing diagn (ImDx0-2)
0 – Immunocompetent (ImDx0)
1 – Immunocompromised with one Dx likely
affecting immune status
2 – Immunocompromised with two or more
Dx likely affecting immune status

Dx: (ImmDx0-7)
0 None (ImDx0)
1 Ca, (ImDx1)
2 transplant/ spleenless (ImDx2)
3 COPD, (ImDx3) etc..
4 DM
5 RA- on prednisone
6 Chemotherapy
7 other
Comorbidities (Cmb0-15)
0 None (Cmb0)
1 Ca (Cmb1) etc..
2 COPD
3 DM
4 CAD
5 Malnutrition
6 ETOH chronic
7 Readmitted, recurrent infection
8 h/o sepsis
9 h/o MDR infection
10 Underlying dementia
11 ESRD on dialysis
12 Obesity
13 CHF
14 PVD
15 Other

Culture results: (CR0-5)
0 negative cultures
1 positive cultures: bacteria
2 positive cultures: fungal
3 positive cultures: viral
4 positive cultures other
5 unknown

C-diff
1 yes
2 no
Site of positive cultures (P+1-9)
1 blood
2 urine
3 wound
4 sputum
5 stool
6 CNS fluid
7 Pleural fluid
8 Peritoneal;
9 other
PATHOGEN:
Gram negative pathogen (Gn1-12)
1 E-coli
2 Klebsiella pneumoniae
3 Enterobacter
4 Acinetobacter
5 Pseudomonas aeruginosa
6 Proteus
7 Serratia
8 Morganella
9 Haemophilus influenzae
10 Campylobacter
11 Neisseria
12 other
Gram positive pathogen (G(+)1-13)
1 Staph aureus MSSA
2 Staph aureus MRSA
3 Staph coagulase (-) epidermidis
4 Streptococcus pneumococcus
5 Strep viridians
6 Strep group A pyrogens
7 Corynebacterium
8 Enterococcus faecium
9 Enterococcus faecalis
10 Clostridum
11 Corynobacterium
12 Bacillus
13 other
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Initial presentation (IniPres1-3)
1 Sepsis
2 Severe Sepsis
3 Septic shock
Acute mental status change (AMS)
1 yes
2 no
Sepsis cause (SCs1-13)
1 Pneumonia (SCs1)
2 UTI (SCs2) etc
3 Pyelonephritis
4 GI/intraabdominal
5 Skin (Cellulitis)
6 Post- Surgery complications
7 Wound infection
8 Meningitis
9 other
10 Neutropenic Fever
11FUO
12 Bacteremia
13 Osteomyelitis
Hospital course (Hcr1-3)
1 ICU w/ pressors and mechanical ventilation
2 ICU w/o mechanical ventilation
3 no pressors, no vent, PCU/other
Progression of Sepsis
1 yes - worse: severe sepsis progressed to
septic shock despite tx (or death)
2 no – better, status did not deteriorate during
hospitalization
Treatment w/ initial Antibiotics (Abt<3h)
1 Yes: <3h from time 0 first antibiotic
administered* (not ordered)
2 No: >3h from time 0 first abt
administered*
Days on Abt (AbtEmp#D)
# number of days on empiric antibiotics
Number of empiric antibiotics (AbtEmp#)
#number of prescribed antibiotic
ABT Deescalated: (AbtDesc)
1 - yes
2- no
Complications (cmp1-11)
1 C-diff
2 MDR organism
3 Surgery
4 Neutropenia
5 Coagulopathy

Atypicals (Atyp1-3)
1 Mycoplasma
2 Chlamydia
3 Ricketts
Other
1 Viral (OthVir
2 Fungal (OthFung)
MDR Organisms (MDR1-6)
1 MRSA
2 VRE
3 CRE
4 C-diff
5 ESBL
6 Other

Antimicrobial class (Ab1-21)
1 – PCN (Ab1)
2 – Extended PCN (Zosyn) (Ab2)
3 – B-lactamase inh PCN (Unasyn)
(Ab3)etc..
4 – Cephalosporin 1st
5 – Cephalosporin 2nd
6 – Cephalosporin 3rd
7 – Cephalosporin 4th
8 – Cephalosporin 5th (Ceftaroline)
9 – Fluoroquinolone 2nd (Cipro)
10 – Quinolone 3rd (Lavo/Moxi)
11 – Macrolides
12 – Tetracycline
13 – Sulfonamides
14 – Carbapenems
15 – Monobactam (Aztreonam)
16 – Glycopeptide (Vanc)
17 – Liptopeptide (Cubicin/Dapto)
18 – Oxazolidinone (Zyvox/linezolid)
19 – Lincosamide (Clindamycin)
20 – Other antibiotics (Tigecycline)
21 – Nitroimidazole (Flagyl)
Other Treatment (OthTx 1-3)
1 – Antifungal (fluconazole)
2 – Antiviral
3 – Other atypical
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6 Abscess
7 Renal failure
8 Respiratory failure
9 Multisystem failure
10 Cardiac complications
11 Other
Potential costs savings
On LOS (Sav$LOS)
1 yes;
2 no
On ABT de-escalation (Sav$Abt)
1 yes;
2 no
Readmitted w/in 30 days (Readm30)
1 yes;
2 no

Appropriate antibiotic for culture results
(AbtAppr)
1 Yes;
2 No

Healthcare Acquired infection (HCaq)
1 yes;
2 No
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APPENDIX F: CONGRESSIONAL BILL

Figure F.1. Bill H.R.3539 - 114th Congress (2015-1016)
11
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APPENDIX G: IRB STATEMENT

MONIKA MROZ <monikamroz1@gmail.com>

Statement about IRB
GASIOROWSKI, BETH <beth.gasiorowski@tenethealth.com>

Wed, May 4, 2016 at 8:04
AM

To: MONIKA MROZ <monikamroz1@gmail.com>

Per our Compliance Officer:

Beth:
I don't have any objections to this audit, as long as, all data is scrubbed of any patient
identifiers. Reading her proposal, it appears patient's PHI is not necessary.
Jim Riley, RN
Hospital Compliance Officer
East Cooper Medical Center
Office: 843-416-6217
Cell: 843-743-5420
Beth Gasiorowski
Director of Risk Management/Patient Safety Officer
Hilton Head Hospital
25 Hospital Center Boulevard
Hilton Head, South Carolina 29926
Office (843) 689-8412
Pager (843) 525-8789
Beth.gasiorowski@tenethealth.com
CONFIDENTIALITY NOTICE: This e-mail transmission, including attachments, if any, is intended for
use only by the address(s) named herein and contains confidential and/or privileged information.
Any unauthorized review, use, disclosure or distribution is strictly prohibited. If you are not the
intended recipient, please notify the sender immediately by reply e-mail or telephone and delete
the original and destroy all electronic and other copies of this message. If you are the intended
recipient but do not wish to receive communications through this medium, please so advise the
sender immediately.
Subject: Statement about IRB

Figure G.1. IRB Statement
A screenshot of the email received from the Safety Officer /Director of Risk Management as per
the Compliance officer.
12
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APPENDIX H: PERMISSION TO USE IMAGES

Figure H.1. Permission to use images
13

A screenshot of the email received from the manager of Image Collection at
VisualDx.com
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APPENDIX I: ICD-10-CM DIAGNOSIS CODES
Diagnosis codes included in reports:


Other sepsis A41



postprocedural sepsis (T81.4)



sepsis following immunization (T88.0)



sepsis following infusion, transfusion or therapeutic injection (T80.2-)



sepsis (due to) (in) actinomycotic (A42.7)



sepsis (due to) (in) anthrax (A22.7)



sepsis (due to) (in) candidal (B37.7)



sepsis (due to) (in) Erysipelothrix (A26.7)



sepsis (due to) (in) extraintestinal yersiniosis (A28.2)



sepsis (due to) (in) gonococcal (A54.86)



sepsis (due to) (in) herpesviral (B00.7)



sepsis (due to) (in) listerial (A32.7)



sepsis (due to) (in) melioidosis (A24.1)



sepsis (due to) (in) meningococcal (A39.2-A39.4)



sepsis (due to) (in) plague (A20.7)



sepsis (due to) (in) tularemia (A21.7)



toxic shock syndrome (A48.3)
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Additional codes included:


A41 Other sepsis



A41.0 Sepsis due to Staphylococcus aureus



A41.01 Sepsis due to Methicillin susceptible Staphylococcus aureus



A41.02 Sepsis due to Methicillin-resistant Staphylococcus aureus



A41.1 Sepsis due to other specified staphylococcus



A41.2 Sepsis due to unspecified staphylococcus



A41.3 Sepsis due to Hemophilus influenzae



A41.4 Sepsis due to anaerobes



A41.5 Sepsis due to other Gram-negative organisms



A41.50 Gram-negative sepsis, unspecified



A41.51 Sepsis due to Escherichia coli [E. coli]



A41.52 Sepsis due to Pseudomonas



A41.53 Sepsis due to Serratia



A41.59 Other Gram-negative sepsis



A41.8 Other specified sepsis



A41.81 Sepsis due to Enterococcus



A41.89 Other specified sepsis



A41.9 Sepsis, unspecified organism



sepsis NOS (A41.9)



streptococcal sepsis (A40.-)

Diagnosis codes excluded from reports:
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sepsis during labor (O75.3)



sepsis following abortion, ectopic or molar pregnancy (O03-O07, O08.0)



bacteremia NOS (R78.81)



neonatal (P36.-)



puerperal sepsis (O85)

Source: ICD10Data.com
(2016 ICD-10-CM Diagnosis Codes A41.* : Other sepsis A41)
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APPENDIX J: EXAMPLES OF DATA COLLECTION WORKSHEETS SET

171
Figure J.1. Data collection worksheets
Worksheet column headings shown, coded variables for raw data, created using Excel®.
14

Legend:
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Patient’s unique # (PtID) --CATEGORICAL
1,2,3,4,5,6,7,8,9…
Age: --NUMERIC
# number of years
Gender --CATEGORICAL
1 male 2 female
Race (Race1-6) --CATEGORICAL
1 Caucasian
2 African American
3 Asian
4 Hispanic
5 Native America;
or: 6 Other
LOS (Length of stay in # of days) --NUMERIC
# number of days spent in hospital
Outcomes
Mortality (OutcMort) YES-NO Yes=1 No=2
1 yes – Alive 2 no - Deceased
Functional status at discharge (OutcFS 0-3) --CATEGORICAL
0 same as pre-hospitalization
1 worse, lost independence, needs more help, declined
2 better then prior to hospitalization
3 Deceased
Discharge (D/C1-6) --CATEGORICAL
Discharge to:
1 Prior living situation/home, independent
2 Extended care facility/ SNF (new)
3 Deceased
4 Higher level of care (transfer to another hospital)
5 Home w/ Home Health/caregivers/more help
6 Discharged to Hospice
Immune status impairing diagnoses (ImDx0-2) --ORDINAL
0 – Immunocompetent (ImDx0)
1 – Immunocompromised with one Dx likely affecting immune status
2 – Immunocompromised with two or more Dx affecting status
Dx: (ImmDx0-7) --CATEGORICAL

0 None (ImDx0)
1 Ca, (ImDx1)
2 transplant/ spleenless (ImDx2)
3 COPD, (ImDx3) etc..
4 DM
5 RA- on prednisone
6 Chemotherapy; or: 7 other
Comorbidities (Cmb0-15) --CATEGORICAL
0 None (Cmb0)
1 Ca (Cmb1) etc..
2 COPD
3 DM
4 CAD
5 Malnutrition
6 ETOH chronic
7 Readmitted, recurrent infection
8 h/o sepsis
9 h/o MDR infection
10 Underlying dementia
11 ESRD on dialysis
12 Obesity
13 CHF
14 PVD;
or: 15 Other
Initial presentation (IniPres1-3) --ORDINAL
1 Sepsis
2 Severe Sepsis
3 Septic shock
Acute mental status change (AMS) --YES-NO Yes=1 No=2
1 yes 2 no
Sepsis cause (SCs1-13) --CATEGORICAL
1 Pneumonia (SCs1)
2 UTI (SCs2) etc
3 Pyelonephritis
4 GI/intraabdominal
5 Skin (Cellulitis)
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6 Post- Surgery complications
7 Wound infection
8 Meningitis;
10 Neutropenic Fever
11FUO
12 Bacteremia
13 Osteomyelitis;
or: 9 other
Hospital course (Hcr1-3) --CATEGORICAL
1 ICU w/ pressors and mechanical ventilation
2 ICU w/o mechanical ventilation
3 no pressors, no vent, PCU/other
Progression of Sepsis -- YES-NO Yes=1 No=2
1 yes - worse: severe sepsis progressed to septic shock or death
2 no – better, status did not deteriorate during hospitalization
Treatment w/ initial Antibiotics (Abt<3h) Yes=1 No=2
1 Yes: <3h from time 0 first antibiotic administered* (not ordered)
2 No: >3h from time 0 first antibiotic administered*
Days on Abt --NUMERIC
# number of days on empiric antibiotics (AbtEmp#D)
Number of empiric antibiotics (AbtEmp#) --NUMERIC
#number of prescribed antibiotic
ABT Deescalated: (AbtDesc) Yes=1 No=2
1 – yes 2- no
Appropriate ABT for Dx (AbtAppr) Yes=1 No=2
1 – yes 2 no
IVF (IVF1-3) --CATEGORICAL
1 yes 30 ml/hr 2 no 3 contraindicated
Lactic Acid 1st drawn w/in 3 hrs (LA1_3h) Yes=1 No=2
1-yes, 2 - no
Lactic Acid sample #1 > 2 (LA1>2) --CATEGORICAL
1 yes 2 no 0 not done
Repeat Lactic Acid 6 hrs (LA2_6h) --CATEGORICAL
1 yes 2 no 0 N/A, not indicated
Cultures (Cult<3h) --CATEGORICAL
1 yes <3h &BLOOD cultures drawn prior to admof antibiotic
2 no >3h &BLOOD cultures drawn/ or not before administration of
antibiotic

0 -- Blood cultures were not done
Cultures (Cult#hrID) --NUMERIC
# number of hr pathogen group described or identified in sample
NUMERIC
Cultures (Cult#hrFIN) --NUMERIC
# number of hours final results of cultures known, including MIC
Culture results: (CR0-5) --CATEGORICAL
0 negative cultures
1 positive cultures: bacteria
2 positive cultures: fungal
3 positive cultures: viral
4 positive cultures other;
or:5 unknown
C-diff --YES-NO Yes=1 No=2
1 yes 2 no
Site of positive cultures (P+1-9) --CATEGORICAL
1 blood
2 urine
3 wound
4 sputum
5 stool
6 CNS fluid
7 Pleural fluid
8 Peritoneal;
or: 9 other
PATHOGEN:
Gram negative pathogen (Gn1-12) --CATEGORICAL
1 E-coli
2 Klebsiella pneumoniae
3 Enterobacter
4 Acinetobacter
5 Pseudomonas aeruginosa
6 Proteus
7 Serratia
8 Morganella
9 Haemophilus influenzae
10 Campylobacter
11 Neisseria; or: 12 other
Gram positive pathogen (G(+)1-13) --CATEGORICAL

174

1 Staph aureus MSSA
2 Staph aureus MRSA
3 Staph coagulase (-) epidermidis
4 Streptococcus pneumococcus
5 Strep viridians
6 Strep group A pyrogens
7 Corynebacterium
8 Enterococcus faecium
9 Enterococcus faecalis
10 Clostridum
11 Corynobacterium
12 Bacillus;
or: 13 other
Atypicals (Atyp1-3) --CATEGORICAL
1 Mycoplasma
2 Chlamydia
3 Ricketts
Other --CATEGORICAL
1 Viral (OthVir
2 Fungal (OthFung)
MDR Organisms (MDR1-6) --CATEGORICAL
1 MRSA
2 VRE
3 CRE
4 C-diff
5 ESBL;
or: 6 Other
Antimicrobial class (Ab1-21) --CATEGORICAL
1 – PCN (Ab1)
2 – Extended PCN (Zosyn) (Ab2)
3 – B-lactamase inh PCN (Unasyn) (Ab3)etc..
4 – Cephalosporin 1st
5 – Cephalosporin 2nd
6 – Cephalosporin 3rd
7 – Cephalosporin 4th
8 – Cephalosporin 5th (Ceftaroline)
9 – Fluoroquinolone 2nd (Cipro)
10 – Quinolone 3rd (Lavo/Moxi)

11 – Macrolides
12 – Tetracycline
13 – Sulfonamides
14 – Carbapenems
15 – Monobactam (Aztreonam)
16 – Glycopeptide (Vanc)
17 – Liptopeptide (Cubicin/Dapto)
18 – Oxazolidinone (Zyvox/linezolid)
19 – Lincosamide (Clindamycin)
20 – Other antibiotics (Tigecycline)
21 – Nitroimidazole (Flagyl)
Other Treatment (OthTx 1-3)
1 – Antifungal (fluconazole)
2 – Antiviral;
3 Other atypical
Appropriate antibiotic for culture results (AbtAppr)Yes=1 No=2
1 Yes;
2 No
Healthcare Acquired infection (HCaq) Yes=1 No=2
1 yes;
2 No
Complications (cmp1-11) --CATEGORICAL
1 C-diff
2 MDR organism
3 Surgery
4 Neutropenia
5 Coagulopathy
6 Abscess
7 Renal failure
8 Respiratory failure
9 Multisystem failure
10 Cardiac complications
11 Other
Potential costs savings On LOS (Sav$LOS) Yes=1 No=2
1 yes;
2 no
On ABT de-escalation (Sav$Abt) Yes=1 No=2
1 yes;
2 no
Readmitted w/in 30 days (Readm30) Yes=1 No=2
1 yes;
2 no

APPENDIX K: EXAMPLES OF VARIABLE CODING SYSTEM
Table K.1. Variable Coding System
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Variable/category Code
Patient’s #
(PtID)
Race
(Race1-6)

Functional
status at
discharge

(OutcFS 0-3)

Discharge
destination

(D/C1-6)

Comorbidities

(Cmb0-15)

Complications

(cmp1-11)

Site of positive
cultures

(P+1-9)

Gram negative
pathogen

(Gn1-12)

Gram positive
pathogen

G(+)1-13)

Antimicrobial
class

(Ab1-21)

Subcategory codes
(#1, 2, 3, 4, 5…n)
1=Caucasian: Race1;
2=African American: Race2;
3=Asian: Race 3; … Race6
0=No change from pre-hospitalization: OutcFS1;
1=Worse, lost independence, declined: OutcFS1;
2=Better then prior to hospitalization: OutcFS2;
3=Deceased: OutcFS3
1=Prior living situation or home, independent: D/C1;
2=Extended care facility/ SNF (new): D/C2;
3=Deceased: D/C3;
4=Higher level of care, transfer to another hospital: D/C4;
5=Home with Home Health, requires more help: D/C5;
6=Discharged to Hospice: D/C6
0=None: Comb0;
1=Cancer Comb1;
2=Chronic Obstructive Lung Disease Comb2;
3=Diabetes Comb3; …Comb15
1=C-diff: comp1;
2=MDR organism: comp2;
3=Surgery: comp3;
4=Neutropenia: comp4; …: comp11)
1=Blood: P+1;
2=Urine: P+2;
3=Wound: P+3;
4=Sputum: P+4 l … : P+9
1=E-coli: Gn1;
2=Klebsiella pneumonia: Gn2;
3=Enterobacter: Gn2;
4=Acinetobacter: Gn4; … : Gn12)
1=Staph aureus MSSA: G(+)1;
2=Staph aureus MRSA: G(+)2;
3=Staph coagulase (-) epidermidis: G(+)3 ;
4=Streptococcus pneumococcus: G(+)4 ; … : G(+)13
1= PCN: (Ab1);
2=Extended PCN: Ab2;
3=B-lactamase inh PCN: Ab3; …Ab21
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APPENDIX L: PERMISSION TO REPRINT
Permission to reprint the PDSA Model for improvement

Figure L.1. Permission to reprint PDSA Model for improvement request
15
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Figure L.2. Permission to reprint PDSA Model for improvement
16
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APPENDIX M: DESCRIPTIVE STATISTICAL DATA
Mortality and Length of Stay Data
Table M.1. Mortality by Age.
22

OutcmMort
Alive
Deceased
Diff (1-2)

N

Mean

Std Dev

Std Err

Minimum

Maximum

108
50

72.3981
78.1600
-5.7619

14.8103
13.2532
14.3394

1.4251
1.8743
2.4528

23.0000
43.0000

97.0000
97.0000

OutcMort Method

Mean

95% CL Mean

Std Dev 95% CL Std Dev

Alive
72.3981 69.5730 75.2233 14.8103 13.0640
Deceased
78.1600 74.3935 81.9265 13.2532 11.0708
Diff (1-2) Pooled
-5.7619 -10.6069 -0.9169 14.3394 12.9095
Diff (1-2) Satterthwaite -5.7619 -10.4301 -1.0936
p<0.05. * T-Test Variable: OutcmMort: Mortality

17.0997
16.5153
16.1284

Table M.2. Mortality by LOS
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OutcmMort
Alive
Deceased
Diff (1-2)

N

Mean

Std Dev

Std Err

Minimum

Maximum

108
50

7.0556
7.0800
-0.0244

4.8872
5.8269
5.2007

0.4703
0.8240
0.8896

1.0000
1.0000

26.0000
27.0000

OutcmMort Method

Mean

95% CL Mean

Std Dev 95% CL Std Dev

Alive
7.0556 6.1233 7.9878 4.8872
4.3110
Deceased
7.0800 5.4240 8.7360 5.8269
4.8674
Diff (1-2) Pooled
-0.0244 -1.7816 1.7328 5.2007
4.6821
Diff (1-2) Satterthwaite -0.0244 -1.9119 1.8630
p=0.9. * T-Test: Variable: OutcmMort: Mortality; LOS: length of hospital stay.
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5.6427
7.2611
5.8495

Age in Relation To LOS and Mortality Between Groups

UP TO 50

51-70

71-80

81-90

91-100

Figure M.1. Mortality by Age and Group.
*By age and groups: dark gray: pre-implementation, light gray: post-implementation group.
17

UP TO 50

51-70

71-80

81-90

91-100

Figure M.2. LOS by Age and Group
*(Dark gray bar = pre-implementation group; light gray = post-implementation group).
18
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Antibiotics Utilization

Vanc

Levaquin

Zosyn

Rocephin

Merem

Flagyl

Cefepime

Cipro

Figure M.3. Antibiotics Distribution
*(Dark gray bar = pre-implementation group; light gray = post-implementation group).
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Table M.3. Most Frequently Used Antibiotics
24

Most Frequent Empiric
Antibiotics used
Vancomycin
Levaquin
Zosyn
Rocephin
Cefepime
Cipro
Merem
Flagyl

Pre (n=86)

Post (n=72)

%
23.3
19.7
18.8
13.9
7.6
6.3
5.8
4.5

%
26.5
22.1
16.2
12.7
7.4
5.4
5.4
4.4
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Sepsis Associated Diseases and Causative Pathogens
Table M.4. Sepsis Cause
25

Pre (n=86)
%
48
38
22
21
10
9
9
7
6
5
3
1
<1

Sepsis Cause
Pneumonia
UTI
Bacteremia
GI/intraabdominal
Post-operative complications
Wound infection
Other
Neutropenic Fever
Skin (Cellulitis)
Pyelonephritis
FUO
Osteomyelitis
Meningitis

Post (n=72)
%
50
47
35
11
3
10
3
1
14
7
3
3
1

25.0%
20.0%
15.0%
10.0%
5.0%
0.0%

Figure M.4. Most Frequently Occurring Microorganisms Responsible for Sepsis.
*(Dark gray bar = pre-implementation group; light gray = post-implementation group)
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Table M.5. Most Frequently Occurring Pathogens
26

Most Frequent Causative Pathogens Observed
Pathogen

Pre (n=86)

Post (n=72)

%
%
17.4%
23.6%
14.0%
12.5%
9.3%
0.0%
8.1%
0.0%
5.8%
2.8%
5.8%
1.4%
5.8%
0.0%
4.7%
0.0%
4.7%
1.4%
3.5%
0.0%
3.5%
0.0%
3.5%
5.6%
3.5%
15.3%
3.5%
6.9%
2.3%
2.8%
2.3%
2.8%
1.2%
0.0%
1.2%
1.4%
1.2%
1.4%
1.2%
1.4%
1.2%
5.6%
1.2%
0.0%
0%
1.4%
0
0.0%
0
2.8%
0
0.0%
0
2.8%
0
2.8%
0
0.0%
0
0.0%
C-diff
2%
3%
MDR
17%
14%
All Sepsis w/ MRSA
10%
7%
MRSA cases among MDR associated with sepsis
60%
50%
ESBL
7%
10%
VRE
7%
0%
* E-coli: bacterium Escherichia coli; MRSA: resistant strain, Methicillin Resistant
Staphylococcus aureus; MSSA: Methicilin Sensitive Staphylococcus aureus; C-diff: Clostridium
difficile; MDR: multi-drug resistant organism.
E-coli
Candida/Fungal
Staph coagulase (-) epidermidis
Enterococcus faecalis
Staph aureus MRSA
Viral (OthVir
Klebsiella pneumoniae
Pseudomonas aeruginosa
Strep viridians
Enterobacter
Haemophilus influenzae
Staph aureus MSSA
Streptococcus pneumococcus
other
Proteus
Enterococcus faecium
Acinetobacter
Strep group A pyrogens
Corynebacterium
Corynobacterium
other
Bacillus
Serratia
Morganella
Campylobacter
Neisseria
Clostridum
Mycoplasma
Chlamydia
Ricketts
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Table M.6. Legend for Data Collection:
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Code:

Applies to:

OutcMort
OutcFS
D/C
ImDx
Cmb
IniPres
AMS
SCs
Hcr
SpsPrgs
Abt<3h
AbtEmp#D
AbtEmp#
AbtDesc
AbtAppr
IVF
LA1
LA1>2
LA2_6h
Cult<3h

Outcomes, Mortality
Functional status at discharge
Discharge
Associated diagnoses affecting immune status
Comorbidities
Initial presentation
Acute mental status change
Sepsis cause
Hospital course
Progression of Sepsis
Treatment with initial Antibiotics per protocol <3 hours from sepsis onset
Number of days on empiric antibiotics
Number of empiric antibiotics prescribed
Antibiotics Deescalated
Appropriate antibiotic for diagnosis
Intravenous fluids per protocol at 30mL/hr and <3 hours from sepsis onset
Lactic Acid 1st drawn <3 hours from sepsis onset
Lactic Acid first sample results > 2
Repeat Lactic Acid in 6 hours
Blood cultures drawn prior to administration of antibiotic and <3 hours from
sepsis onset
Number of hours pathogen group described or identified in a sample
Number of hours until final cultures results available, including MIC
Culture results
Clostridium difficile
Site of positive cultures
Gram negative pathogen
Gram positive pathogen
Viral
Fungal
Multi-drug resistant organisms
Antimicrobial class
Other Treatment
Appropriate antibiotic for culture results
Healthcare Acquired infection
Complications
Potential costs savings on length of stay
Potential costs savings on antibiotics de-escalation
Readmitted within 30 days

Cult#hrID
Cult#hrFIN
CR
C-diff
P+
Gn
G(+)
OthVir
OthFung
MDR
Ab
OthTx
AbtAppr
HCaq
Cmp
Sav$LOS
Sav$Abt
Readm30
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